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Voorwoord 
 
Het zit er op! Na vier jaren hard werken en zwoegen eindelijk de eindmeet bereikt en wat een 
gevoel...  Onbeschrijflijk. De tijd is zo verbazingwekkend snel gegaan, en dan bedoel ik vooral dat 
laatste jaar. Zonder er bij stil te staan en voordat je het werkelijk beseft, ben je dat (voor)laatste aan 
het doen: het voorwoord schrijven. Dat is niet het meest professionele deel, er mogen al eens typo’s 
e.d. in voorkomen (al zou ik me toch schamen als hier ook maar één dt-fout in staat), maar het is 
toch een heel belangrijk iets. Ja, want deze vier jaren zijn allemaal iets draaglijker en plezanter 
gemaakt door een heleboel mensen, zowel op het werk als daarnaast, en ik wil dan ook niets liever 
dan deze mensen allemaal te bedanken. 
In eerste instantie wil ik mijn drie promotoren bedanken voor de kans om dit mooie doctoraat te 
starten en te vervolledigen. Bruno, Jeroen en Karin, merci! Jullie stonden me alle drie met raad en 
daad bij wanneer ik dit nodig had. Ik herinner me zelfs telefoontjes tijdens de weekends en 
vakanties; momenten waarop het niet moest of verwacht werd, maar het toch werd gedaan om mij 
vooruit te helpen. We hebben ettelijke meetings en discussies gehad, en ik kan me geen enkele 
bedenken waarin er geen nieuwe ideeën zijn ontstaan, of waarin er geen oplossingen voor 
bestaande problemen werden bedacht. Ik heb ontzettend veel aan jullie advies gehad, en dat zal ik 
niet vergeten. Ik wil hier van de gelegenheid gebruik maken om één persoon uitdrukkelijk te 
bedanken. Karin, ik wil je ontzettend hard bedanken voor de steun die ik van jou kreeg gedurende 
heel mijn doctoraat, maar vooral tijdens dat laatste jaar. Jij was de persoon die me een duwtje in de 
rug gaf als ik het nodig had, of me overtuigde van mijn kunnen als ik even een dipje had. Iedereen 
die onder jouw begeleiding staat, mag zichzelf gelukkig prijzen, en als ik ooit ook maar jouw kunnen 
kan evenaren, heb ik mijn doel bereikt. Jij bent een topvrouw – respect. 
Natuurlijk wil ik ook een aantal mensen uit het labo bedanken. Ik denk dan vooral aan JosD, want 
zonder hem was mijn thesis letterlijk drie hoofdstukken kleiner geweest. Jos, merci om mij alles over 
proteïneopzuiveringen met hand en tand uit te leggen. Door jou ben ik een ‘pro’ geworden in 
opzuiveringen, want jij leerde me alles tot in de puntjes aan. Bij elke foutmelding op het systeem nam 
jij de tijd om mij uit te leggen wat er mis was en hoe ik dat kon oplossen. Zo leerde je me 
bijvoorbeeld hoe ik filters kon vervangen of wat ik moest doen om lucht uit het systeem te krijgen. Al 
die dagenlange opzuiveringen zouden niet zijn gelukt als ik jouw hulp niet had, dus bij deze, bedankt! 
Daarnaast wil ik Els, Tanne en Annelies bedanken, die me (wellicht tot vervelends toe) zo vaak 
hebben geholpen met van alles en nog wat. Bijvoorbeeld het gieten van liters agar omdat mijn platen 
weeral op waren en ik die dag weeral 300 platen nodig had, of het helpen met uitplatingen omdat 
mijn experimenten zo groot waren dat het alleen niet haalbaar was, of het klaarmaken van stalen 
voor het andere labo en het inzetten van MIC-testjes omdat ik aan het schrijven was. Dikke merci! 
Ook wil ik Maarten bedanken voor al zijn advies rond proteïnen/peptiden, gelelektroforese, PCR, 
cloneren, etc., maar meer nog voor de vele babbels die we hadden. Na Nicolas was jij wel degene 
die wat leven in de brouwerij bracht, en dat vooral na drie koppen koffie om 10h00 ’s ochtends in de 
entkamer. Phalguni, thank you very much for the opportunity to work with you for several years on 
the DMF platform. I think this collaboration was a success with respect to outcome, but more 
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importantly, it was fun and I learned a lot of new things. I also enjoyed the talks we had besides work, 
and I wish you all the best. Within a few months, it is your turn, and I am positive that you will do a 
great job. Tot slot wil ik heel de PFI- en MeBioS-groep bedanken. We hebben vaak wat afgelachen 
tijdens de spaghetti-avonden bij Karin of op de PFI-weekends. Wat betreft dat laatste, ik krijg nog 
steeds de slappe lach als ik aan pingpong denk, Jasper, Katrijn en Tanne. Also the nice dinners, 
Biosensordays followed by a barbeque, bowling events and so on with the MeBioS group members 
were fun. Thank you guys!  
Niet enkel de mensen in het labo, maar ook personen buiten PFI zullen mij bijblijven. Merci Anita om 
zo vaak die administratieve rompslomp te regelen wanneer ik bijvoorbeeld pakjes wou verzenden, 
maar niet wist hoe dat nu precies moest. Of André, die elke keer er iets was stukgegaan in het labo, 
dat altijd snel herstelde met een lach. Ook met de doctoraatsstudenten uit de andere CMPG-groepen 
heb ik leuke tijden beleefd. Bijvoorbeeld de sportcompetities met dé twee CMPG teams: Team André 
en Team JosD. Netbal, handbal, frisbee, honkbal, … sommige sporten gingen me beter af dan 
andere (een gebroken vinger en een spierscheur zijn nu toch ook zo erg niet?), maar stuk voor stuk 
zijn dit leuke herinneringen. Ook mijn bureaugenootjes zou ik willen bedanken. Bram, Patrizia, Seppe 
en Mariya, merci voor alle steun – thanks for the support! Het is een apart gevoel om deel uit te 
maken van een bureau waarin vier personen samen de eindfase van het doctoraat doorlopen. 
Iedereen had wel eens een dipje: het schrijven lukte niet, of we wisten niet exact welke statistiek te 
gebruiken, maar we hielpen elkaar er altijd terug bovenop. We spraken elkaar moed in en gaven 
elkaar raad op de momenten dat het nodig was, of vulden de tijd met babbelen over koetjes en 
kalfjes als we besloten dat het toch niet meer voor vandaag ging zijn, maar dat het morgen echt wel 
beter ging gaan. Het is dan ook leuk dat we alle vier de eindmeet hebben bereikt! 
Tot slot wil ik mijn familie, schoonfamilie en vrienden bedanken voor alle steun gedurende de laatste 
vier jaren. Er zijn een aantal moeilijke periodes geweest tijdens mijn doctoraat, en die zijn een pak 
gemakkelijker gemaakt door jullie steun. Hanne, merci voor de vele babbels tijdens het fitnessen en 
het lopen, zowel op professioneel vlak als over dagdagelijkse dingen. Sabine en Joyce, bedankt voor 
de bezoekjes en telefoontjes wanneer Pieter in het buitenland zat, zodat ik wat minder alleen was. 
Kris en Luc, ook aan jullie een welgemeende dank je wel voor jullie telefoontjes op belangrijke 
dagen, dagen die jullie noteerden in jullie agenda, zoals sollicitaties of mijn prelim, om te vragen hoe 
het was geweest. Toch wil ik vooral Pieter vanuit de grond van mijn hart bedanken. Pieter, we 
hebben elkaar leren kennen tijdens ons doctoraat en we hebben vaak samen moeten werken, wat 
het niet altijd gemakkelijk maakte om ook daarbuiten iets op te bouwen. Vorig jaar heb ik je door dik 
en dun gesteund tijdens je finale fase, en nu doe jij niets minder dan dat voor mij. Merci om er voor 
mij te zijn, op de momenten dat ik gefrustreerd thuis kwam omdat er weer iets niet was gelukt of 
omdat er bepaalde zaken waren gebeurd op het werk. Bij jou kon ik ventileren en daardoor ook de 
zaken relativeren. Ik ben er zeker van dat wij een goed duo vormen, en ik hoop dan ook dat wat wij 
hebben, nooit verloren gaat. 
Goed, ik denk dat hiermee alles is gezegd. CMPG en MeBioS, ik heb een leuke tijd gehad, toffe 
mensen ontmoet, maar het is tijd voor iets anders, iets nieuws. Aan iedereen nog eens een dikke 
merci en wie weet tot later! Groetjes, Kim 
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Abstract 
Invasive fungal infections (IFIs), such as candidemia and invasive aspergillosis, are a major threat to 
immunocompromised patients and patients with respiratory disorders. IFIs are associated with high 
morbidity and mortality rates, and are mainly caused by Candida spp. The latter are increasingly 
associated with medical device-related infections, as they can form biofilms on the surface of for 
instance catheters, orthopaedic implants and implantable electronic devices (such as cardiovascular 
pacemakers). C. albicans biofilm cells are resistant towards a broad range of antifungal drugs and 
current treatment options for fungal biofilm-related infections are limited. To date, only miconazole, 
caspofungin, anidulafungin and liposomal formulations of amphotericin B are effective against these 
biofilms. Moreover, treatment with these antifungal drugs can result in severe side effects, including 
hepatotoxicity and nephrotoxicity. Hence, there is a need for novel antifungal treatment options. 
Antimicrobial peptides (AMPs) are of great interest in the search for novel therapeutics, as their 
multiple modes of action reduce the ability of microorganisms to develop resistance. Moreover, 
antifungal AMPs are characterized by fungicidal activity and induce rapid killing of a range of 
microorganisms. One particular family of such AMPs are plant defensins. Plant defensins are in 
general nontoxic to human cells, as they specifically target fungal membrane compounds, and were 
shown to induce production of reactive oxygen species and apoptosis in C. albicans, Saccharomyces 
cerevisiae and/or other fungi. 
A first aim in this research project was to further elucidate the mechanisms of action of three 
antifungal plant defensins, i.e. HsAFP1, RsAFP2 and AtPDF2.3, using C. albicans and S. cerevisiae 
as models. Insight in the mechanisms of action of these defensins and elucidation of the tolerance 
mechanisms used by fungal pathogens to resist their action will improve our understanding on how to 
effectively kill these pathogens. In this work, the antibiofilm potential of HsAFP1 and RsAFP2 was 
investigated towards C. albicans biofilms. Both HsAFP1 and RsAFP2 can prevent formation of C. 
albicans biofilms, however, they cannot eradicate them. Further structure-activity relationship 
analysis of HsAFP1 revealed the importance of the γ-core and adjacent regions in antibiofilm activity. 
This is the first report on plant defensins possessing antibiofilm activity. Next, the ion channel 
inhibitory activity of AtPDF2.3 was investigated, as in silico analysis revealed that the AtPDF2.3 
amino acid sequence carries a partial toxin signature. The latter was previously assigned to scorpion 
toxins active on ion channels. Electrophysiological recordings indicated that this plant defensin 
blocks potassium channels in a similar way as scorpion toxins. In S. cerevisiae, AtPDF2.3 antifungal 
action triggers activation of a tolerance mechanism involving potassium transport and/or 
homeostasis. As such, a link was found between potassium channel inhibitory activity and antifungal 
activity involving potassium transport and/or homeostasis. 
The second aim of this project was to further unravel the mechanism of action of the conventional 
antifungal drug amphotericin B, and as such improve our understanding of amphotericin B-induced 
killing. Amphotericin B interacts with ergosterol in the fungal membrane, which ultimately leads to 
fungal cell death. However, information on amphotericin B-induced events leading to fungal cell 
death is very limited. Several reports already indicated the importance of analysing cellular 
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heterogeneity with respect to dynamic cell responses towards various stimuli, which hinted us to also 
investigate amphotericin B-induced events with spatiotemporal resolution. To this end, a novel digital 
microfluidic (DMF) platform for single cell analysis of S. cerevisiae cells was developed and 
implemented. This device allows for monitoring cells with spatiotemporal resolution, which is not 
possible using bulk methods. In a first instance, a proof of concept for using the DMF platform to 
monitor membrane permeabilization in yeast cells during antifungal treatment with amphotericin B 
was designed. The device was validated by comparing results obtained on the DMF platform with 
those obtained in bulk by flow cytometry. Similar results were found for both experimental designs, 
and therefore, the DMF device was found suitable for single cell analysis of yeast cells during 
antifungal treatment. Further research focused on investigating the role of superoxide and nitric oxide 
radicals in amphotericin B’s fungicidal action. Superoxide radicals were found to be important in 
amphotericin B’s fungicidal action, whereas nitric oxide radicals seem to mediate a tolerance 
mechanism toward this agent. In addition, a detailed kinetic study revealed that inhibition of nitric 
oxide radical production increases and accelerates superoxide radical production, membrane 
permeabilization and loss of reproduction capacity in yeast.  
In summary, the results of this doctoral research contributed to a better understanding of the 
mechanisms of action of and the tolerance mechanisms to HsAFP1, RsAFP2, AtPDF2.3 and 
amphotericin B. For the first time, plant defensins were reported to have antibiofilm activity, thereby 
expanding the knowledge on plant defensin biological activities. Furthermore, this thesis describes 
plant defensins as potential novel antifungal lead molecule for further development into novel 
antifungal and/or antibiofilm drugs to combat fungal infections. In addition, it demonstrates the use of 
a novel DMF platform in the identification of compounds’ mechanisms of action and characterization 
of  potential synergistic interactions. 
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Samenvatting 
Invasieve schimmelinfecties (ISIs), zoals candidemie en invasieve aspergillose, vormen een grote 
bedreiging voor patiënten met een verlaagde weerstand of luchtwegaandoeningen. ISIs worden 
geassocieerd met een hoge morbiditeit en mortaliteit, en worden vooral veroorzaakt door Candida 
spp. Deze Candida spp. worden steeds meer geassocieerd met infecties op medische apparaten, 
omdat zij biofilmen kunnen vormen op het oppervlak van bijvoorbeeld katheters, orthopedische 
implantaten en implanteerbare elektronische apparaten (zoals pacemakers). C. albicans biofilmcellen 
zijn resistent aan een hele reeks antifungale geneesmiddelen, waardoor de huidige behandelingen 
gelimiteerd zijn. Enkel miconazole, caspofungin, anidulafungin en liposomale vormen van 
amfotericine B zijn werkzaam tegen deze biofilmen. Bovendien kan behandeling met deze 
antifungale geneesmiddelen resulteren in ernstige bijwerkingen, waaronder hepatotoxiciteit en 
nefrotoxiciteit. Er is dus een nood aan nieuwe antifungale behandelingen. 
Antimicrobiële peptiden (AMPs) zijn zeer interessant in de zoektocht naar nieuwe therapeutica, 
doordat zij meerdere werkingsmechanismen hebben waardoor de kans op resistentieontwikkeling 
door micro-organismen verlaagd wordt. Bovendien worden antifungale AMPs gekarakteriseerd door 
een fungicide werking en induceren zij snel celdood in een waaier van micro-organismen. Een 
specifieke groep van AMPs omvat de plantdefensinen. Plantdefensinen zijn algemeen gezien niet 
toxisch voor humane cellen, aangezien zij specifiek interageren met componenten in het 
schimmelmembraan. Daarnaast induceren deze peptiden de productie van reactieve zuurstofspecies 
en apoptose in C. albicans, Saccharomyces cerevisiae en/of andere schimmels. 
Een eerste doel in dit onderzoeksproject was om de werkingsmechanismen van drie 
plantdefensinen, zijnde HsAFP1, RsAFP2 en AtPDF2.3, te ontrafelen door gebruik te maken van C. 
albicans en S. cerevisiae als modelsystemen. Zowel inzicht in het werkingsmechanisme van 
verschillende antifungale componenten, als ontrafeling van mogelijke tolerantiewegen die gebruikt 
worden door schimmelpathogenen om aan deze antifungale werking te ontkomen, verbeteren onze 
kennis over hoe deze pathogenen op een efficiënte manier af te doden. In dit werk werd nagegaan of 
HsAFP1 en RsAFP2 de vorming van C. albicans biofilmen kan tegengaan en/of de afbraak van 
bestaande biofilmen kan bewerkstelligen. Zowel HsAFP1 als RsAFP2 kunnen C. albicans 
biofilmvorming tegengaan, maar kunnen echter bestaande biofilmen niet afbreken. Uit HsAFP1-
gebaseerde structuur-activiteit-relatie analyses bleek dat de γ-core samen met de flankerende 
regio’s belangrijk is voor de antibiofilm-activiteit tegen C. albicans. Dit is de eerste keer dat 
antibiofilm-activiteit van plantdefensinen wordt gerapporteerd. Daarnaast werd onderzocht of 
AtPDF2.3 een inhibitor is van bepaalde ionenkanalen, aangezien uit in silico analyse bleek dat de 
aminozuursequentie van AtPDF2.3 een gedeeltelijke toxinesignatuur draagt. Deze toxinesignatuur 
werd reeds toegekend aan schorpioentoxines die werkzaam zijn op ionenkanalen. 
Elektrofysiologische metingen gaven aan dat AtPDF2.3 kaliumkanalen kan blokkeren op een 
gelijkaardige manier als werd beschreven voor schorpioentoxines. In S. cerevisiae lijkt de antifungale 
activiteit van AtPDF2.3 een tolerantiemechanisme te activeren waarbij kaliumtransport en –
homeostase een rol spelen. Zo werd er een link gevonden tussen de antifungale activiteit, met 
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betrokkenheid van kaliumtransport en –homeostase enerzijds, en inhiberende activiteit op 
kaliumkanalen anderzijds. 
Het tweede doel van dit onderzoek was het verder ontrafelen van het werkingsmechanisme van 
amfotericine B, om zo beter te kunnen begrijpen hoe dit antimycoticum celdood induceert. Van 
amfotericine B is reeds geweten dat het interageert met ergosterol in het schimmelmembraan, wat 
uiteindelijk leidt tot celdood. Echter, informatie over amfotericine B-geïnduceerde gebeurtenissen die 
leiden tot celdood, is schaars. Verschillende studies hebben reeds aangetoond dat het analyseren 
van heterogeniteit in celpopulaties, en meer specifiek de dynamische responsen, naar verschillende 
stimuli, belangrijk is. Dit gaf ons de aanleiding om ook de amfotericine B-geïnduceerde 
gebeurtenissen te onderzoeken met spatiotemporele resolutie. Hiertoe werd een nieuw digitaal 
‘microfluidics’ (DMF)-platform voor ‘single cell’-analyse van S. cerevisiae ontwikkeld en 
geïmplementeerd. Dit platform laat toe om individuele S. cerevisiae cellen te analyseren met 
spatiotemporele resolutie. Zulke resolutie is niet haalbaar met de standaard technieken gebruikt in 
‘bulk’ analyses.  
In eerste instantie werd een ‘proof-of-concept’ uitgewerkt, waarin membraan-permeabilisatie van 
gistcellen tijdens amfotericine B-behandeling werd onderzocht. Het toestel werd gevalideerd door de 
resultaten behaald op het DMF-platform te vergelijken met deze behaald via flowcytometrische 
analyses in ‘bulk’. Gelijkaardige resultaten werden behaald in beide setups, waardoor het DMF-
platform geschikt werd bevonden voor ‘single cell’-analyse van gistcellen tijdens antifungale 
behandeling. Daarna werd de functie van superoxide- en stifstofoxide-radicalen in de fungicide 
werking van amfotericine B onderzocht. Superoxide-radicalen zijn belangrijk in de fungicide werking 
van amfotericine B, in tegenstelling tot stikstofoxide-radicalen die een rol lijken te spelen in 
tolerantiemechanismen aan dit antimycoticum. Een gedetailleerde studie van de kinetiek waarmee 
superoxide-radicalen en membraan-permeabilisatie voorkomen gaf aan dat inhibitie van de productie 
van stikstofoxide-radicalen resulteert in zowel verhoogde als versnelde productie van superoxide-
radicalen, membraan-permeabilisatie en verlies van reproductiecapaciteit in gist. 
We concluderen dat de resultaten behaald in dit doctoraal onderzoek bijdragen tot een betere kennis 
van de werkingsmechanismen van en tolerantiemechanismen aan HsAFP1, RsAFP2, AtPDF2.3 en 
amfotericine B. Dit is de eerste keer dat antibiofilm activiteit van plantdefensinen wordt 
gerapporteerd, waardoor de kennis omtrent de biologische activiteiten van plantdefensinen wordt 
verbreed. Daarnaast beschrijft deze thesis plantdefensinen als mogelijke ‘lead’ voor de ontwikkeling 
van nieuwe antifungale geneesmiddelen om schimmelinfecties tegen te gaan, op basis van hun 
antifungale en/of antibiofilm-activiteit. Verder toont deze thesis aan dat het DMF-platform besproken 
in dit werk kan worden gebruikt om de werkingsmechanismen van componenten te identificeren en 
mogelijke synergistische interacties tussen componenten te karakteriseren. 
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List of abbreviations 
●OH  hydroxyl radical 
αKTxs  scorpion toxins active on potassium channels 
ACN  acetonitrile 
AmB  amphotericin B 
AMB  amphotericin B 
AMPs  antimicrobial peptides 
BEC-2  Biofilm Eradication Concentration-2 
BEC50  Biofilm Eradicating Concentration 50 
BIC-2  Biofilm Inhibition Concentration-2 
BIC50  Biofilm Inhibitory Concentration 50 
BMGY  buffered complex glycerol medium 
BMMY  buffered complex methanol medium 
CAS  caspofungin 
CFU  Colony Forming Units 
CPZ/SAM cefoperazone-sulbactam 
CSαβ  cysteine-stabilized αβ-motif 
CTB  CellTiter-Blue 
DAF-FM DA 4-Amino-5-Methylamino-2’ 7’-difluorofluorescein Diacetate 
DDS  2,2-dimethyl-2-silapentane-5-sulfonate 
DEP  dielectrophoresis 
DHE  dihydroethidium 
DMF  digital microfluidic 
DMSO  dimethylsulphoxide 
ECOSY  exclusive correlation spectroscopy 
EK  potassium equilibrium potential 
EWOD  electrowetting-on-dielectric 
EPL  expressed protein ligation 
FACS  fluorescence-activated cell sorting 
FICI  Fractional Inhibitory Concentration Index 
FTIR  Fourier transform infrared spectroscopy 
GIPC  glycoinositolphosphorylceramide 
GlcCer  glucosylceramide 
GSLs  glycosphingolipids 
HOG  high-osmolarity glycerol 
HSQC  heteronuclear single-quantum coherence 
IC  inhibitory concentration 
IFIs  invasive fungal infections 
IPC  inositolphosphorylceramide 
IPL  intein-mediated protein ligation 
ISI  invasieve schimmelinfecties 
VIII 
 
IV  current-voltage 
L-NAME N-Nitro-L-arginine methyl ester hydrochloride 
MALDI-MS matrix-assisted laser desorption/ionization mass spectrometry 
MEM  Minimal Essential Medium 
MIC-2  Minimum Inhibitory Concentration-2 
MIPC  mannosylinositolphosphorylceramide 
M(IP)2C mannosyldiinositolphosphorylceramide 
MMH  minimal medium supplemented with HEPES 
NCL  native chemical ligation 
NMR  nuclear magnetic resonance 
NO●  nitric oxide radical 
NOESY  nuclear Overhauser effect spectroscopy 
O2●-  superoxide radical 
OD490nm  optical density 490 nm 
OD600nm  optical density 600 nm 
ONOO‾  peroxynitrite  
PA  phosphatidic acid 
PBS  phosphate-buffered saline 
PC  phosphatidylcholine 
PDB  potato dextrose broth 
PI  propidium iodide 
PIP/TAZ piperacillin-tazobactam 
PTH  potato defensin-1 
QSOX  Quiescin Sulfhydryl Oxidase 
ROS  reactive oxygen species 
RNS  reactive nitrogen species 
RPMI  Roswell Park Memorial Institute-1640 medium 
SAR  structure-activity relationship 
SCA  single cell analysis 
SEM  standard error of the mean 
SEM  scanning electron microscopy 
SN1  snakin-1 
SPPS  solid phase peptide synthesis 
YEPD  yeast extract, peptone, glucose 
YPD  yeast extract, peptone, glucose 
WT  wild type 
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1.1. Outline 
The incidence of fungal infections, including invasive fungal infections (IFIs) such as candidemia and 
invasive aspergillosis, is increasing worldwide. Especially patients hospitalised in the intensive care 
unit and patients suffering from cancer, organ transplant, HIV/AIDS and respiratory disorders are 
targeted by fungal diseases (1-8). IFIs are associated with high morbidity and mortality rates. For 
instance, during 2001-2010, 35.876 IFIs cases were reported in France, including invasive 
candidemia (43.4%), Pneumocystis jirovecii pneumonia (26.1%) and invasive aspergillosis (23.9%). 
The overall mortality rate was found to be 27.6%, and increased over that period by 2.9% per year 
(6).  
IFIs are mainly caused by Candida spp., and although C. albicans has been considered the most 
frequently isolated pathogen in IFI for years, non-albicans Candida spp. are increasingly associated 
with candidemia (9-12). Candida spp. are frequently associated with medical device-related 
infections, as they can form biofilms on the surface of for instance catheters and orthopaedic 
implants (13, 14). These biofilms are more resistant to antimicrobial therapy than planktonic cells (15) 
and only few antifungal agents are effective against fungal biofilms. These agents include 
miconazole, caspofungin, anidulafungin and liposomal formulations of amphotericin B (AmB) (16-18). 
In addition to resistance occurrence towards these antifungals, other disadvantages of these agents 
might include high toxicity, poor solubility and limited or inconvenient dosage forms (19, 20). Hence, 
there is a need for identification and characterization of novel antifungal agents to combat fungal 
infections.  
In view of the latter, antimicrobial peptides (AMPs), such as plant defensins, are of great interest. 
Many AMPs are characterized by bactericidal and/or fungicidal activity. In addition, their multiple 
modes of action reduce the ability of microorganisms to develop resistance (21, 22). Plant defensins 
are a specific group of AMPs, that are characterized by a typical cysteine-stabilized αβ motif. These 
peptides interact with specific fungal membrane compounds and are therefore regarded as nontoxic 
to human cells. Moreover, plant defensins are reported to induce the production of reactive oxygen 
species and apoptosis in C. albicans, Saccharomyces cerevisiae and/or other fungi. In addition to the 
identification and characterization of potential novel antifungal compounds, one should also focus on 
further unravelling the mechanisms of action of known antifungal drugs, such as amphotericin B. 
Amphotericin B interacts with ergosterol in the fungal membrane and induces fungal cell death. 
However, little information is available with respect to amphotericin B-induced events leading to 
fungal cell death. In addition, several reports already highlighted the importance of analysing cellular 
heterogeneity with respect to dynamic cell responses towards various stimuli (the reader is referred 
to Chapter 8 for more details). This hinted us to also analyse the cellular responses towards 
amphotericin B treatment with spatiotemporal resolution. 
The aim of my PhD research was to further elucidate the mechanisms of action of three antifungal 
plant defensins, i.e. HsAFP1, RsAFP2 and AtPDF2.3, and amphotericin B using C. albicans and S. 
cerevisiae as models. Knowledge on the mode of action of these antifungal agents and elucidation of 
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the tolerance mechanisms, possibly utilized by fungal pathogens to resist their action, will improve 
our understanding on how to effectively kill these pathogens. 
This PhD manuscript is a compilation of four peer-reviewed articles and two articles in preparation. 
Chapter 1 outlines the PhD research in a broader context thereby linking all chapters. Chapter 2 
provides a thorough introduction on the diverse mechanisms of antifungal action of plant defensins 
and gives insight into their synthetic or recombinant production (23). Subsequent chapters describe 
the obtained results in context of newly discovered biological activities of plant defensins (Chapter 3-
5) and implementation of a novel microfluidic tool for single cell analysis (SCA) of yeast cells to 
investigate compounds’ mechanisms of action (Chapter 6-7). More specifically, in Chapter 3 we 
investigated the potential antibiofilm activity of the coral bell defensin HsAFP1 and analyzed its ability 
to act synergistically with the conventional antifungals AmB and caspofungin against C. albicans 
biofilms. In addition, we gained insight into the active site of HsAFP1 for both its antibiofilm activity 
and its potential to act synergistically with caspofungin, by performing structure-activity relationship 
studies (24). Similarly, in Chapter 4 we investigated the antibiofilm and synergistic activity properties 
of the radish defensin RsAFP2 against C. albicans. In Chapter 5, we analyzed the potential of the 
Arabidopsis thaliana defensin AtPDF2.3 to block sodium and potassium channels, based on its 
sequence similarities with potassium channel-inhibiting scorpion toxins. Moreover, we identified the 
fungal membrane target of AtPDF2.3.  
In a second part of this thesis, we focused on the development and implementation of a novel digital 
microfluidic (DMF) platform for SCA of S. cerevisiae with spatiotemporal resolution, which is not 
possible with bulk methods. In Chapter 6, we designed a proof of concept for capturing individual 
yeast cells in a microwell array and subsequently monitored the cell responses with respect to 
membrane permeabilization during AmB treatment (25). In Chapter 7, we further demonstrated the 
use of this DMF platform in elucidating the mechanism of action of bioactive compounds and 
characterizing synergistic interactions between such two compounds. In view of the latter, we 
assessed the kinetics of superoxide radical production and membrane permeabilization during AmB 
treatment while inhibiting nitric oxide radical production by L-NAME.  
Finally, in Chapter 8, general conclusions and perspectives are presented, in which future 
advancements for marketing plant defensins as novel therapeutics are described. In addition, we 
elaborate on upgrading the DMF platform by implementing for instance single cell proteomics and 
metabolomics on-chip. 
 
  
Outline 
4 
1.2. References 
1. Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H, et al. Estimated burden of 
fungal infections in Germany. Mycoses. 2015;5:22-8. 
2. Osmanov A, Denning DW. Burden of serious fungal infections in Ukraine. Mycoses. 
2015;5:94-100. 
3. Badiane AS, Ndiaye D, Denning DW. Burden of fungal infections in Senegal. Mycoses. 
2015;5:63-9. 
4. Corzo-Leon DE, Armstrong-James D, Denning DW. Burden of serious fungal infections in 
Mexico. Mycoses. 2015;5:34-44. 
5. Sinko J, Sulyok M, Denning DW. Burden of serious fungal diseases in Hungary. Mycoses. 
2015;5:29-33. 
6. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Population-based 
analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 
2014;20(7):1149-55. 
7. Mortensen KL, Denning DW, Arendrup MC. The burden of fungal disease in Denmark. 
Mycoses. 2015;5:15-21. 
8. Chrdle A, Mallatova N, Vasakova M, Haber J, Denning DW. Burden of serious fungal 
infections in the Czech Republic. Mycoses. 2015;5:6-14. 
9. Oren I, Paul M. Up to date epidemiology, diagnosis and management of invasive fungal 
infections2014. 
10. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, et al. Declining 
incidence of candidemia and the shifting epidemiology of Candida resistance in two US 
metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 
2015;10(3). 
11. Mittal S, Goel S, Chaudhary U. "Changing trends of Candidemia and antifungal susceptibility 
pattern in a tertiary health care centre:". Infect Disord Drug Targets. 2015;28:28. 
12. Aguilar G, Delgado C, Corrales I, Izquierdo A, Gracia E, Moreno T, et al. Epidemiology of 
invasive candidiasis in a surgical intensive care unit: an observational study. BMC Res 
Notes. 2015;8(491):015-1458. 
13. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 
2004;17(2):255-67. Epub 2004/04/16. 
14. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003;11(1):30-6. 
15. Donlan RM. Role of biofilms in antimicrobial resistance. Asaio J. 2000;46(6):S47-52. 
16. Delattin N, Cammue BPA, Thevissen K. Reactive oxygen species-inducing antifungal agents 
and their activity against fungal biofilms. Future Medicinal Chemistry. 2014;6(1):77-90. 
17. Desai JV, Mitchell AP, Andes DR. Fungal biofilms, drug resistance, and recurrent infection. 
Cold Spring Harb Perspect Med. 2014;4(10). Epub 2014/10/03. 
18. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol. 
2012;2012(10):528521. Epub 2012/04/21. 
19. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol. 
2002;19(3):139-43. 
Chapter 1 
5 
20. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of 
Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. 
Antimicrobial agents and chemotherapy. 2002;46(6):1773-80. 
21. Laverty G, Gorman SP, Gilmore BF. The Potential of Antimicrobial Peptides as Biocides. 
International journal of molecular sciences. 2011;12(10):6566. 
22. Giuliani A, Pirri G, Nicoletto S. Antimicrobial peptides: an overview of a promising class of 
therapeutics. Open Life Sciences2007. p. 1. 
23. Vriens K, Cammue BP, Thevissen K. Antifungal Plant Defensins: Mechanisms of Action and 
Production. Molecules. 2014;19(8):12280-303. Epub 2014/08/26. 
24. Vriens K, Cools TL, Harvey PJ, Craik DJ, Spincemaille P, Cassiman D, et al. Synergistic 
Activity of the Plant Defensin HsAFP1 and Caspofungin against Candida albicans Biofilms 
and Planktonic Cultures. PLoS One. 2015;10(8):e0132701. Epub 2015/08/08. 
25. Kumar PT, Vriens K, Cornaglia M, Gijs M, Kokalj T, Thevissen K, et al. Digital microfluidics 
for time-resolved cytotoxicity studies on single non-adherent yeast cells. Lab Chip. 
2015;15(8):1852-60. Epub 2015/02/25. 
 
6 
 
  
 
  
 
 
 
 
 
 
Chapter 2 
 
Antifungal plant defensins: mechanisms of action and 
production1 
 
                                                        
1
 This chapter is published as: 
Vriens, K., Cammue, B.P.A. and Thevissen, K. (2014). Antifungal plant defensins: 
mechanisms of action and production. Molecules 19 (8): 12280-303 
Mechanism of action and production of antifungal plant defensins 
 
8 
 
Contributions of individual authors to the manuscript ‘Antifungal plant defensins: 
mechanisms of action and production’. 
KV wrote the manuscript. BPAC and KT critically read and approved the manuscript. 
  
Chapter 2  
 
 
9
Antifungal plant defensins: mechanisms of action  
and production 
Kim Vriens 1, Bruno P.A. Cammue 1,2,* and Karin Thevissen 1 
1 Centre of Microbial and Plant Genetics, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, 
Heverlee 3001, Belgium 
2 Department of Plant Systems Biology, VIB, Technologiepark 927, Ghent 9052, Belgium 
 
*Author to whom correspondence should be addressed; E-Mail: bruno.cammue@biw.vib-
kuleuven.be; Tel.: +32-1632-9682; Fax: +32-1632-1966. 
 
Abstract 
Plant defensins are small, cysteine-rich peptides that possess biological activity towards a broad 
range of organisms. Their activity is primarily directed against fungi, but bactericidal and insecticidal 
actions have also been reported. The mode of action of various antifungal plant defensins has been 
studied extensively during the last decades and several of their fungal targets have been identified to 
date. This review summarizes the mechanism of action of well-characterized antifungal plant 
defensins, including RsAFP2, MsDef1, MtDef4, NaD1 and Psd1, and points out the variety by which 
antifungal plant defensins affect microbial cell viability. Furthermore, this review summarizes 
production routes for plant defensins, either via heterologous expression or chemical synthesis. As 
plant defensins are generally considered non-toxic for plant and mammalian cells, they are regarded 
as attractive candidates for further development into novel antimicrobial agents. 
Keywords: mechanism of action; antimicrobial peptide; plant defensin; RsAFP2; NaD1; 
MsDef1; MtDef4; Psd1; heterologous protein expression; chemical protein synthesis 
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2.1. Introduction 
Like all living organisms, plants are repeatedly confronted with attacks by for instance insects, fungi 
and bacteria. In order to cope with these pests and pathogens, plants have developed a number of 
defence mechanisms, including the production of antimicrobial peptides (AMPs). Expression of these 
AMPs can be constitutive in e.g., storage organs and reproductive tissues or can be induced 
systemically as well as locally, in e.g., leaves, during microbial invasion or injury [1-3]. Plant AMPs 
are small cationic peptides that exert biological activity against a broad range of organisms. Their 
activity is primarily directed against fungi, but bactericidal and insecticidal actions are also reported. 
These defence-related peptides have a compact structure that is stabilized by intramolecular 
disulphide bridges, enhancing structural and thermodynamic stability [2]. Based on their tertiary 
structure, they are subdivided into distinct classes, being thionins, defensins, knottins, lipid transfer 
proteins, heveins, snakins and cyclotides (reviewed in [2, 4-7]). As the scope of this review is focused 
on plant defensins, the other classes of AMPs will not be discussed. For more detailed information on 
antifungal AMPs, the reader is referred to [8-10]. 
2.2. Plant defensins 
Plant defensins are present in all plant families, including the Brassicaceae, Fabaceae and 
Solanaceae. These peptides were primarily found in the seeds, but leaves and flowers are also 
common sources [11-16]. They are either constitutively expressed in storage and reproductive 
organs or produced upon pathogenic attack or injury as part of a systemic defence response [2]. In 
addition, production of plant defensins is also induced in response to environmental stress, such as  
drought [17, 18], and signalling molecules, including methyl jasmonate, ethylene and salicylic acid [19, 
20]. 
2.2.1. Structure 
Plant defensins are small, cationic peptides with a length of approximately 45–54 amino acids. Their 
structure typically comprises a cysteine-stabilized αβ-motif (CSαβ) with a prominent α-helix and a 
triple-stranded antiparallel β-sheet that is stabilized by four disulphide bridges [21-23]. A subclass  
of the plant defensin family comprises defensins with 10 cysteine residues, resulting in a total  
of five disulphide bonds. The fifth disulphide bond seems to reinforce a conserved hydrogen bond 
and is likely to confer additional thermodynamic stability of the defensin, as compared to other 
defensins, by replacing non-covalent hydrophobic interactions or hydrogen bonds with a covalent 
bond [24]. To our knowledge, this extra pair of cysteines has only been reported for PhD1 and PhD2, 
both floral defensins isolated from Petunia hybrida [16, 24]. 
According to the structure of their precursor protein, plant defensins can be subdivided into two 
groups. A first group comprises defensins in which the precursor is composed of a signal sequence 
and a mature defensin domain. The signal sequence targets the protein to the endoplasmic 
reticulum, where it is folded and subsequently enters the secretory pathway. In a second and less 
common group, the precursor protein contains an additional C-terminal prodomain that is 
proteolytically removed during or after transit through the secretory pathway [16, 25]. This type of 
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defensins have been identified in solanaceous plants, such as Nicotiana alata and Petunia hybrida 
[16]. Recently, Lay and co-workers assigned a cytoprotective and subcellular targeting function to 
this prodomain [26]. 
2.2.2. Biological activity 
Plant defensins possess a variety of biological activities (reviewed in [27-29]). They have been 
reported to inhibit protein synthesis, enzyme activity and ion channel function. Some plant defensins 
even exhibit antiproliferative activity towards cancer cells or proved effective against HIV reverse 
transcriptase. To date, only a few plant defensins are shown to inhibit the growth of bacteria, 
whereas their antifungal activity has been studied extensively [27, 28]. It has become clear that, 
although a similar activity might be observed for several defensins, their mode of action can be 
extremely  
diverse with regard to target molecules and (sub)cellular localization [30]. In order to illustrate this 
variety, this review will focus on the mode of antifungal action of plant defensins isolated from 
Raphanus sativus (RsAFP2), Pisum sativum (Psd1), Medicago spp. (MsDef1 and MtDef4) and 
Nicotiana alata (NaD1). 
2.3. Mode of action of plant defensins 
Extensive research during the past decades has allowed us to identify a number of key features by 
which plant defensins exert their antimicrobial activity. It has been demonstrated that defensins can 
specifically interact with host membrane compounds, such as bacterial lipid II receptors (reviewed  
in [31]), fungal sphingolipids (reviewed in [31]) and fungal phospholipids [32]. Fungal sphingolipids 
are classified into two groups, i.e., phosphosphingolipids and glycosphingolipids (GSLs). The most 
common GSL is glucosylceramide (GlcCer), which is synthesized by glucosylceramide synthase, 
encoded by the GCS gene, and glycoinositolphosphorylceramide (GIPC) [33, 34]. The latter can be 
further subdivided into inositolphosphorylceramide (IPC), mannosyl-IPC (MIPC) and mannosyldi-IPC 
(M(IP)2C), which are formed by sequential addition of inositolphosphate and mannose. The final step 
in this reaction, i.e., converting MIPC to M(IP)2C, requires inositolphosphate transferase, encoded by 
the IPT1 gene (reviewed in [35]). Different plant defensins have been shown to interact with different 
classes of sphingolipids: the plant defensin RsAFP2 from radish [11] interacts with GlcCer [36], 
whereas the plant defensin DmAMP1 from dahlia [37] interacts with M(IP)2C [38, 39]. In contrast, the 
plant defensins NaD1 from tobacco was recently shown to interact with a variety of phospholipids, 
including phosphatidylinositol mono-/bis-/tri-phosphates, phosphatidylserine and phospatidic acid, 
but not with sphingolipids [32]. In case of plant defensins that interact with sphingolipids, it was found 
that the presence of specific sphingolipids was essential mediating cell death of fungi and yeast, 
since yeast mutants deficient in genes involved in sphingolipid biosynthesis were resistant towards 
these peptides. For instance, S. cerevisiae strains with a non-functional IPT1 allele, and thus lacking 
M(IP)2C in their membranes, were found highly resistant towards DmAMP1 as compared to the wild 
type (WT) [38]. In line, deletion of the GSC gene resulted in an increased resistance towards 
RsAFP2 for Pichia pastoris and Candida albicans knockout strains as compared to the 
corresponding  
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WTs [36]. Similar observations were made for MsDef1 and a Δgcs Fusarium graminearum strain 
[40]. Furthermore, Neurospora crassa mutants displaying structurally different GlcCer, novel 
glycosphingolipids and an altered level of steryl glucosides in their membranes were found more 
resistant towards RsAFP2, DmAMP1 and HsAFP1 when compared to the WT, suggesting that the 
specific structure of sphingolipids in the fungal membrane is crucial for sensitivity towards plant 
defensins [41]. In addition, interaction of Sd5 and Psd1 with respectively fungal GlcCer- [42] and 
phosphatidylcholine- (PC) [43] containing vesicles further highlights the importance of fungal 
sphingolipids as interaction sites for plant defensins. 
Upon interaction with their target, plant defensins are either internalized by the fungal cell and 
interact with intracellular targets, or they stay at the cell surface and induce cell death through 
induction of a signalling cascade. While the latter has been reported for RsAFP2 [44], cellular uptake 
was observed for NaD1 [45, 46], MtDef4 [47] and Psd1 [48]. Recently, Sagaram and colleagues 
identified a RGFRRR motif in the MtDef4 sequence that is thought to be a translocation signal 
required for fungal cell entry, since replacement of this motif with AAAARR or RGFRAA abolished the 
ability of the peptide to enter the cell [47]. However, this sequence is, to our knowledge, not present 
in other plant defensins that enter the fungal cell. This suggests multiple mechanisms by which 
defensins are internalized by the cell. Proposed mechanisms include receptor-mediated 
internalization, membrane translocation (i.e., transient membrane permeabilization and lipid-assisted 
pore formation) and membrane permeabilization (reviewed in [49]). Membrane permeabilization has 
been described for plant defensins, however, it is suggested to be a secondary effect rather than the 
key to microbial killing, since it only occurs at concentrations well above the concentration required 
for growth inhibition [50]. Alternatively, ROS production and hence oxidative stress, most often play a 
role in defensin-mediated cell death, as has been reported for many plant defensins including 
RsAFP2 [51], HsAFP1 [52], DmAMP1 [53] and NaD1 [45]. 
Another common feature of plant defensins is the loss of their antifungal activity by an increase in 
ionic strength of the growth medium. Especially divalent cations, such as Ca2+ and Mg2+, seem to 
play an important role in this phenomenon [11, 13, 15, 37, 54]. Since the antagonistic effect strongly 
depends on the test fungus and type of the defensin, it is suggested that electrostatic interactions 
alter the target site on the fungal membrane, and hence reduce the affinity of the defensin to bind the 
membrane, rather than altering the conformation of the defensin itself [55]. However, Oard and Karki 
proposed another mechanism for inhibition of antimicrobial activity by cations which is in contrast 
with this interpretation. They found that the structure of β-purothionin, a thionin purified from wheat, is 
altered by the presence of K+ and Mg2+, making the peptide more rigid and impairing interaction with 
its target. Structural changes in this case include elongation of α1-helix, unfolding of α2-helix and an 
overall change in loop conformation [56]. Inhibition of antimicrobial activity by the presence of cations 
seems to be a common theme for AMPs in general, since it is also observed for thionins, insect 
defensins and mammalian defensins and is not solely associated with antifungal activity [56-60].  
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Table 1. Overview of the plant defensins discussed in this review. NA: not available. 
Defensin 
name 
Source 
UNIPROT 
accession number 
Protein Data Bank 
accession number 
Reference 
RsAFP1 Radish seeds P69241 1AYJ [11] 
RsAFP2 Radish seeds P30230 NA [11] 
MsDef1 Alfalfa seeds Q9FPM3 1H3R (theoretical model) [14] 
MtDef4 Barrel clover seeds G7L736 2LR3 [61] 
Psd1 Pea pods P81929 1JKZ [13] 
NaD1 Tobacco flowers Q8GTM0 1MR4 [62] 
 
In order to illustrate the variety of mechanisms of action by which plant defensins exhibit their 
antifungal activity, four case studies will be discussed in the next sections. The plant defensins 
discussed include RsAFP1 and RsAFP2 from radish [11], Psd1 from pea pods [13], MsDef1 from 
alfalfa [14] and MtDef4 from barrel clover [61], and NaD1 from tobacco [16] and are listed in Table 1. 
A multiple alignment of the amino acid sequences of these defensins is presented in Figure 1, in 
which the regions important for their antifungal activity are highlighted.  
 
 
Figure 1 Amino acid sequence alignment of RsAFP1, RsAFP2, MsDef1, MtDef4, Psd1 and NaD1. Multiple 
alignment was performed using the alignment tool from UniProt. Cysteine-pairing is shown at the top of the 
figure. Highly conserved residues are shown in grey; (-) denote gaps in the alignment. Arrows represent the 
position of the β-strands; the helix represents the position of the α-helix. Purple boxes indicate regions important 
for antifungal activity: boxes with dashed and full lines in the RsAFP1 sequence represent the first and second 
site in the tertiary structure, resp., important for antifungal activity [15, 47, 63]; blue boxes represent peptide 
fragments that exhibit antifungal activity similar to the parental peptide and hence, are important for antifungal 
activity [43, 47, 63, 64]. 
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A schematic overview of the proposed mechanism of action of the plant defensins discussed in this 
review is given in Figure 2. 
2.3.1. Plant defensins from radish: RsAFP1 and RsAFP2 
RsAFP1 and RsAFP2 are antifungal defensins found in the seeds of radish [11, 36, 65]. Regarding 
their antifungal activity, it was shown that RsAFP2 is more potent than RsAFP1 (2-30-fold dependent 
on the test fungus), although differences between the two peptides solely consist of two amino acid 
substitutions [11]. Analysis of the RsAFP2 primary structure showed two adjacent sites involved in 
antifungal action. 
These two regions might constitute two sites contacting a single receptor/interaction site or might 
indicate two binding sites that interact with two receptor/interaction sites [66]. The membrane target 
of RsAFP2 has been identified as fungal GlcCer [36] and since sphingolipids, such as GlcCers, are 
clustered with other membrane compounds to form lipid rafts [67], the hypothesis of RsAFP2-
interaction with multiple interaction sites is plausible. 
Interaction of RsAFP2 with its membrane target is essential, however not sufficient for antifungal 
activity, as [Y38G]RsAFP2, an RsAFP2 variant devoid of antifungal activity, is able to interact with 
GlcCer [36, 66]. Other RsAFP2-associated aspects leading to fungal cell death have been described. 
Ion fluxes take part in RsAFP2-induced cell death, since a rapid K+ efflux and Ca2+ influx was 
observed in RsAFP2-treated N. crassa hyphae [50]. Moreover, Ca2+ influx has been correlated with 
the antifungal potency of RsAFP2 [66], however, no blockage of L-type Ca2+ channels is observed 
[15]. In addition, production of ROS was shown in RsAFP2-treated C. albicans cells, suggesting a 
downstream signalling cascade of RsAFP2-binding to GlcCer [51]. In line with these findings, Aerts 
and colleagues demonstrated that RsAFP2 induces programmed cell death or apoptosis in C. 
albicans. Moreover, RsAFP2-induced apoptosis involves caspases, but not metacaspase Mca1 [68]. 
Cell wall stress has been associated with RsAFP2 activity as well. As GlcCers are also abundant in 
the cell wall (i.e., approx. 40% of GlcCer is located in the cell wall) [44], this is not surprising. RsAFP2 
activates the cell wall integrity pathway by increasing the level of dually phosphorylated Mkc1p [44], a 
MAP kinase in C. albicans associated with oxidative stress, changes in osmotic pressure, cell wall 
damage and a decrease in growth temperature [69]. In line, RsAFP2 was shown to activate MAP 
kinase signalling cascades in F. graminearum, without involvement of the Hog1 MAP kinase pathway 
[61]. Furthermore, RsAFP2 was found to induce accumulation of membrane phytoC24-ceramides, 
affect septin formation and localization and impair the yeast-to-hyphae transition in C. albicans [44].  
The exact binding site of RsAFP2 to GlcCer is still unknown, however, the region encompassing the 
β2-β3 loop is suggested to play a role in binding to the fungal membrane, as synthetic derivatives of 
this region, displayed in Figure 1, exhibited antifungal activity and binding to the membrane is 
essential to induce fungal cell death [64, 66, 70]. Furthermore, position 38 and 39 were shown critical 
for antifungal action, as amino acid substitutions at these positions significantly altered the potency of 
the peptide in vitro [66]. Interestingly, [Y38G]RsAFP2, which is devoid of antifungal activity, is still 
able to interact with its membrane target, and hence, target binding and antifungal activity seem not 
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controlled by the same peptide region [36]. Noteworthy is the fact that loop regions have been 
demonstrated to be important for antifungal activity in other plant defensins as well, including Psd1, 
MsDef1 and MtDef4 [15, 43, 63]. 
In conclusion, the mode of action of RsAFP2 is suggested to involve (i) recognition of and binding 
with GlcCer in the fungal membrane and cell wall; (ii) activation of the CWI pathway and MAP kinase 
signalling pathways, excluding the Hog1 MAP kinase pathway; (iii) production of ROS; (iv) induction 
of ion fluxes; (v) activation of caspases, but not metacaspase; (vi) induction of cell wall stress;  
(vii) accumulation of membrane phytoC24-ceramides; (viii) abnormal septin formation and localization; 
(ix) impairment of the yeast-to-hyphae transition and (x) fungal cell death. In which order step (ii) to 
(ix) take place, has yet to be elucidated. A schematic overview of the proposed mechanism of action 
of RsAFP2 can be found in Figure 2A. 
Figure 2 Schematic overview of the proposed mechanisms of action of the plant defensins discussed in this 
review. (A) RsAFP1 and RsAFP2; (B) Psd1; (C) MsDef1; (D) MtDef4; (E) NaD1. For detailed information on the 
Roman numerals displayed in the figures, the reader is referred to Section 3.1 (A), 3.2 (B), 3.3 (C), 3.4 (D) and 
3.5 (E) of this review. 
2.3.2. Plant defensin from Pea: Psd1 
Psd1 is an antifungal defensin isolated from pea seeds [13]. Almeida and colleagues estimated other 
biological activities of Psd1 based on in silico analysis of the surface topology using various  
well-characterized defensins and toxins. Although no correlation could be demonstrated between 
antifungal or antibacterial activity and the surface electrostatic potential of the considered peptides, 
the study showed a clear correlation between K+ channel inhibitory activity and peptide surface 
topology. Since Psd1 shows a surface topology similar to that of peptides and toxins belonging to the 
latter group, it is therefore implied to act as a K+ channel inhibitor [71].  
The fungal membrane target of Psd1 has not yet been identified, but is suggested to be GlcCer 
and/or ergosterol [43, 72]. Analysis of the Psd1 lipid selectivity by fluorescence spectroscopy 
revealed that the peptide is likely to be adsorbed on or slightly inserted into the fungal membrane 
during initial interaction. Furthermore, this study showed that Psd1 does not interact with membranes 
containing GlcCer derived from soybean, nor with cholesterol-enriched lipid bilayers, such as 
mammalian cell membranes, which highlights its therapeutic potential [72]. The exact binding site for 
membrane interaction is thought to be Psd1 Loop1, displayed in Figure 1, since the peptide 
corresponding to this region still interacts with GlcCer-containing vesicles. Moreover, this region was 
found to exhibit significant conformational changes upon binding with GlcCer, as compared to the 
conformational accommodation during nonspecific binding to phosphocholine. Hence, interaction of 
Psd1 with the fungal membrane is probably due to conformational selection [43]. 
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Upon membrane binding, Psd1 is internalized by the cell and interacts with nuclear proteins, as was 
shown via a GAL4-based yeast two-hybrid assay by Lobo and colleagues [48]. Cyclin F was 
identified as the main target of Psd1, which plays a key role in nuclear translocation of Cyclin B and 
cell cycle progression [48, 73-75]. In vivo studies with Psd1 on retinal neuroblasts showed that Psd1 
affects interkinetic nuclear migration and hence, impairs cell cycle progression [48]. 
Taken together, the mechanism of action of Psd1 is not yet completely understood, however, a 
proposed mode of action includes (i) adsorption on the fungal membrane surface; (ii) interaction with 
GlcCer and/or ergosterol in the fungal membrane; (iii) insertion of Psd1 into the fungal membrane;  
(iv) nuclear translocation and interaction with Cyclin F, resulting in cell cycle impairment and  
(v) fungal cell death. In which order step (iii) to (v) take place has yet to be identified. A schematic 
overview of the proposed mechanism of action of Psd1 is represented in Figure 2B. 
2.3.3. Plant defensins from Medicago spp.: MsDef1 and MtDef4 
MsDef1 and MtDef4 are antifungal defensins found in Medicago spp. [14, 61]. MsDef1 is suggested 
to display a similar mode of antifungal action as the virally encoded toxin KP4 from the fungus 
Ustilago maydis, since both peptides strongly block the mammalian L-type Ca2+ channel in a specific 
manner [15]. Interaction of toxins with K+ channels has been reported by Zhu and colleagues, who 
hypothesized that defensins with a Lys-Cys4-Xaa-Asn motif interact with K+ channels when the 
flexible loop of the peptide is deleted and hence, steric hindrance is reduced [76]. The same might 
hold true for other ion channels, such as Ca2+ channels. Similarities in modes of action between KP4 
and MsDef1 are further demonstrated by a more pronounced hyperbranching of fungal hyphae upon 
treatment with these peptides as compared to treatment with RsAFP2 [15]. Moreover, the antifungal 
activity of MsDef1 and KP4 is strongly abrogated by addition of exogenous Ca2+ and since addition of 
other metals (K+, Mg2+ and Na+) did not affect peptide activity, Ca2+ is suggested to be involved in 
MsDef1 mode of action [15]. Recently, Muñoz and colleagues confirmed that MsDef1, as well as 
MtDef4, disrupt Ca2+ signalling and/or homeostasis and that this phenomenon is not caused by direct 
membrane permeabilization [77]. 
GCS was found essential in MsDef1-mediated growth inhibition, which implies the involvement of 
GlcCer as a fungal membrane target [40]. This is in line with recent findings by Muñoz and 
colleagues who concluded that MsDef1-sensitivity is mediated by GlcCer in filamentous fungi [77]. 
Molecular targets involved in MsDef1-tolerance include MAP kinase signalling cascades, with 
exception of the Hog1 MAP kinase pathway, and were similar to the observations made for RsAFP2. 
Immunoblot analysis revealed rapid activation of Gpmk1 and Mgv1 MAP kinases upon MsDef1 
treatment [61], which regulate processes related to cell wall integrity, sexual reproduction and 
pathogenicity [78, 79]. Interestingly, RsAFP2 activates the cell wall integrity pathway and exerts its 
antifungal activity from the extracellular space [44]. Since MsDef1 and RsAFP2 seem to activate the 
same MAP kinase signalling cascades [61], they are suggested to have a similar mode of action. 
Hence, MsDef1 is suggested to induce fungal cell death through activation of signalling cascades 
involving MAP kinases without entering the fungal cell. 
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In contrast to MsDef1 activity, GCS is not important for MtDef4-mediated fungal growth inhibition and 
MtDef4 activity seems independent of MAP kinase signalling cascades. Furthermore, MsDef1 
induces extensive hyperbranching of fungal hyphae, whereas MtDef4 does not, suggesting different 
mechanisms of action for MsDef1 and MtDef4 [61]. Both peptides were shown to induce membrane 
permeabilization, however, membrane permeabilization was significantly higher in hyphae treated 
with MtDef4 as compared to treatment with MsDef1, which is consistent with the in vitro antifungal 
potency of the peptides [63]. Sagaram and colleagues reported internalization of MtDef4 in the fungal 
cell and identified the RGFRRR motif in the MtDef4 sequence as a translocation signal that is 
required for fungal cell entry. In addition, MtDef4 was shown to interact with cytosolic phosphatidic 
acid (PA), dependent on the presence of the RGFRRR motif [47]. These results are consistent with 
previous findings that correlate the antifungal activity of MtDef4 with the presence of that motif [63]. 
Recently, Muñoz and colleagues reported that MsDef1 and MtDef4 affect conidial germination, 
conidial anastomosis tube fusion and conidial cell death in N. crassa in significantly different ways. 
High fungicidal concentrations of MtDef4 caused rapid and complete inhibition of germination, with 
cell death occurring rather fast, whereas treatment of conidia with high MsDef1 concentrations 
resulted in a delayed cell death and complete inhibition of germination was not reached. Moreover, it 
was shown that the RGFRRR motif in MtDef4 is not only important for cell entry and binding to PA, 
but it furthermore plays a role in inhibition of cell fusion [77]. 
As is the case for various plant defensins, structure-activity studies have been performed for MsDef1 
and MtDef4. Both the N-terminal and the C-terminal region of MsDef1, displayed in Figure 1, were 
found important for antifungal activity and, in line with the observations made for RsAFP2, position 38 
is critical for antifungal action [15, 66]. The MsDef1 and MtDef4 C-terminal domains are also 
suggested to play a role in Ca2+ homeostasis [77]. Furthermore, Spelbrink and colleagues 
demonstrated the importance of the loops for antifungal activity in the MsDef1 tertiary structure, 
which has been reported for Psd1, RsAFP2 and MtDef4 as well [15, 43, 63, 66, 70]. Structure-activity 
determinants of MtDef4 demonstrated the importance of the γ-core motif, composed of β2 and β3 
strands and the interposed loop, for antifungal activity. Here, cationic and hydrophobic residues are 
considered important for antifungal action, as the MtDef4 γ-core alone is able to inhibit fungal growth, 
whereas the γ-core of MsDef1 is not. Both F37 and R38 are critical for antifungal activity in MtDef4, 
since the hexapeptide RGFRRR present in the MtDef4 γ-core is capable of inducing growth inhibition 
and membrane permeabilization, while RGARRR and RGFARR are not [63]. In addition, replacement 
of RGFRRR with RGFRAA or AAAARR abolished the ability of the peptide to enter the fungal cell as 
well as to interact with intracellular PA, suggesting that both fungal cell entry and PA binding  
are mediated by the RGFRRR loop [47], again highlighting the importance of peptide loops for 
antifungal activity. 
In conclusion, MsDef1 and MtDef4 seem to have different mechanisms of antifungal action, however, 
their complete mode of action remains to be elucidated. The proposed mechanism of antifungal 
action for MsDef1 includes: (i) interaction with the fungal membrane, presumably GlcCer; (ii) 
activation of Gpmk1 and Mgv1 MAP kinase signalling cascades; (iii) (partial) inhibition of conidial 
germination; (iv) disruption of Ca2+ signalling and/or homeostasis and (v) delayed fungal cell death. 
In which order step (ii) to (v) take place has yet to be identified. The hypothesized mechanism of 
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action of MtDef4 comprises (i) recognition of the fungal membrane; (ii) translocation of the peptide to 
the cytosol via the RGFRRR motif; (iii) interaction with cytosolic PA and supposedly subsequent 
interference with PA signalling and/or biosynthesis; (iv) disruption of Ca2+ signalling and/or 
homeostasis; (v) inhibition of conidial germination; (vi) inhibition of cell fusion and (vii) rapid fungal 
cell death. In which order (ii) to (vii) take place remains to be elucidated. A schematic overview of the 
proposed mechanism of action of MsDef1 and MtDef4 is given in Figures 2C,D, respectively. 
2.3.4. Plant defensin from tobacco: NaD1 
NaD1 is a floral defensin from the tobacco plant and exhibits antifungal properties [16]. The 
membrane target of NaD1 was recently identified by Poon and colleagues as the phospholipid PIP2, 
which is present in eukaryotic cell membranes. It was shown that NaD1 forms 14-mer oligomers, 
mediated by PIP2, and that this oligomerization is important for membrane permeabilization and lysis 
of the fungal cell [32]. Upon interaction and permeabilization of the cell membrane, NaD1 enters 
fungal hyphae and is localized to the cytoplasm, where it causes granulation of the cytoplasm and 
induces ROS production [45]. NaD1 is implied to induce cell death via oxidative stress, as ROS and 
nitric oxide (NO) production was observed upon treatment of C. albicans cells [80]. These findings 
are consistent with results reported by Bleackley and colleagues, in which mitochondrial genes are 
implicated in NaD1 mode of action [81]. 
Recently, Hayes and colleagues reported the importance of the high-osmolarity glycerol (HOG) 
pathway in tolerance to NaD1, being the sole stress-responsive pathway involved in NaD1 action that 
was screened in this study [80]. Although the HOG pathway is mainly involved in protection against 
osmotic stress and osmotic stress does not contribute significantly to NaD1 mode of action [80], 
these findings are not surprising, since Hog1p is also known to participate in tolerance to oxidative  
stress [82]. Interestingly, the HOG pathway is excluded in the mode of action of MsDef1 and 
RsAFP2, whereas other MAP kinase signalling cascades play a key role in tolerance to these 
defensins [61]. These findings clearly suggest distinct modes of action of MsDef1 and RsAFP2 on 
the one hand, and NaD1 on the other. Another novel finding in the NaD1 mechanism of action is the 
identification of Agp2p as a regulator of the potency of the peptide [81]. Agp2p is a plasma 
membrane protein that regulates the transport of positively charged molecules. Upon NaD1 
treatment, cells lacking AGP2 show a delayed membrane permeabilization, reduced uptake of NaD1 
and are overall more resistant to NaD1 treatment compared to the WT. Deletion of AGP2 probably 
results in an accumulation of positive charges on the surface of the cell, thereby repelling cationic 
peptides from the surface [81].  
Taken together, the NaD1 mechanism of action includes (i) interaction with the fungal cell 
membrane; (ii) translocation to the cytoplasm; (iii) PIP2-mediated oligomerization of NaD1 (14-mer) 
(iv) membrane permeabilization; (v) possible interaction with intracellular targets; (vi) ROS and NO 
production, i.e., oxidative stress; (vii) activation of the HOG pathway; (viii) membrane disruption and 
(ix) fungal cell death. In which order (ii) to (ix) take place has yet to be identified. A schematic 
overview of the proposed mechanism of action of NaD1 is shown in Figure 2E. 
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2.4. Production of plant defensins 
Due to their selective toxicity towards microbial cells and their unique mode of action, plant defensins 
are attractive candidates for further development as novel antimicrobial agents. However, 
development of plant defensins for medicinal or biotech purposes requires large amounts of purified 
peptides. Extraction of plant defensins from natural sources is rather complicated due to their low 
abundance and the presence of a variety of other compounds in these plant parts. Chemical 
synthesis and heterologous production are therefore convenient alternatives to obtain large amounts 
of functional peptides. In addition, these approaches allow for the production of mutant peptides, 
which are interesting to include in structure-activity studies. In the following part, these techniques as 
well as their advantages and drawbacks are discussed. 
2.4.1. Chemical synthesis of proteins 
Synthesis of proteins by chemical means has recently gained interest, as it allows the generation of 
proteins that cannot be produced biologically, e.g., labelled peptides. Various strategies have been 
developed in which proteins can be synthesized, often consisting of combinations of solid-phase 
peptide synthesis (SPPS), native chemical ligation (NCL) and enzyme-catalyzed ligation (reviewed  
in [83-86]).  
In SPPS, a peptide is synthesized in a stepwise manner on a polymeric resin through sequential 
steps of coupling and deprotection of protected amino acids. Both Fmoc (9-fluorenylmethyl carbamate) 
and Boc (di-tert-butyl dicarbonate) strategies can be used in SPPS to protect the N-terminus of the 
amino acid being coupled and hence prevent polymerization or non-specific reactions (reviewed  
in [87-89]. SPPS plays a key role in peptide synthesis, however, studies have shown that following 
this method, only peptides containing less than 50 amino acids can be reliably prepared with 
acceptable yields and purity [83]. Hence, other strategies have to be implemented when synthesizing 
larger peptides and proteins. To this end, a strategy of peptide segment condensation is used in 
which unprotected peptide fragments, often produced by SPPS, are subjected to ligation methods 
such as NCL. Subsequent cycles of NCL results in the formation of a linear polypeptide chain [83, 
90, 91]. A major drawback of this technique is the mandatory use of an N-terminal cysteine residue, 
as cysteines are seldom conveniently distributed throughout a peptide sequence. Furthermore, the 
polypeptide is generated from the C-terminus towards the N-terminus and not vice versa [85]. 
Another approach to couple two peptides includes enzyme-assisted ligation, in which enzymes are 
used as catalysts to promote peptide bond formation. This approach complements chemical ligation 
strategies and has great significance since these enzymes are naturally involved in protein 
modifications in vivo and are rated nontoxic, whereas many chemicals employed in NCL are 
unfavourable for food applications of the peptides. Nonetheless, the use of enzymes in protein 
crosslinking is still in its infancy and further research is essential to improve enzyme-assisted peptide 
ligation (extensively reviewed in [84]).  
Proteins often require post-translational and conformational modifications in order to render biological 
activity. As post-translational modifications cannot be provided via chemical synthesis, a strategy 
termed expressed protein ligation (EPL) or intein-mediated protein ligation (IPL) is employed. 
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Following this method, semisynthetic peptides are created by fusion of recombinant peptide 
fragments to synthetic peptide fragments. Since post-translational modifications mainly occur at the 
termini of peptides, EPL is a plausible approach to obtain functional peptides [91, 92]. When a 
disulphide bond pattern is essential, (re-)folding of the protein is advised and oxidative folding is 
performed [93-96]. In a first attempt, oxidative folding is often employed in a direct manner, i.e. a 
one-step oxidative folding procedure, as it allows for a spontaneous fold in which the protein is 
energy-stable and assumed to acquire its native conformation. In addition, it is less expensive and 
time-consuming as compared to regioselective oxidative folding in which individual cysteine pairs are 
deprotected and oxidized sequentially to allow subsequent formation of disulphide bonds [97]. 
Functional peptides can be synthesized following SPPS and NCL methods, as was reported for 
conotoxins, snakins and defensins [94, 95, 97-99]. For instance, the insect defensin lucifensin, 
synthesized by Fmoc-SPPS and folded using a one-step oxidative folding technique, showed 
biological activity against Bacillus subtilis, Micrococcus luteus and Staphylococcus aureus with MIC-
values of 1.2 µM, 0.6 µM and 41 µM, resp., whereas linear unfolded lucifensin and lucifensin 
analogues folded by 1 out of 3 disulphide bridges were inactive (MIC > 100 µM) [99]. Furthermore, 
human β-defensin 4 (HBD4) and HBD4 analogues, synthesized using Fmoc-SPPS and folded 
employing a three-step oxidative folding procedure, showed antimicrobial activity against Escherichia 
coli, Pseudomonas aerigunosa, S. aureus and C. albicans. However, only the completely folded 
peptide showed a similar or a 2-fold decreased activity, depending on the test organism, as 
commercially available HBD4 [98]. Although it seems that plant defensins can be produced by 
chemical means, multidisulphide-containing peptides are not always successfully produced, as 
multiple isoforms are generated during folding [96]. In addition, chemical synthesis is rather 
expensive due to a high cost of reagents, and peptide aggregation and formation of by-products 
renders this method often unfavourable [100, 101]. These observations highlight the need for other 
systems to generate functional proteins, as will be discussed in the next section. 
2.4.2. Heterologous expression of proteins 
Heterologous expression of proteins is a widely used technique and different expression systems 
have been reported to date. The main host systems used for recombinant production of AMPs 
include Escherichia coli and Pichia pastoris (reviewed in [102]).  
2.4.2.1. Heterologous expression of proteins in E. coli 
Protein expression in E. coli is relatively simple and inexpensive and the variety of available 
plasmids, fusion partners and strains makes it often the preferred method for production of  
AMPs [103, 104]. However, major drawbacks have been reported using bacteria for effective AMP 
production as discussed below.  
First of all, the recombinant protein often needs to be fused to a carrier protein to neutralize its 
toxicity towards the host and to increase its solubility to avoid formation of inclusion bodies [105]. 
This fusion partner needs to be released during or after purification of the protein of interest via 
enzymatic or chemical cleavage to render functional proteins, which results in a decreased yield 
[102]. In addition, fusion proteins are not necessarily properly folded and production of these proteins 
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can result in so-called “soluble inclusion bodies” [105]. Recently, it was shown that co-expression of 
the human Quiescin Sulfhydryl Oxidase (QSOX), a chaperone with thiol/disulphide oxidase activity, 
in the cytoplasm of E. coli can counter protein misfolding and increase the yield of soluble cysteine-
rich proteins [106, 107]. Although such approach improves protein production in E. coli, other obstacles 
remain. 
Direct secretion mechanisms are not present in E. coli strains used for recombinant protein 
production, which complicates protein purification. Protein secretion can be obtained, however, by 
destabilization of the E. coli structural components or by using leaky strains that lack certain 
structural components or mutant strains in which secretion modules derived from pathogenic E. coli 
or other species are incorporated [103, 108-111].  
Finally, and most importantly, the protein of interest often requires complex folding, including the 
formation of multiple disulphide bonds and/or glycosylation. In both cases, an eukaryotic system is 
preferred [112]. In addition, Puertas and colleagues reported that the protein yield, when using E. coli 
as a host for recombinant production, is inversely proportional to the cysteine content of the protein 
[113]. This indicates the need for other expression systems when producing proteins with a high 
cysteine content, such as plant defensins. Yet, production of functional defensins in E. coli has been 
reported. For instance, using E. coli both the spruce defensin PgD5 and the Scots pine defensin 
PsDef1 were produced while displaying a high antifungal activity [114, 115]. In line, functional potato 
snakin-1 (SN1) and defensin-1 (PTH1) were generated using E. coli as a host [116].  
Nevertheless, peptides produced in eukaryotic systems are often more active, i.e., characterized by a 
lower MIC-value, as compared to peptides produced in prokaryotic systems. The latter is possibly 
due to structural defects or misfolding. For instance, Kant and co-workers found that the corn 
defensin PDC1 exhibited a 2-fold higher antifungal activity when produced in P. pastoris as 
compared to its production in E. coli. In addition, Fourier transform infrared spectroscopy (FTIR) 
revealed more  
β-sheets and less random structures when PDC1 was produced in P. pastoris [117]. Similar 
observations were made for other proteins. Both human adiponectin and alkaline phosphatase from 
archaea were found more active when produced in P. pastoris as compared to their counterparts in  
E. coli [118, 119]. Hence, these observations highlight the advantages of using P. pastoris for 
generation of functional and properly folded proteins.  
2.4.2.2. Heterologous expression of proteins in P. pastoris 
Yeasts are largely used for production of recombinant proteins due to their eukaryotic nature. Unlike 
bacteria, yeasts have the ability to implement many post-translation modifications, including 
disulphide bond formation, glycosylation and processing of signal sequences. These features make 
them attractive hosts for AMP production. Recently, the yeast P. pastoris has gained interest as a 
host for protein production for several reasons, as discussed below [120-126]. 
Firstly, P. pastoris displays a high growth rate and allows for high cell densities to be reached, 
resulting in a higher protein yield as compared to yields obtained with other eukaryotic systems 
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(reviewed in [102]). P. pastoris is of particular interest for large-scale productions of recombinant 
proteins, since the growth media are cheap, universal and well defined. Furthermore, when handling 
fermenter setups in which pH, aeration, feed rate, etc. are controlled, P. pastoris can easily grow to 
ultra-high cell densities, which in turn leads to an increased protein yield [127].  
Further enhancement of the protein yield can be obtained by using multicopy transformants during 
protein production (reviewed in [128]). Multiple copies of the plasmid are often incorporated in the 
Pichia genome through crossover events and are integrated in a head-to-tail manner at the same 
locus. When using proper plasmids such as pPICZ plasmids containing a ZeocinTM resistance gene, 
multicopy transformants are selected in a straightforward manner by modulating the antibiotic 
concentration and screening for an increased antibiotic resistance [129].  
Thirdly, protein production in P. pastoris can be initiated by exogenous addition of inducing agents 
(reviewed in [126]). Initiation of protein production at any given time point is an asset, since biomass 
generation, and hence protein yield, is not affected by the potential toxicity of the protein towards the 
host [127].  
Finally, proteins produced by P. pastoris are easily exported to the culture medium using signal 
sequences, such as the S. cerevisiae α-factor sequence, which facilitates downstream processing [122, 
126]. Other signal sequences that direct the protein of interest to the secretory pathway are reviewed 
by Ahmad and colleagues [126]. A minor drawback associated with the use of the α-factor secretion 
signal is the presence of protein isoforms in which additional amino acids are incorporated at the  
N-terminus of the protein due to incomplete processing of the STE13 protease [126, 130]. A non-
native N-terminus can influence the biological activity of the protein, as was reported for the pea 
defensin Psd1 [130, 131] and the shrimp AMP Ch-penaeidin [132], and is therefore inadmissible. 
Addition of an alanine or protease cleavage site at the N-terminus of the protein is recommended as 
it allows for successful cleavage of the signal sequence [126, 130, 133, 134].  
P. pastoris has been successfully used for the production of AMPs, including hPAB-β, a variant of 
human β-defensin, and shrimp Ch-penaeidin [132, 135]. Likewise, defensins from pea, tomato, 
mungbean, Mexican turnip, corn, tobacco, radish, alfalfa and barrel clover were successfully 
produced in P. pastoris [15, 40, 117, 130, 133, 136-138]. These observations highlight the ease of 
using P. pastoris for production of AMPs, and more specifically, plant defensins. 
2.5. Conclusions 
Plant defensins are interesting candidates for use in medicinal and biotech purposes and can be 
produced via heterologous expression in eukaryotic hosts. PDFs are generally considered non-toxic 
to plant and mammalian cells and have distinct modes of action, involving specific interactions with 
the cell surface [39]. They are therefore suggested to have great therapeutic potential, however, 
literature falls short on studies reporting the in vivo performance of PDFs in an animal model. To our 
knowledge, only RsAFP2 has been reported to show in vivo efficacy in a murine candidiasis model 
upon intravenous administration [65]. In addition, the mechanisms of action of various PDFs have not 
Mechanism of action and production of antifungal plant defensins 
24 
 
yet been identified or are not yet fully understood. Hence, further research is needed to demonstrate 
the therapeutic potential of PDFs and to elucidate their mechanisms of action. 
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Abstract 
Plant defensins are small, cysteine-rich peptides with antifungal activity against a broad range of 
yeast and fungi. In this study we investigated the antibiofilm activity of a plant defensin from coral 
bells (Heuchera sanguinea), i.e. HsAFP1. To this end, HsAFP1 was heterologously produced using 
Pichia pastoris as a host. The recombinant peptide rHsAFP1 showed a similar antifungal activity 
against the plant pathogen Fusarium culmorum as native HsAFP1 purified from seeds. NMR analysis 
revealed that rHsAFP1 consists of an α-helix and a triple-stranded antiparallel β-sheet stabilised by 
four intramolecular disulfide bonds. We found that rHsAFP1 can inhibit growth of the human 
pathogen Candida albicans as well as prevent C. albicans biofilm formation with a BIC50 (i.e. the 
minimum rHsAFP1 concentration required to inhibit biofilm formation by 50% as compared to control 
treatment) of 11.00 ± 1.70 µM. As such, this is the first report of a plant defensin exhibiting inhibitory 
activity against fungal biofilms. We further analysed the potential of rHsAFP1 to increase the activity 
of the conventional antimycotics caspofungin and amphotericin B towards C. albicans. Synergistic 
effects were observed between rHsAFP1 and these compounds against both planktonic C. albicans 
cells and biofilms. Most notably, concentrations of rHsAFP1 as low as 0.53 µM resulted in a 
synergistic activity with caspofungin against pre-grown C. albicans biofilms. rHsAFP1 was found non-
toxic towards human HepG2 cells up to 40 µM, thereby supporting the lack of a general cytotoxic 
activity as previously reported for HsAFP1. A structure-function study with 24-mer synthetic peptides  
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spanning the entire HsAFP1 sequence revealed the importance of the γ-core and its adjacent 
regions for HsAFP1 antibiofilm activity. These findings point towards broad applications of rHsAFP1 
and its derivatives in the field of antifungal and antibiofilm drug development. 
 
Key words: plant defensin, HsAFP1, proton NMR analysis, Candida albicans, fungal biofilm, 
recombinant protein production, structure-function relationship 
 
3.1. Introduction 
Plant defensins are small, basic, cysteine-rich peptides with a conserved structure known as a 
cysteine-stabilized αβ-motif [1-3]. Although the tertiary structure of some plant defensins [2,4-7] is 
known, the structure of many defensins is yet to be determined. Plant defensins exhibit antimicrobial 
activity against a wide range of microorganisms [8-10], whereas they are in general non-toxic to 
human cells [11-13]. To date, there has been a particular focus on their antifungal activity and 
several fungal targets have been identified, including membrane sphingolipids and phospholipids [14-
20]. Upon interaction with the fungal membrane, plant defensins are either internalized into the cell 
and interact with cytosolic or nuclear proteins, or they remain localized at the cell wall or membrane 
of the fungus [4,21-23]. The mechanisms by which plant defensins induce fungal cell death are 
diverse, but common aspects are observed. These include the production of reactive oxygen species 
(ROS) and the induction of apoptosis [24].  
Despite the fact that their mechanisms of antifungal action have been studied extensively, no reports 
exist about the activity of plant defensins against fungal biofilms. Biofilms are self-organised microbial 
communities embedded in a polymeric matrix that grow on a biotic or abiotic surface, such as 
catheters or other medical implants. Many fungal species are able to form biofilms, however, 
Candida spp. play a predominant role in mixed-species fungal biofilms [25-28]. Such biofilm cells are 
tolerant towards most conventional antimycotics and there are only few novel agents that can be 
used to treat biofilm-related infections. To date, only miconazole, caspofungin, anidulafungin and 
liposomal formulations of amphotericin B are used to effectively treat these infections [29-31], and 
hence, there is a need to identify novel antibiofilm compounds. 
In this study, we used the defensin from coral bells, HsAFP1, which was previously characterized by 
Osborn and colleagues [32], and assessed its potential antibiofilm activity. HsAFP1 inhibits the 
growth of various plant pathogenic fungi, including Botrytis cinerea, Verticillium albo-atrum and 
Fusarium culmorum, and causes swelling of germ tubes and hyphae in the latter [32]. In addition, it 
was reported that HsAFP1 shows antifungal activity against Saccharomyces cerevisiae and the 
human pathogen C. albicans, and induces apoptosis in the latter [33]. Furthermore, it was shown that 
HsAFP1 has a low in vitro frequency of resistance occurrence in planktonic C. albicans cultures (i.e. 
less than 1 in 2,000,000 mutants) [11]. In an attempt to unravel HsAFP1’s mode of antifungal activity, 
this defensin was tested against the complete S. cerevisiae deletion mutant library for identification of 
yeast mutants with altered HsAFP1 sensitivity [33]. In this study, 84 yeast genes were identified that 
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were found to be implicated in governing HsAFP1 tolerance or sensitivity of yeast [33]. Since 
HsAFP1 has a potent antifungal activity towards C. albicans, we further analysed its potential activity 
towards C. albicans biofilms. To this end, we heterologously expressed HsAFP1 using the yeast 
Pichia pastoris and determined the solution structure of recombinant (r) rHsAFP1 by NMR analysis. 
Subsequently, we tested the activity of the plant defensin alone and in combination with conventional 
antimycotics against C. albicans biofilms. In view of the latter, a multi-drug approach in which multiple 
compounds are administered and a synergistic effect is observed, can be effectively used to combat 
biofilm-related infections [34]. Finally, we conducted a structure-function study, using 24-mer 
synthetic peptides spanning the entire HsAFP1 region. The HsAFP1 derivatives were tested against 
C. albicans planktonic cultures and biofilms, and their potential to synergistically enhance the activity 
of caspofungin was analysed.  
3.2. Materials and methods 
3.2.1. Strains and reagents 
Pichia pastoris strain X33 was used for heterologous production of HsAFP1. Fusarium culmorum 
strain K0311 was used to evaluate the antifungal activity of the recombinant peptide and to compare 
it with that of native HsAFP1 purified from seeds, in a fungal growth inhibitory assay [32]. C. albicans 
strain SC5314 was used in all biofilm experiments. rHsAFP1 toxicity testing was performed on 
HepG2, human hepatoma cells [35], purchased from ATCC (catalogue number HB-8065; Rockville, 
MD, USA).  
All culture media were purchased from LabM (UK), unless stated otherwise. For heterologous 
production, P. pastoris was cultured in YPD (1% yeast extract, 2% peptone and 2% glucose), BMGY 
(buffered complex glycerol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 1% glycerol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin) or BMMY 
(buffered complex methanol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 0.5% methanol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin). F. 
culmorum was grown in half strength PDB (1.2% potato dextrose broth). Biofilm experiments were 
performed in RPMI-1640 medium (Roswell Park Memorial Institute-1640 medium; pH 7) with L-
glutamine and without sodium bicarbonate (purchased from Sigma Aldrich, St.-Louis, MO, USA), 
buffered with MOPS (Sigma Aldrich, St.-Louis, MO, USA). Amphotericin B and caspofungin 
(Cancidas) were purchased from Sigma Aldrich (St. Louis, MO, USA) and Merck (Beeston 
Nottingham, UK), respectively. HepG2 cells were grown in MEM (Minimal Essential Medium, Gibco, 
Invitrogen; CA, USA), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin, and cultured using standard cell culture conditions (37°C, 5% 
CO2, 95% humidity). The Cell Proliferation Kit II (XTT) and Cell Proliferation ELISA BrdU 
(colorimetric) kit were purchased from Roche Diagnostics (Mannheim, Germany). 
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3.2.2. Production and purification of recombinant (r) rHsAFP1 
The PCR fragment encoding mature HsAFP1 was cloned in frame with the α-factor secretion signal 
present in the pPICZαA transfer vector, after which the plasmid was integrated into the genome of 
Pichia pastoris X33 strain via double homologous recombination. This transgenic P. pastoris strain 
was grown in YPD overnight at 30°C and 250 rpm. BMGY medium was inoculated with the overnight 
culture to an optical density at 600 nm (OD600nm) of 0.5 and grown for 24 hours at 30°C and 200 rpm. 
Cells were pelleted by sterile centrifugation at 8000 rpm for 10 minutes at room temperature and re-
suspended in BMMY medium, thereby concentrating the culture 4-fold and inducing gene 
expression. The culture was grown for 96 hours at 25°C, and 2.5% methanol (v/v%) was added to 
the culture every 24 hours to maintain induction of gene expression. After induction, cells were 
pelleted at 8000 rpm for 10 minutes at 4°C and the cleared supernatant, containing the peptides of 
interest, was filter sterilized through a Steritop-GP 0.22 µm Express PLUS membrane Bottle-top filter 
(EMD Millipore, MA, USA). The filtered supernatant was then subjected to automated tangential flow 
filtration using an automated peristaltic pump (Spectrum Laboratories, CA, USA) and a hollow fiber 
module with 1 kDa cut-off mPES membranes (Spectrum Laboratories, CA, USA). During the 
ultrafiltration, the sample was concentrated a 15-fold and subsequently dialyzed against 50 mM 
sodium acetate pH 5. 
rHsAFP1 was purified by cation exchange chromatography, using 75 mL SP sepharose High 
Performance resin (GE Healthcare, UK) packed in a XK26/20 column (GE Healthcare) and 50 mM 
sodium acetate buffers at pH 5. The flow rate was maintained at 5 mL/min. Elution of the peptides 
was carried out by a washing step with 10% (v/v%) elution buffer (50 mM sodium acetate, 1 M 
sodium chloride, pH 5) for 10 column volumes (CV), followed by a linear gradient to 50% (v/v%) 
elution buffer in 15 CV, resulting in a peak at approximately 29% (v/v%) elution buffer. The eluted 
fraction was further purified by reversed phase chromatography employing a Gemini C18 250x10 
column (Phenomenex, CA, USA) and acetonitrile (ACN) for elution of the bound peptides. The flow 
rate was maintained at 4.6 mL/min. Elution of the peptides was carried out by a washing step at 15% 
(v/v%) ACN for 1.9 CV, followed by a linear gradient to 35% (v/v%) ACN in 2.3 CV. Elution of 
rHsAFP1 occurred at 28%. The eluted fraction was vacuum dried by centrifugal evaporation 
(SpeedVac Savant, Thermo Fisher Scientific, MA, USA), re-dissolved in MilliQ water and subjected 
to a micro bicinchoninic acid assay (Pierce, Thermo Scientific, USA) according to the manufacturer’s 
instructions, to determine the protein concentration. Bovine serum albumin served as a reference 
protein. At least 40 mg/L of culture of purified rHsAFP1 was obtained.  
3.2.3. Characterization of rHsAFP1 by NMR 
Dry powder (1 mg) of rHsAFP1 was dissolved in 500 µL of 10% D2O/90% H2O (~pH 4) for NMR 
experiments. Spectra were recorded at 298 K on a Bruker Avance-600 spectrometer. Two-
dimensional NMR experiments included total correlation spectroscopy (TOCSY [36]) using a MLEV-
17 spin lock sequence [37] with a mixing time of 80 ms; nuclear Overhauser effect spectroscopy 
(NOESY [38]) with a mixing time of 150, 200, or 300 ms; exclusive correlation spectroscopy (ECOSY 
[39]); and 13C and 15N heteronuclear single-quantum coherence (HSQC [40]). Solvent suppression 
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was achieved using excitation sculpting with gradients [41]. Spectra were acquired with 4096 
complex data points in F2 and 512 increments in the F1 dimension. Slowly exchanging amide 
protons were identified by spectra also recorded in 100% D2O. 
Spectra were processed using TopSpin (Bruker) software. The t1 dimension was zero-filled to 1024 
real data points, and 90˚ phase-shifted sine bell window functions were applied prior to Fourier 
transformation. Chemical shifts were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate 
(DSS). Processed spectra were analysed and assigned using CcpNmr Analysis [42]. Spectra were 
assigned using the sequential assignment protocol [43]. 
3.2.4. Structure calculations 
Structure calculations were based on distance restraints derived from NOESY spectra recorded in 
both 10% and 100% D2O. Initial structures were generated using the program CYANA [44], followed 
by addition of restraints for the disulfide bonds, hydrogen bonds as indicated by slow D2O exchange 
and sensitivity of amide proton chemical shift to temperature, chi1 restraints from ECOSY and 
NOESY data, and backbone phi and psi dihedral angles restraints generated using the program 
TALOS+ [45]. The structural family was generated using torsion angle dynamics, refinement and 
energy minimization in explicit solvent and protocols as developed for the RECOORD database [46] 
within the program CNS [47]. A family of structures consistent with the experimental restraints was 
then visualized using MOLMOL [48] and assessed for stereochemical quality using MolProbity [49]. 
Coordinates and NMR chemical shift assignments have been submitted (PDB ID: 2n2q; BMRB ID: 
25605). 
3.2.5. Antifungal activity assays 
To test whether rHsAFP1 is as potent as HsAFP1 purified from the seeds of coral bells, we analysed 
the antifungal activity of both peptides against F. culmorum, following the standard CLSI protocol 
M28-A2 [50], with minor modifications as previously described by Osborn and colleagues [32]: an 
inoculum of approximately 104 spores/mL of F. culmorum was suspended in half strength PDB and 
added to a two-fold dilution series of rHsAFP1 in water.  Seed-derived HsAFP1 was purified 
according to the protocol as previously described by Osborn and colleagues [32]. The IC50 value, 
which is the concentration required for 50% growth inhibition as compared to control treatment, was 
determined by measuring the optical density at 490 nm (OD490nm) after 48 hours of incubation and 
was confirmed microscopically. The antifungal activity of rHsAFP1 against C. albicans was 
subsequently analysed according to the standard CLSI protocol M27-A3 [51] with minor 
modifications: an inoculum of approximately 106 cells/mL was suspended in RPMI-1640 medium and 
added to a two-fold dilution series of rHsAFP1 in water. The DMSO concentration was similar to that 
in the biofilm assays, i.e. 0.5% DMSO. The MIC50 value, i.e. the minimum concentration required to 
reduce planktonic growth by 50% as compared to control treatment, was determined by measuring 
the OD490nm after 24 hours of incubation. 
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3.2.6. Antibiofilm activity assays 
3.2.6.1. Biofilm inhibition assay 
The Biofilm Inhibitory Concentration 50 value (BIC50; the minimum concentration required to reduce 
biofilm formation by 50% as compared to control treatment) of rHsAFP1 was determined using the 
following antibiofilm assay: a C. albicans SC5314 overnight culture, grown in YPD, was diluted to an 
optical density (600 nm) of 0.1 in RPMI 1640 medium and 100 μL of this suspension was added to 
the wells of a round-bottomed microtitre plate (TPP, Tradingen, Switzerland). After 1 h of adhesion at 
37°C, the medium was aspirated and the biofilms were washed with 100 μL phosphate-buffered 
saline (PBS) to remove non-adherent cells. Fresh RPMI 1640 medium, followed by an rHsAFP1 
concentration series was added to the biofilms. The DMSO concentration was similar to that in the 
checkerboard assays, i.e. 0.5%. Biofilms were allowed to grow for 24 h at 37°C and were 
subsequently washed with PBS and quantified with CellTiter-Blue (CTB; Promega, WI, USA)) [52] by 
adding 100 μL of CTB diluted 1/10 in PBS to each well. After 1 h of incubation in the dark at 37°C, 
the fluorescence was measured with a fluorescence spectrometer (λEx/λEm: 535/590 nm). The 
fluorescence values of the samples were corrected by subtracting the average fluorescence value of 
the CTB of uninoculated wells (blank). The percentage of surviving biofilm cells was calculated 
relative to the control treatment (0.5% DMSO). 
3.2.6.2. Biofilm eradication assay 
The Biofilm Eradicating Concentration 50 value (BEC50; the minimum concentration required to 
reduce the viability of the cells in a pre-grown biofilm by 50% as compared to control treatment) of 
rHsAFP1 was determined using the BEC50 determination assay as described by De Cremer and co-
workers [53]. Briefly, a C. albicans SC5314 overnight culture, grown in YPD, was diluted to an optical 
density (600 nm) of 0.1 in RPMI 1640 medium and 100 μL of this suspension was added to the wells 
of a round-bottomed microtitre plate (TPP, Tradingen, Switzerland). After 1 h of adhesion, the 
biofilms were washed with 100 μL PBS to remove non-adherent cells, followed by addition of 100 µL 
RPMI 1640 medium. The biofilms were allowed to grow for 24 h at 37°C. Next, an rHsAFP1 
concentration series in RPMI was added to the biofilms. The DMSO concentration was similar to that 
in the checkerboard assays, i.e. 0.5%. The biofilms were incubated for another 24 h at 37°C, after 
which they were washed and quantified with CTB as described above.  
3.2.6.3. Checkerboard assay 
C. albicans biofilms or C. albicans planktonic cultures were grown as described above. A 
combination of rHsAFP1 and antimycotic (caspofungin or amphotericin B), two-fold diluted across the 
columns and rows of a 96-well plate, respectively, was added to the planktonic culture or to the 
biofilms. Biofilms were treated either after 1 hour or 24 hours starting from the adhesion phase to 
analyse biofilm inhibition or biofilm eradication, respectively. After 24 hours incubation at 37°C, the 
MIC50 values were determined by measuring the OD490nm, whereas BIC50 and BEC50 values were 
determined using CTB as described above. In all experiments, the DMSO concentration was kept at 
0.5%. Synergy was determined by calculating the Fractional Inhibitory Concentration Index (FICI) 
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[54,55], in which the actual concentration of compound A (i.e. rHsAFP1) in the checkerboard 
experiment was used, as indicated in Tables 1-3 and Table 4. 
3.2.7. Scanning electron microscopy (SEM) 
Qualitative analysis of samples was performed using scanning electron microscopy (XL30-FEG, 
FEI). Samples were prepared using a protocol previously described [56]. Briefly, the biofilm-
containing titanium discs were rinsed in PBS and fixed in gluteraldehyde (2.5% v/v in a cacodylate 
buffer). Samples were rinsed three times in PBS, and subsequently dehydrated in a series of 
ethanol/H2O solutions with increasing alcohol content, followed by air drying. Finally, a thin 
conductive Au-Pd film was sputtered (Edwards S150) on the samples and SEM was operated at 
standard high-vacuum settings and using 10 mm working distance and 20 keV accelerating voltage. 
3.2.8. rHsAFP1 toxicity in HepG2 cells 
HepG2 cells were seeded at 10.000 cells/well in 96 well-plates and incubated for 24 hours. 
Subsequently, cells were treated with water (untreated) or rHsAFP1 (0.01 µM - 40 µM) for 24 hours 
after which cell viability or cell proliferation was determined using the “Cell Proliferation Kit II (XTT)”, 
as described previously [57], or the “Cell Proliferation ELISA BrdU (colorimetric) kit”, according to the 
manufacturer’s instructions, respectively. 
3.2.9. Structure-function analysis of HsAFP1 
Synthesis and purification of the 24-mer peptides (HsLin01-HsLin06) spanning the HsAFP1 amino 
acid sequence was performed as described previously [58]. Cysteine residues were replaced by α-
aminobutyric acid to avoid formation of disulfide bonds.  
3.2.10. Data analysis 
Data were analysed with GraphPad Prism (GraphPad Software, Inc., CA, USA). For dose-response 
data, sigmoidal curves were generated using nonlinear regression. The concentration required to 
cause 50% planktonic growth inhibition (IC50 or MIC50), reduction of biofilm formation (BIC50) and 
biofilm eradication (BEC50) as compared to control treatment was derived from the whole dose-
response curves. In all experiments, mean ± standard error of the mean (SEM) for n ≥ 3 is 
presented. Unpaired Student t-tests were performed to analyse significant differences between the 
IC50 value of native HsAFP1 and that of recombinant HsAFP1, and between the MIC50, BIC50 and 
BEC50 of caspofungin or amphotericin B alone and the combination of these compounds with 
rHsAFP1 or its derivatives in the checkerboard assays. To analyse significant differences in cell 
viability or cell proliferation between untreated and rHsAFP1-treated HepG2 cells in the rHsAFP1 
toxicity assays, unpaired Student t-tests were performed. In all cases, P<0.05 was defined as 
statistically significant. 
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3.3. Results 
3.3.1. rHsAFP1 shows potent antifungal activity against filamentous fungi 
rHsAFP1 was produced in Pichia pastoris and subsequently purified using cation exchange and 
reversed phase chromatography. A yield of at least 40 mg/L of culture of purified rHsAFP1 was 
obtained. The antifungal activity of HsAFP1 against a broad range of fungi,  including the 
fungus Fusarium culmorum, has been reported previously [32]. In this respect, Osborn and 
colleagues showed that native HsAFP1 can inhibit growth of F. culmorum with an IC50 value of 1 
µg/mL [32]. Hence, to assess the potency of rHsAFP1, we tested the antifungal activity of rHsAFP1 
and native HsAFP1 against F. culmorum according to the method of Osborn [32]. We found the IC50 
values of the recombinant and native peptide against F. culmorum not to be significantly different, i.e. 
0.45 ± 0.13 µM and 0.23 ± 0.02 µM respectively, with a  P-value of 0.1707, and hence, rHsAFP1 
seems as potent as native HsAFP1 
3.3.2. Characterization of rHsAFP1 by NMR 
The solution structure of rHsAFP1 was solved via NMR analysis, a technique that has been 
previously used to characterize the structures of other plant defensins, including RsAFP1, MtDef4, 
Psd1 and NaD1 [2,4-6]. A sequence alignment of HsAFP1 with these peptides and RsAFP2 is 
presented in Figure 1A, showing the disulfide bond pattern common for plant defensins [59,60].  
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Figure 1 Sequence alignment of HsAFP1 with other plant defensins. (A) Amino acid sequence alignment of 
NaD1 [6], Psd1 [5], MtDef4 [61], RsAFP1 [62], RsAFP2 [62] and HsAFP1 [32], matching their cysteine residues 
(numbered I-VIII). Multiple alignment was performed using the COBALT alignment tool [63]. Cysteine-pairing is 
shown at the top of the figure. Highly conserved residues are shown in grey; (-) denote gaps in the alignment. 
Blue boxes represent peptide fragments that exhibit antifungal activity similar to the parental peptide, and hence, 
are important for antifungal activity [4,64-66]. The orange box indicates the position of the γ-core. (B) Amino acid 
sequence alignment of HsAFP1 and the HsAFP1 linear peptide fragments (HsLin01-HsLin06). Multiple 
alignment was performed using the COBALT alignment tool [63]. Highly conserved residues are shown in grey; 
(-) denote gaps in the alignment. The orange box indicates the position of the γ-core.  
 
The NMR spectra of rHsAFP1 showed the sample to be of high purity and good dispersion in the 
amide region was indicative of a highly structured peptide. Two-dimensional spectra were recorded 
at several temperatures in the range 283 to 303 K to obtain full proton assignments. The proton 
assignments for rHsAFP1 are presented in supplemental information (S1 Table). Secondary 
chemical shift analysis was then used to locate elements of secondary structure. Hα secondary shifts 
are calculated by subtracting the chemical shift of the alpha proton from “random coil” values [67]. 
Deviations greater than 0.1 ppm from random coil are indicative of structured peptides, with positive 
values present for beta type structures and negative values for helical structures. The secondary Hα 
shifts of rHsAFP1 are shown in Figure 2 and indicate that the solution structure of rHsAFP1 consists 
of both α-helix and β-strand elements. 
 
Figure 2 Secondary shift analysis of rHsAFP1, pH 4.0 at 298 K. Regions of α-helix and β-strand are 
indicated at the top of the figure. 
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The three-dimensional structure of rHsAFP1 was calculated from 614 distance restraints, 15 
hydrogen bond pairs, and a total of 90 dihedral angle restraints (supplemental information S2 Table). 
The disulfide connectivities (I-VIII, II-V, III-VI, IV-VII) were fully consistent with the NOE data and 
were included as restraints in the structure calculations. Similarly to RsAFP1 [2], one proline (Pro9) is 
present in the trans configuration and the second (Pro44) has a cis peptide bond. Figure 3A shows 
the ensemble of structures superimposed over the backbone heavy-atoms of all residues (rmsd 1.16 
± 0.40 Å). A ribbon representation of the lowest energy structure is shown in Figure 3B. Analysis of 
the structures shows that 96% of residues fall in the most favored regions of the Ramachandran plot 
and a mean MolProbity score of 1.8 indicates good structural quality. rHsAFP1 forms a compact 
globular fold with a three turn α-helix spanning residues Ser20-Arg30 and a triple-stranded anti-
parallel β-sheet (β1 = Leu5-Pro9; β2 = Ala38-His40; β3 = Lys47-Gln53) forming another element of 
secondary structure. The four disulfide bonds are arranged in a typical cysteine-stabilized αβ motif in 
that the α-helix is tethered to the β-sheet by two disulfide bonds to the central strand (Cys23-Cys39 
and Cys27-Cys50). There are three loops present in the molecule that link β-strand 1 with the helix, 
the helix to β-strand 2, and the β-strands 2 and 3. These loops are reasonably well-defined although 
the loop that incorporates a β-turn between strand 2 and 3 is apparently more flexible as judged by 
greater disorder in the structural ensemble in this region. 
 
 
Figure 3 Three-dimensional structure of rHsAFP1. (A) A family of 20 lowest energy structures superimposed 
over all backbone heavy atoms; (B) A ribbon representation with disulfide bonds shown in yellow. The termini 
are labeled as N and C. Diagrams were generated using MOLMOL. 
3.3.3. rHsAFP1 prevents C. albicans biofilm formation 
At first, we assessed the antifungal activity of rHsAFP1 against planktonic C. albicans cells. rHsAFP1 
showed antifungal activity against planktonic C. albicans cultures, with a MIC50 value of 18.00 ± 4.60 
µM. Subsequently, we investigated the ability of rHsAFP1 to prevent or eradicate C. albicans 
biofilms. rHsAFP1 inhibited C. albicans biofilm formation, resulting in a BIC50 value of 11.00 ± 1.70 
µM. Fifty percent eradication of C. albicans biofilms by this peptide, as compared to control 
treatment, was not observed at the highest tested concentration, i.e. 109.00 µM (i.e. BEC50 of 
rHsAFP1 is > 109.00 µM) (data not shown). 
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In order to investigate the effect of rHsAFP1 on the growth of C. albicans biofilms, SEM images of 
biofilms grown for 4 hours in the presence or absence of rHsAFP1 (11.8 µM) were taken. As shown 
in Figure 4, cells in the untreated biofilms were able to form a dense hyphal network, covering the 
titanium discs. In contrast, no true biofilm was formed in the presence of 11.8 µM rHsAFP1, as in this 
case, biofilms mainly consisted of cells attached to the titanium disc without formation of a hyphal 
network.  
 
Figure 4 Scanning electron microscopy images of 4 hours-old biofilms, grown in the presence or 
absence (untreated) of 11.8 µM rHsAFP1. Images at multiple magnifications (500x, 1000x and 2000x) are 
presented. 
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3.3.4. rHsAFP1 acts synergistically with caspofungin or amphotericin B against C. albicans  
As rHsAFP1 prevented C. albicans biofilm formation, we further investigated the effect of rHsAFP1 
on the biofilm inhibitory and eradicating activity of conventional antimycotics, such as caspofungin 
and amphotericin B. To this end, checkerboard assays were performed and the corresponding FICI 
values were calculated to determine whether rHsAFP1 acts synergistically with these compounds 
against C. albicans biofilms (Figure 5 and Tables 1 and 2).  
Figure 5 Synergy between rHsAFP1 and caspofungin or amphotericin B, for (A) biofilm inhibition, as 
determined by CTB assay; (B) biofilm eradication, as determined by CTB assay; and (C) growth inhibition of 
planktonic cultures. Growth was analysed by measuring the OD490. Sigmoidal curves were generated using data 
of at least three independent experiments (n ≥ 3), using the model Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-
X)*HillSlope)) in GraphPad Prism. Dose response curves of caspofungin in the presence of synergistic 
concentrations of rHsAFP1 are presented. Black arrows represent synergy. Coloured lines represent different 
rHsAFP1 doses, as follows: brown: 16.8 µM; red: 8.4 µM; orange: 4.2 µM; dark yellow: 2.1 µM; green: 1.05 µM; 
turquois: 0.53 µM; blue: 0.26 µM and black: 0 µM. 
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In the biofilm inhibition assays (Table 1), synergistic effects (FICI ≤ 0.5) were observed between 
rHsAFP1 and caspofungin: rHsAFP1 increased the activity of caspofungin at concentrations of 1.05 
µM and 2.1 µM, resulting in a 2.5-fold and 3.7-fold reduction of the caspofungin BIC50, respectively. 
Although not synergistic, 0.53 µM, 4.2 µM and 8.4 µM rHsAFP1 also reduced the BIC50 of 
caspofungin significantly (P<0.05). No synergistic effects were observed between rHsAFP1 and 
amphotericin B in the biofilm inhibition assays, however, a range of 1.05 µM to 8.4 µM rHsAFP1 
significantly reduced the amphotericin B BIC50. Moreover, we also found that rHsAFP1 acted 
synergistically with caspofungin or amphotericin B in the eradication of C. albicans biofilms (Table 2): 
all rHsAFP1 concentrations tested (i.e. a range from 0.53 µM to 16.8 µM rHsAFP1) increased the 
biofilm eradicating capacity of caspofungin and although only 8.4 µM rHsAFP1 displayed synergy 
with amphotericin B, multiple concentrations significantly reduced the BEC50 of amphotericin B.  
To assess whether the synergistic effects observed between rHsAFP1 and amphotericin B or 
caspofungin against C. albicans biofilms were biofilm-specific, a similar checkerboard assay was 
performed on planktonic C. albicans cells (Table 3). Synergistic effects were observed between 
rHsAFP1 and caspofungin or amphotericin B against planktonic C. albicans cells and hence, synergy 
between rHsAFP1 and these compounds seems not biofilm-specific. Synergy between rHsAFP1 and 
amphotericin B was observed at lower rHsAFP1 concentrations as compared to those observed 
between rHsAFP1 and caspofungin. Interestingly, the concentration range of rHsAFP1 that acted 
synergistically with caspofungin against planktonic C. albicans cells was more restricted as 
compared to a C. albicans biofilm setup: all rHsAFP1 concentrations tested (i.e. 0.53 µM to 16.8 µM) 
increased caspofungin activity against C. albicans biofilms in the biofilm eradication assays, whereas 
only 2.1 µM and 4.2 µM rHsAFP1 acted synergistically with caspofungin against planktonic C. 
albicans cells. In addition, only 1.05 µM and 2.1 µM rHsAFP1 enhanced caspofungin activity against 
C. albicans biofilms in the biofilm inhibition assays. This indicates that synergy between caspofungin 
and rHsAFP1 is more evident in the eradication of C. albicans biofilms. In contrast, synergy between 
amphotericin B and rHsAFP1 was more pronounced against planktonic C. albicans cultures, as 
various rHsAFP1 concentrations (i.e. 0.53 µM to 2.1 µM) acted synergistically with amphotericin B 
against planktonic C. albicans cells and only 8.4 µM rHsAFP1 increased amphotericin B activity 
against C. albicans biofilms in the biofilm eradication assay. No synergistic effects between 
amphotericin B and rHsAFP1 were observed in the biofilm inhibition assays. 
  
 
Table 1 Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against C. albicans SC5314 biofilms, resulting in biofilm formation inhibition*  
Compound(s) [rHsAFP1] (µM) BIC50 CAS or AMB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.72 ± 0.05 NA NA  
CAS + rHsAFP1 8.4 0.05 ± 0.00 15.8 0.86 *** 
4.2 0.10 ± 0.01 7.1 0.54 *** 
2.1 0.20 ± 0.01 3.7 0.47  
1.05 0.28 ± 0.04 2.5 0.49  
0.53 0.42 ± 0.02 1.7 0.64 ** 
0.26 0.65 ± 0.07 1.1 0.93 NS 
AMB alone 0 1.23 ± 0.15 NA NA  
AMB + rHsAFP1 8.4 0.60 ± 0.07 2.1 1.28 ** 
4.2 0.53 ± 0.05 2.3 0.83 ** 
2.1 0.56 ± 0.04 2.2 0.65 ** 
1.05 0.67 ± 0.06 1.8 0.64 * 
0.53 0.81 ± 0.11 1.5 0.71 NS 
0.26 0.93 ± 0.11 1.3 0.78 NS 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to 
inhibit biofilm formation by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, 
not applicable; CAS, caspofungin; AMB, amphotericin B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were performed in 
case FICI did not indicate synergy to analyse significant differences between the effect of the compound alone and the combination of compound and rHsAFP1; the 
significance level is presented (*, ** and *** represent P<0.05, P<0.01 and P<0.001, respectively; NS, no significant difference). 
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Table 2 Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against C. albicans SC5314 biofilms, resulting in eradication of C. albicans biofilm 
cells*  
Compound(s) [rHsAFP1] (µM) BEC50 CAS or AMB (µM) ± SEM Fold change FICI (<) Significance level 
CAS alone 0 0.40 ± 0.08 NA NA  
CAS + rHsAFP1 16.8 0.04 ± 0.01 9.7 0.26  
8.4 0.06 ± 0.00 7.2 0.22  
4.2 0.07 ± 0.00 5.7 0.21  
2.1 0.10 ± 0.01 4.0 0.27  
1.05 0.12 ± 0.01 3.3 0.32  
0.53 0.15 ± 0.02 2.7 0.37  
AMB alone 0 1.67 ± 0.30 NA NA  
AMB + rHsAFP1 16.8 0.61 ± 0.17 2.7 0.52 * 
8.4 0.66 ± 0.22 2.5 0.47 
 
4.2 0.82 ± 0.19 2.1 0.53 * 
2.1 0.95 ± 0.28 1.8 0.59 NS 
1.05 1.07 ± 0.29 1.6 0.65 NS 
0.53 1.28 ± 0.28 1.3 0.77 NS 
*BEC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BEC50, minimum concentration that is required to reduce 
viability of 24 hours-old biofilm cells by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two 
compounds; NA, not applicable; CAS, caspofungin; AMB, amphotericin B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were 
performed in case FICI did not indicate synergy to analyse significant differences between the effect of the compound alone and the combination of compound and rHsAFP1; 
the significance level is presented (*, ** and *** represent P<0.05, P<0.01 and P<0.001, respectively; NS, no significant difference). 
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Table 3 Synergistic activity of rHsAFP1 with caspofungin or amphotericin B against C. albicans SC5314 planktonic cultures*  
Compound(s) [rHsAFP1] (µM) MIC50 CAS or AMB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.02 ± 0.01 NA NA  
CAS + rHsAFP1 8.4 0.01 ± 0.00 8.6 0.58 NS 
4.2 0.01 ± 0.00 4.0 0.48  
2.1 0.01 ± 0.00 2.6 0.50  
1.05 0.01 ± 0.00 1.8 0.63 NS 
0.53 0.02 ± 0.00 1.2 0.86 NS 
0.26 0.02 ± 0.01 1.1 0.90 NS 
AMB alone 0 0.44 ± 0.06 NA NA  
AMB + rHsAFP1 8.4 0.14 ± 0.01 3.2 0.78 ** 
4.2 0.15 ± 0.01 3.0 0.57 ** 
2.1 0.15 ± 0.01 2.9 0.47  
1.05 0.17 ± 0.01 2.6 0.44  
0.53 0.18 ± 0.02 2.4 0.44  
0.26 0.25 ± 0.01 1.8 0.58 * 
*MIC50 values were determined by measuring the OD at 490 nm; mean ± SEM for n ≥ 3 independent experiments is presented; MIC50, minimum inhibitory concentration that 
is required to reduce planktonic growth by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two 
compounds; NA, not applicable; CAS, caspofungin; AMB, amphotericin B. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were 
performed in case FICI did not indicate synergy to analyse significant differences between the effect of the compound alone and the combination of compound and rHsAFP1; 
the significance level is presented (* and ** represent P<0.05 and P<0.01, respectively; NS, no significant difference). 
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3.3.5. rHsAFP1 does not affect HepG2 cell viability and proliferation 
Various plant defensins are reported to be non-toxic to human cells due to their fungal membrane-
specific interactions [11]. As no records exist yet on potential toxicity of HsAFP1, we analysed the 
effect of rHsAFP1 on human hepatoma cells (HepG2) and found that rHsAFP1 did not affect HepG2 
cell viability nor cell proliferation up to 40 µM, the highest rHsAFP1 concentration tested in this setup. 
No statistically significant differences were found in cell viability and proliferation between untreated 
and rHsAFP1-treated cells (S1 Figure). 
3.3.6. The γ-core and adjacent regions are important for rHsAFP1 antibiofilm activity 
In order to gain insights in the structure-function relationship of HsAFP1 against C. albicans 
planktonic and biofilm cells, we conducted a structure-function relationship study using HsAFP1-
derived linear fragments. The selection of fragments was based on the procedure used by Schaaper 
et al. [68]. We synthesized 24-mer peptides with an 18-mer overlap, spanning the entire HsAFP1 
amino acid sequence and analysed these peptides for their activity towards F. culmorum and C. 
albicans planktonic cultures and biofilms. The sequences of the linear fragments (HsLin01-HsLin06) 
are presented in Figure1B. Figure 6 shows a diagram in which the HsLin peptides are imposed on 
the rHsAFP1 structure, according to their amino acid sequence. Note that (i) the cysteine residues 
are replaced by α-aminobutyric acid to avoid formation of disulfide bonds and that (ii) the CSαβ 
scaffold is not present in the HsLin peptides, and therefore, the peptides do not adopt the same 
conformation as the mature rHsAFP1. 
Figure 6 Representation of the HsLin peptides imposed on the rHsAFP1 structure, according to the 
amino acid sequence. HsLin peptides are shown as a thick blue line in the same orientation as rHsAFP1; other 
residues of rHsAFP1, not present in the HsLin peptide, are shown as a thin blue line. Note that (i) the cysteine 
residues are replaced by α-aminobutyric acid to avoid formation of disulfide bonds and that (ii) the CSαβ scaffold 
is not present in the HsLin peptides, and therefore, the peptides do not adopt the same conformation as the 
mature rHsAFP1. 
HsAFP1 and caspofungin act synergistically against Candida albicans  
 
54  
 
None of the linear HsAFP1-derived fragments inhibited the growth of F. culmorum up to the highest 
tested concentration, 1.5 µM, whereas rHsAFP1 inhibited growth of this fungus with an IC50 value of 
0.45 ± 0.13 µM. In addition, these truncated peptides did not inhibit the growth of C. albicans in 
contrast to full-length rHsAFP1. Hundred percent growth inhibition of C. albicans planktonic cells was 
observed at 70 µM for rHsAFP1, whereas concentrations up to 350 µM of the peptides were not 
sufficient to cause 100% growth inhibition. Furthermore, only HsLin06 inhibited C. albicans biofilm 
formation to the same extent as rHsAFP1: the BIC50 values of HsLin06 and rHsAFP1 were 10.80 ± 
3.59 µM and 11.00 ± 1.70 µM, respectively (Table 4), suggesting that the sequence comprising 
HsLin06 is important for antibiofilm activity. HsLin03 and HsLin05 showed antibiofilm activity as well, 
however, with a 10- to 15-fold higher BIC50 value than that of rHsAFP1 or HsLin06. Other fragments 
did not inhibit biofilm formation up to 175 µM, the highest tested concentration. We further analysed 
the potential of the peptides to increase the activity of caspofungin to prevent biofilm formation. We 
found that HsLin06, but also HsLin01 and HsLin05, acted synergistically with caspofungin to inhibit 
C. albicans biofilm formation in a range of 0.75 µM to 1.5 µM (Figure 7 and Table 5 for HsLin06 and 
S2 Figure for the other HsLin). We did not observe synergistic effects between the other linear 
fragments and caspofungin for preventing biofilm formation (S2 Figure).  
 
Table 4 Structure-function relationship study of HsAFP1-derived fragments against C. albicans biofilms* 
Peptide BIC50 (µM) ± SEM Significance level 
rHsAFP1 11.00 ± 1.70  
HsLin01 >175 *** 
HsLin02 >175 *** 
HsLin03 96.78 ± 15.90 ** 
HsLin04 >175 *** 
HsLin05 160.00 ± 33.36 * 
HsLin06 10.80 ± 3.59 NS 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; 
BIC50, minimum inhibitory concentration that is required to inhibit biofilm formation by 50% as compared to 
control treatment. Unpaired Student t-tests were performed to analyse significant differences between the effect 
of the linear fragments and rHsAFP1; the significance level is presented (*, ** and *** represent P<0.05, P<0.01 
and P<0.001, respectively; NS, no significant difference). 
  
 
Table 5 Synergistic activity of HsLin06 with caspofungin against C. albicans SC5314 biofilms, resulting in biofilm formation inhibition* 
Compound(s) [HsLin06] (µM) BIC50 CAS (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.90 ± 0.05 NA NA  
CAS + HsLin06 175 0.04 ± 0.00 25.67 16.25 *** 
87.5 0.03 ± 0.00 27.87 8.14 ** 
43.75 0.07 ± 0.01 14.27 4.13 *** 
21.88 0.07 ± 0.01 13.50 2.11 *** 
10.94 0.07 ± 0.02 13.67 1.09 *** 
5.47 0.07 ± 0.02 13.03 0.59 *** 
 
1.5 0.13 ± 0.00 7.76 0.28 
 
 
0.75 0.22 ± 0.01 4.45 0.31 
 
0.38 0.48 ± 0.04 2.04 0.57 * 
0.19 0.68 ± 0.09 1.43 0.78 NS 
0.09 1.05 ± 0.10 0.93 1.18 NS 
0.05 0.93 ± 0.05 1.05 1.05 NS 
 
*BIC50 values were determined by CTB assay; mean ± SEM for n ≥ 3 independent experiments is presented; BIC50, minimum inhibitory concentration that is required to 
inhibit biofilm formation by 50% as compared to control treatment; FICI, Fractional Inhibitory Concentration Index, FICI ≤ 0.5 indicates synergy between two compounds; NA, 
not applicable; CAS, caspofungin. Values in bold represent synergistic effects between two compounds. Unpaired Student t-tests were performed in case FICI did not indicate 
synergy to analyse significant differences between the effect of the compound alone and the combination of compound and rHsAFP1; the significance level is presented (*, ** 
and *** represent P<0.05, P<0.01 and P<0.001, respectively; NS, no significant difference). 
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Figure 7 Synergy between caspofungin and HsLin06 for biofilm inhibition. Metabolic activity was measured 
using CTB. Sigmoidal curves were generated using data of at least three independent experiments (n ≥ 3), 
using the model Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) in GraphPad Prism. Dose response 
curves of caspofungin in the presence of synergistic concentrations of HsLin06 are presented. Black arrows 
represent synergy. Coloured lines represent different HsLin doses, as follows: blue: 1.5 µM; purple: 0.75 µM and 
black: 0 µM. 
3.4. Discussion 
We have generated recombinant (r) HsAFP1, a plant defensin from the seeds of coral bells 
(Heuchera sanguinea) [32], in Pichia pastoris with a yield of at least 40 mg/L of culture of purified 
peptide. The recombinant peptide rHsAFP1 was characterized by potent antifungal activity, similar to 
that of HsAFP1 purified from seeds. NMR analysis revealed that rHsAFP1 adopts the characteristic 
cysteine-stabilised αβ-motif, similar to other plant defensins [2,4-6]. The NMR results, together with 
the results of the antifungal activity assays, led us to conclude that P. pastoris is an ideal 
heterologous production system for plant defensins as highly structured and active peptides were 
obtained, without affecting their antifungal activity. 
Plant defensins might be of interest in the development of novel antimycotics, as they are in general 
non-toxic towards human cells [11-13] and there is a strong need for novel agents to combat fungal 
infections. The latter is of great importance in fungal biofilm-related infections, as only few 
compounds can be used to treat these diseases [29-31]. It was already shown that the plant defensin 
HsAFP1 is characterized by potent antifungal activity towards C. albicans [33], and more 
interestingly, by a low in vitro frequency of resistance occurrence in planktonic C. albicans cultures 
[11]. Hence, we investigated the potential antibiofilm activity of rHsAFP1 against C. albicans biofilms. 
rHsAFP1 prevented C. albicans biofilm formation, resulting in a BIC50 value of 11.00 ± 1.70 µM, 
whereas the peptide was not able to eradicate C. albicans biofilms. SEM images of C. albicans 
biofilms indicated that control biofilms were able to form a dense hyphal network within four hours 
after adhesion to the surface, whereas biofilms grown in the presence of rHsAFP1 mainly consisted 
of cells attached to the surface without formation of a hyphal network. It needs to be further 
investigated whether this observation is due to inhibition of the yeast-to-hypha transition by rHsAFP1.  
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Note that the latter has been previously reported for the plant defensin RsAFP2 in planktonic C. 
albicans cultures [22], and might indicate a similar mechanism of action for RsAFP2 and rHsAFP1, 
although different fungal membrane targets might be involved [33]. Checkerboard assays revealed 
that, although all tested concentrations of rHsAFP1 acted synergistically with caspofungin in 
eradication of C. albicans biofilms, only specific rHsAFP1 doses proved synergistic with caspofungin 
in inhibiting C. albicans biofilm or planktonic cell growth. The underlying molecular mechanism 
resulting in the improved activity of rHsAFP1 in combination with caspofungin for eradicating biofilms 
is not clear. In case of amphotericin B, most pronounced synergies with rHsAFP1 were apparent 
against planktonic C. albicans cells, although still in a rather limited rHsAFP1 concentration range. 
We found that rHsAFP1 did not affect the cell viability and cell proliferation of human hepatoma cells 
(HepG2) up to 40 µM, the highest concentration tested in this setup, suggesting that rHsAFP1 is not 
toxic to human cells. This is in line with previous reports on the non-toxicity of plant defensins 
towards human cells [11-13].   
A structure-function relationship study with 24-mer peptides spanning the entire HsAFP1 amino acid 
sequence showed that the γ-core and its adjacent regions are important for antibiofilm activity, as 
only HsLin06 had a similar antibiofilm activity to that of rHsAFP1. In addition, we found that antifungal 
and antibiofilm activity of rHsAFP1 against C. albicans are probably not linked, as HsLin06 inhibited 
biofilm formation to the same extent as rHsAFP1 without inhibiting planktonic growth. Checkerboard 
analyses revealed that HsLin01, HsLin05 and HsLin06 acted synergistically with caspofungin in the 
prevention of C. albicans biofilm formation. Hence, it seems that antibiofilm activity is not essential to 
increase the activity of caspofungin against C. albicans biofilms, indicating that antibiofilm activity and 
the ability to cause synergistic effects with caspofungin are not linked. Synergy between caspofungin 
and other compounds, including toremifene citrate, tyrocidines, posaconazole, cefoperazone-
sulbactam (CPZ/SAM), piperacillin-tazobactam (PIP/TAZ) and colistin, against Candida biofilms has 
been described before [54,69-71] and might point to a general effect of caspofungin against fungal 
biofilms. In this respect, we recently identified a biofilm-specific enhancement of caspofungin activity 
by toremifene citrate against C. albicans and C. glabrata biofilms, resulting in up to 20-fold reduction 
of the caspofungin BIC50 [54]. Similarly, it was reported that CPZ/SAM and PIP/TAZ enhance 
caspofungin activity in vitro and in vivo against C. albicans. In that study, CPZ/SAM is suggested to 
have more affinity for the same efflux pump as caspofungin, leading to an increase in intracellular 
levels of caspofungin and hence, synergy between caspofungin and CPZ/SAM [70]. In another 
report, Chen and colleagues demonstrated that posaconazole exhibits synergistic antifungal activity 
with caspofungin in vitro and in vivo against C. albicans [71]. In addition, it was reported that 
tyrocidines exhibit a pronounced synergistic biofilm-eradicating activity in combination with 
caspofungin and amphotericin B against C. albicans biofilms [69]. In the latter study, a more 
pronounced synergy between tyrocidines and caspofungin was observed as compared to 
amphotericin B, and, as amphotericin B and tyrocidines both target cell membranes, it was 
hypothesized that the observed effect was due to competition for this target. This hypothesis might 
also be valid for our observations, as plant defensins specifically target the fungal membrane [18] 
and a higher synergy between rHsAFP1 and caspofungin was observed as compared to rHsAFP1 
and amphotericin B.  
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Finally, Zeidler and co-workers reported synergy between echinocandins and colistin against 
Candida spp.. They suggested that this synergy is a result of echinocandin-mediated weakening of 
the cell wall that leads to facilitated colistin-targeting of fungal membranes, which in turn reinforces 
the antifungal activity of echinocandins [72].  Whether this is the case for rHsAFP1, needs to be 
further investigated.  
This study is the first to report the activity of a plant defensin towards fungal biofilms in vitro and 
indicates, together with other reports on the antifungal and/or antibiofilm activity of human and insect 
defensins [73-80], the relevance of using defensins as an approach to combat fungal biofilm-
associated infections. We showed that rHsAFP1 inhibited C. albicans planktonic growth and biofilm 
formation, and did not affect the viability and proliferation of human HepG2 cells in vitro. The latter 
indicates that HsAFP1 does not exhibit a general cytotoxicity, which is supported by its lack of 
inhibitory activity to bacteria [32]. It was already shown that the plant defensin RsAFP2 is 
prophylactically effective against murine candidiasis [81], pointing to the in vivo potential of plant 
defensins. Moreover, we showed that rHsAFP1 acted synergistically with caspofungin against C. 
albicans biofilms and planktonic cells. In addition, we found that certain linear HsAFP1-derived 
fragments also increased the activity of caspofungin to prevent biofilm formation. A combinatorial 
approach to combat fungal infections is often more effective and decreases the chance of resistance 
occurrence [34]. Our results indicate a potentiating effect of rHsAFP1 and its derivatives on 
caspofungin, which should be further investigated in vivo. Taken together, rHsAFP1 and its 
derivatives are interesting peptides for further development as an antifungal or antibiofilm agent for 
use alone or in a multi-drug approach to combat fungal infections. 
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3.6. Supporting Information 
S1 Table 1H assignments for rHsAFP1 in 10% D2O/90% H2O, pH 4.0 at 298 K. 
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S2 Table Statistical analysis of rHsAFP1 structures.  
 
 
 
S2 Table Statistical analysis of rHsAFP1 structures*  
Experimental restraints  
Total no. distance restraints 602 
Intraresidue 162 
Sequential 173 
Medium range, i-j<5 66 
Long range, i-j≥5 201 
Hydrogen bond restraints 30 
Disulphide bond restraints 24 
Dihedral angle restraints  
Phi 45 
Psi 37 
Chi1 19 
Total number of restraints per residue 14.0 
Rms deviation from mean structure, Å  
Backbone atoms 1.04 ± 0.24 
All heavy atoms 1.66 ± 0.24 
Stereochemical qualitya  
Residues in most favoured Ramachandran region, % 85.5 ± 3.1 
Ramachandran outliers, % 1.5 ± 1.8 
Unfavourable sidechain rotamers, % 9.0 ± 5.7 
Clashscore, all atoms 2.4 ± 1.4 
Overall MolProbity score 2.27 ± 0.18 
*All statistics are given as mean ± SD. 
aAccording to MolProbity [1]. 
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S1 Figure rHsAFP1 does not affect HepG2 cell viability and cell proliferation. HepG2 cells were treated 
with water (control treatment) or rHsAFP1 (0.01 µM – 42 µM) for 24 hours. Cell viability and cell proliferation 
were determined by XTT staining and BrdU staining, respectively, and results were expressed relative to cells 
receiving control treatment. Mean and SEM of three experiments in quadruplicate is shown. No statistically 
significant differences were found in cell viability and cell proliferation between untreated (control treatment) and 
rHsAFP1-treated cells up to the highest tested rHsAFP1 concentration (i.e. 40 µM)  (Unpaired Student t-test; 
P<0.05 was defined as statistically significant). 
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S2 Figure Synergy between caspofungin and HsLin01 (A), HsLin02 (B), HsLin03 (C), HsLin04 (D) and 
HsLin05 (E) for biofilm inhibition. Metabolic activity is measured using CTB. Sigmoidal curves were generated 
using data of at least three independent experiments (n ≥ 3), using the model Y=Bottom+(Top-
Bottom)/(1+10^((LogIC50-X)*HillSlope)) in GraphPad Prism. Dose response curves of caspofungin in the 
presence of synergistic concentrations of HsLin are presented. Black arrows represent synergy. Coloured lines 
represent different HsLin doses, as follows: brown: 43.75 µM; orange: 21.88 µM; dark yellow: 10.94 µM; green: 
5.47 µM; blue: 1.5; purple: 0.75 µM µM and black: 0 µM. 
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Abstract 
The radish defensin RsAFP2 was previously characterized as a peptide with potent antifungal activity 
against several plant pathogenic fungi and human pathogens, including Candida albicans. RsAFP2 
induces apoptosis and impairs the yeast-to-hypha transition in C. albicans. As the yeast-to-hypha 
transition is considered important for progression to mature biofilms, we analyzed the potential 
antibiofilm activity of recombinant (r)RsAFP2, heterologously expressed in Pichia pastoris, against C. 
albicans biofilms. We found that rRsAFP2 prevents C. albicans biofilm formation with a BIC-2 (i.e. the 
minimal rRsAFP2 concentration that inhibits biofilm formation by 50% as compared to control 
treatment) of 1.65 ± 0.40 mg/mL. Moreover, biofilm-specific synergistic effects were observed 
between rRsAFP2 and the antimycotics caspofungin and amphotericin B, pointing to the potential of 
RsAFP2 as a novel antibiofilm compound. In addition, we characterized the solution structure of 
rRsAFP2 and compared it to that of RsAFP1, another defensin present in radish seeds. These 
peptides have similar amino acid sequences, except for two amino acids, but RsAFP2 was 
previously found to be 2- to 30-fold more potent than RsAFP1 against many fungi. A structural 
comparison of both defensins via NMR analysis revealed that also rRsAFP2 adopts the typical 
cysteine-stabilized αβ-motif of plant defensins, however, no structural differences were found 
between these peptides that might result in the observed differential antifungal potency. This 
suggests that their differential antifungal activities are probably due to the higher net positive charge 
of rRsAFP2. 
 
Key words: plant defensin, RsAFP2, recombinant protein production, NMR analysis, Candida 
albicans, fungal biofilm 
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4.1. Introduction 
Plant defensins are small, basic, cysteine-rich peptides with biological activity against a wide range of 
microorganisms [1-3]. To date, it is primarily their antifungal activity that has been studied and 
several fungal targets, such as membrane compounds and intracellular proteins, have been 
identified. It was shown that plant defensins specifically interact with fungal membrane sphingolipids 
[4, 5] and phospholipids [6], and that, upon interaction with the membrane, some plant defensins 
enter the cell and interact with nuclear or cytosolic proteins [7-9]. In addition, various plant defensins 
have been shown to induce apoptosis [10, 11] and/or the production of reactive oxygen species 
(ROS) [9, 10, 12-14],  leading to fungal cell death. 
In this study, we focused on the radish defensins RsAFP1 and RsAFP2. A sequence alignment of 
these peptides, matching their cysteine residues (numbered I-VIII), is presented in Figure 1. Both 
peptides are present in radish seeds and previous analysis of their antifungal activity revealed that 
RsAFP2 is 2- to 30-fold more potent than RsAFP1 against several fungi [15]. The solution structure 
of RsAFP1 was elucidated in 1998 by Fant and colleagues, and was the first reported structure of a 
plant defensin [16]. As the amino acid sequence of RsAFP2 only differs by two amino acids to that of 
RsAFP1, we were interested in identifying structural difference(s) between these defensins in order 
to explain their differential antifungal potency. To this end, we heterologously produced RsAFP2 
using Pichia pastoris as a host, resulting in a yield of at least 100 mg recombinant (r)RsAFP2 per liter 
of culture supernatant, elucidated its solution structure by NMR and compared it to that of RsAFP1. 
 
Figure 1 Sequence alignment of RsAFP1 and RsAFP2. Sequences were aligned matching their cysteine 
residues, using the COBALT alignment tool [17]. Cysteine pairing is shown at the top of the figure. Highly 
conserved residues in plant defensin sequences are shown in grey. Blue boxes indicate differences between the 
amino acid sequence of RsAFP1 and that of RsAFP2. 
During the past decade, the mechanism of action of RsAFP2 has been intensively studied. RsAFP2 
specifically interacts with the fungal sphingolipid glucosylceramide (GlcCer) [18], after which it 
induces the production of ROS [13], caspase-mediated apoptosis [11], and cell wall stress in C. 
albicans cells, the latter by activation of the cell wall integrity pathway [19]. RsAFP2 was also shown 
to activate MAP kinase signalling cascades in F. graminearum, excluding the Hog1 MAP kinase 
pathway [20]. In addition, RsAFP2 induces accumulation of phytoC24-ceramides, affects septin 
formation and localization and impairs the yeast-to-hypha transition in C. albicans [19].  
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In view of the latter, RsAFP2 might prevent C. albicans biofilm formation, as the yeast-to-hypha 
transition, besides cell adhesion and production of the extracellular matrix, is considered important 
for progression to mature biofilms in C. albicans [21].  
Biofilms are self-organized microbial communities encased by a polymeric matrix that grow on biotic 
or abiotic surfaces, such as catheters or other medical implants. In fungal biofilms, Candida spp. play 
a predominant role [22-25]. These biofilms are highly resistant towards most conventional 
antimycotics, with few exceptions, including miconazole, caspofungin, anidulafungin, and liposomal 
formulations of amphotericin B [26-29]. Recently, we found that the coral bells defensin HsAFP1 
prevents C. albicans biofilm formation and increases caspofungin’s activity against C. albicans 
biofilms [30].  
Therefore, in this study, we additionally analyzed the antibiofilm potential of rRsAFP2, and assessed 
its activity in a multi-drug approach with the conventional antimycotics caspofungin and amphotericin 
B against C. albicans biofilms.  
4.2. Materials and methods 
4.2.1. Strains and reagents 
Pichia pastoris strain GS115 (C181-00, Life Technologies, CA, USA) was used for heterologous 
production of RsAFP2. Fusarium graminearum WT and ∆gcs strain [31], i.e. a strain lacking 
glucosylceramide synthase, were used to evaluate the antifungal activity of the recombinant peptide. 
C. albicans strain SC5314 was used in all biofilm experiments. 
All culture media were purchased from LabM (UK), unless stated otherwise. For heterologous 
production, P. pastoris was cultured in YPD (1% yeast extract, 2% peptone and 2% glucose), BMGY 
(Buffered Glycerol complex Medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 1% glycerol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin) or BMMY 
(Buffered Methanol complex Medium; 1% yeast extract, 2% peptone, 0.5% methanol, 100 mM K3PO4 
pH 6, 4 x 10-5% biotin). F. graminearum was grown in half strength PDB (1.2% potato dextrose 
broth). Biofilm experiments were performed in MM (minimal medium) supplemented with 50 mM 
HEPES (pH 7) (MMH; 0.77 g/L complete amino acid supplement mixture (Bio 101 Systems), 6.7 g/L 
yeast nitrogen base w/o amino acids (Becton Dickinson, UK), 20 g/L glucose). 
4.2.2. Production and purification of recombinant (r) rRsAFP2 
rRsAFP2 was produced in Pichia pastoris and purified by cation exchange chromatography and 
reversed-phase chromatography, following the protocol previously described for production and 
purification of rHsAFP1 [30] with minor modifications: P. pastoris strain GS115 was used for 
expression of rRsAFP2 and induction of gene expression was performed for 72 h at 25°C, during 
which 2% methanol (v/v%) was added to the culture every 24 h to maintain induction. In addition, an 
automated peristaltic pump (Spectrum Laboratories, CA, USA) and a Vivaflow 200 cassette with a 2-
kDa cut-off Hydrosart membrane (Invitrogen, CA, USA) were used for ultrafiltration. Purification of 
rRsAFP2 using cation exchange chromatography and reversed-phase chromatography resulted in 
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peaks at approximately 28% and 33% elution buffer, respectively. Following this protocol, at least 
100 mg of rRsAFP2 was obtained per liter of culture supernatant. 
4.2.3. Antifungal activity assays 
To assess the antifungal activity of rRsAFP2 against F. graminearum, a two-fold dilution series of the 
peptide in sterile water was prepared in 96-well plates, after which 10 µL of peptide was mixed with 
90 µL of half strength PDB containing 104 spores/mL of F. graminearum. The IC50 value, which is 
the concentration that inhibits 50% growth as compared to control treatment, was determined by 
microscopy after 48 h. The antifungal activity of rRsAFP2 against C. albicans was analyzed 
according to the standard CLSI (Clinical and Laboratory Standards Institute) protocol M27-A3 with 
minor modifications [32]: the tests were performed in MMH, a suitable medium for assessing 
antifungal activity of plant defensins [33], and an inoculum of approximately 106 cells/mL was 
supplemented with DMSO, resulting in a similar DMSO concentration as for the antibiofilm activity 
assays, i.e. 0.5% DMSO. The MIC-2 value, i.e. the minimal concentration required to inhibit 50% 
growth as compared to control treatment, was determined by measuring the optical density at 490 
nm (OD490nm) after 24 h. 
4.2.4. Antibiofilm activity assays 
4.2.4.1. Biofilm inhibition assay 
The Biofilm Inhibition Concentration-2 value (BIC-2; the minimum concentration required to reduce 
biofilm formation by 50% as compared to the control treatment) of rRsAFP2 was determined using 
the antibiofilm assay as described by Delattin and co-workers, with minor modifications [34]: the 
dilution series of the peptide was prepared in sterile water and the inoculum was supplemented with 
DMSO, resulting in a similar DMSO concentration as for the checkerboard assays, i.e. 0.5% DMSO. 
Biofilm inhibition assays were carried out in MMH. 
4.2.4.2. Biofilm eradication assay 
The Biofilm Eradication Concentration-2 value (BEC-2; the minimum concentration required to 
diminish pre-grown biofilms by 50% as compared to the control treatment) of rRsAFP2 was 
determined using the BEC-2 determination assay as described by De Cremer and co-workers, with a 
minor modification [35]: biofilm eradication assays were carried out in MMH.  
4.2.4.3. Checkerboard antibiofilm assay 
C. albicans biofilms or C. albicans planktonic cultures were grown as described above. A 
combination of rRsAFP2 and compound (caspofungin or amphotericin B), two-fold diluted across the 
columns and rows of a 96-well plate, respectively, was added to the biofilms after 1 h or 24 h of 
adhesion to analyze biofilm inhibition or biofilm eradication, respectively. After 24 h incubation at 
37°C, the biofilms were quantified using CTB (CellTiter-Blue; Promega, WI, USA), as described 
earlier [36]. Synergy was determined by calculating the Fractional Inhibitory Concentration Index 
(FICI) using the formula ܨܫܥܫ = ܨܫܥ஺ + 	ܨܫܥ஻ = ܥ஺ ܯܫܥ஺⁄ + ܥ஻ ܯܫܥ஻⁄ , where ܯܫܥ஺ and ܯܫܥ஻ are the 
MICs of the drugs A and B alone, respectively, and ܥ஺ and ܥ஻ are the concentrations of the drugs A 
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and B at iso-effective combinations, respectively [37]. Note that ܥ஻ values were derived from the 
whole dose-response curves, whereas ܥ஺ values represent the actual concentration of drug A (i.e. 
RsAFP2) in the checkerboard experiments, as indicated in Tables 1-3. 
4.2.5. Scanning electron microscopy (SEM) 
Qualitative analysis of samples was performed using scanning electron microscopy (XL30-FEG, 
FEI). Samples were prepared according to the protocol described by De Brucker and colleagues [38]. 
Briefly, biofilms were grown on titanium discs for 24 h. After rinsing these discs in PBS, they were 
fixed in gluteraldehyde (2.5% v/v in a cacodylate buffer), rinsed in PBS and subsequently dehydrated 
in a series of ethanol/H2O solutions with increasing alcohol content, followed by air drying. Finally, a 
thin conductive Au-Pd film was sputtered (Edwards S150) on the samples and SEM was operated at 
standard high-vacuum settings and using 10 mm working distance and 20 keV accelerating voltage. 
4.2.6. Data analysis 
Data were analyzed with GraphPad Prism (GraphPad Software, Inc., CA, USA) using nonlinear 
regression to generate sigmoidal curves, employing the model 
ܻ = ܤ݋ݐݐ݋݉ + (ܶ݋݌ − ܤ݋ݐݐ݋݉) (1 + 10(୪୭୥ ூ஼ହ଴ି௑)∗ு௜௟௟ௌ௟௢௣௘)⁄ . The concentrations required to cause 
50% growth inhibition (MIC-2), biofilm prevention (BIC-2) and biofilm eradication (BEC-2) were 
derived from the whole dose-response curves. Unpaired Student t-tests were performed to analyze 
significant differences between the MIC-2, BIC-2 and BEC-2 of caspofungin or amphotericin B alone 
and the combination of these compounds with rRsAFP2 in the checkerboard assays. In all cases, P 
< 0.05 was defined as statistically significantly different.  
4.2.7. Characterization of rRsAFP2 by NMR 
rRsAFP2 (1 mg) was dissolved in 500 L of 10% D2O/90% H2O (~pH 4) for NMR experiments. All 
spectra were recorded on a Bruker Avance-600 spectrometer at 298 K or 288–308 K for variable 
temperature experiments. Two-dimensional NMR experiments included TOCSY using a MLEV-17 
spin lock of 80 ms, NOESY with a mixing time of 200 ms, ECOSY, 13C-HSQC, and 15N-HSQC. 
Solvent suppression was achieved using excitation sculpting and spectra were acquired with 4096 
complex data points in F2 and 512 increments in the F1 dimension. The t1 dimension was zero-filled 
to 1024 real data points, and 90˚ phase-shifted sine bell window functions were applied prior to 
Fourier transformation. Spectra were also recorded in 100% D2O to identify slowly exchanging amide 
protons. Chemical shifts were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate (DSS). 
Processed spectra were analyzed and assigned using CcpNmr Analysis [39]. Spectra were assigned 
using the sequential assignment protocol [40]. 
4.2.8. Structure calculations 
Structure calculations were based on distance restraints derived from NOESY spectra recorded in 
both 10% and 100% D2O. Initial structures were generated using torsion angle dynamics in the 
program CYANA [41], followed by addition of restraints for the disulfide bonds, hydrogen bonds as 
indicated by slow D2O exchange and sensitivity of amide proton chemical shift to temperature, chi1 
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restraints and stereo-specific assignments of α-methylene protons from ECOSY and NOESY data, 
and backbone phi and psi dihedral angles restraints generated using the program TALOS+ [42]. The 
final structural family was generated within the program CNS [43] using torsion angle dynamics 
followed by refinement and energy minimization in explicit solvent and protocols as developed for the 
RECOORD database [44]. Final structures were analyzed for stereochemical quality using 
MOLPROBITY [45], visualized using MOLMOL [46], and the 20 structures with lowest energy and 
best quality chosen to represent the solution structure of rRsAFP2. Coordinates and NMR chemical 
shift assignments have been submitted (PDB ID: 2n2r ; BMRB entry 25609). 
4.3. Results 
4.3.1. rRsAFP2 shows GlcCer-dependent antifungal activity  
rRsAFP2 was produced in Pichia pastoris and subsequently purified using cation exchange and 
reversed-phase chromatography. A yield of at least 100 mg of rRsAFP2 was obtained per liter of 
culture supernatant. The antifungal activity of rRsAFP2 was tested against F. graminearum and 
compared to the antifungal activity of native RsAFP2 purified from radish seeds [15]. Similar IC50 
values are observed for the recombinant and native peptide against F. graminearum, i.e. 2 µg/mL 
(data not shown). In addition, we found that the F. graminearum ∆gcs mutant is equally resistant to 
rRsAFP2 as native RsAFP2, indicating that rRsAFP2 shows GlcCer-specific antifungal activity, as 
has been demonstrated for native RsAFP2 [18, 31]. 
4.3.2. rRsAFP2 prevents C. albicans biofilm formation 
As RsAFP2 blocks the yeast-to-hypha transition in C. albicans [19], which is important for biofilm 
formation [21], we analyzed the activity of rRsAFP2 against C. albicans biofilms. Since rRsAFP2 
does not show antifungal or antibiofilm activity in RPMI-1640 medium (data not shown), we 
performed all assays in MMH, a suitable medium for assessing antifungal activity of plant defensins 
[33]. We found that rRsAFP2 does not show antifungal activity against planktonic C. albicans cultures 
in this medium up to 2 mg/mL, and the MIC-2 value is therefore defined as > 2 mg/mL (data not 
shown). Subsequently, we investigated the ability of rRsAFP2 to prevent or eradicate C. albicans 
biofilms in MMH medium. We found that rRsAFP2 can prevent C. albicans biofilm formation, resulting 
in a BIC-2 value of 1.65 ± 0.40 mg/mL. Eradication of C. albicans biofilms by rRsAFP2 is not 
observed up to 2 mg/mL (i.e. BEC-2 of rRsAFP2 is > 2 mg/mL). 
SEM images of biofilms grown for 4 hours in the presence or absence of rRsAFP2 (1.65 mg/mL) 
were taken to further investigate the effect of the peptide on C. albicans biofilm formation. In the 
presence of 1.65 mg/mL rRsAFP2, C. albicans cells adhering to the discs do not grow as biofilms as 
hyphal formation is completely inhibited by the peptide. Instead, only C. albicans cells in the yeast 
phenotype are detected at the surface of the discs. In contrast, in the absence of rRsAFP2, C. 
albicans cells form a dense biofilm network covering the entire discs (Figure 2). 
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Figure 2 Scanning electron microscopy images of 4 hours old C. albicans biofilms, grown in the presence or 
absence (untreated) of 1.65 mg/mL rRsAFP2. Images at multiple magnifications (500x, 1000x and 2000x) are 
presented. 
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4.3.3. rRsAFP2 acts synergistically with caspofungin against C. albicans biofilms 
As rRsAFP2 prevents C. albicans biofilm formation, we further analyzed the effect of rRsAFP2 on the 
biofilm inhibitory and eradicating activity of caspofungin and amphotericin B, two commercially 
available antimycotics belonging to the echinocandin and polyene class of antifungal agents, 
respectively [47], that are characterized by antibiofilm activity. However, a multidrug approach can be 
used to improve the efficacy of these antimycotics against biofilm-associated infections, which are 
often difficult to treat [48]. To this end, checkerboard assays were performed and the corresponding 
FICI values were calculated to determine whether rRsAFP2 acts synergistically with these 
antimycotics against C. albicans biofilms, i.e. FICI ≤ 0.5 (Figure 3 and Table 1 and 2).  
 
Figure 3 Synergy between rRsAFP2 and caspofungin or amphotericin B for biofilm inhibition (A and B) and 
biofilm eradication (C). Metabolic activity was measured by CTB assay. Sigmoidal curves were generated using 
data of three independent experiments (n=3), using the model 
ܻ = ܤ݋ݐݐ݋݉ + (ܶ݋݌ − ܤ݋ݐݐ݋݉) (1 + 10(୪୭୥ ூ஼ହ଴ି௑)∗ு௜௟௟ௌ௟௢௣௘)⁄  in GraphPad Prism. Dose response curves of 
caspofungin (A and C) or amphotericin B (B) in the presence of synergistic concentrations of rRsAFP2 are 
presented. Black arrows represent synergy. Colored lines represent different rRsAFP2 doses, with green: 10 
µg/mL; red: 5 µg/mL; blue: 2.5 µg/mL and black: 0 µg/mL. 
  
 
 
Table 1 Synergistic activity of rRsAFP2 with caspofungin or amphotericin B against C. albicans SC5314 biofilms, resulting in biofilm formation inhibition* 
 
Compound(s) [rRsAFP2] (µg/mL) BIC-2 CAS or AmB (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.76 ± 0.16 NA NA  
CAS + rRsAFP2 10 0.13 ± 0.03 5.7 0.18  
 
5 0.20 ± 0.01 3.9 0.26  
 
2.5 0.32 ± 0.03 2.4 0.42 
 
 
1.25 0.63 ± 0.04 1.2 0.82 NS 
 
0.625 0.66 ± 0.18 1.2 0.86 NS 
 
0.3125 0.74 ± 0.22 1.0 0.96 NS 
AmB alone 0 1.74 ± 0.34 NA NA  
AmB + rRsAFP2 10 0.77 ± 0.10 2.3 0.45  
 
5 0.81 ± 0.08 2.2 0.47 
 
 2.5 1.15 ± 0.17 1.5 0.66 NS 
 1.25 1.33 ± 0.16 1.3 0.76 NS 
 0.625 1.62 ± 0.44 1.1 0.93 NS 
 0.3125 1.72 ± 1.23 1.0 0.99 NS 
 
*BIC-2 values were determined by CTB assay; n = 3 independent experiments; BIC-2, minimal inhibitory concentration that inhibits biofilm formation by 50%; NA, not 
applicable; CAS: caspofungin; AMB: amphotericin B. Synergistic compound combinations are presented in bold. Unpaired Student t-tests were performed in case FICI did not 
indicate synergy to analyze significant differences between the compound alone and the combination of compound and rRsAFP2; no significant differences were found (NS).  
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Table 2 Synergistic activity of rRsAFP2 with caspofungin against C. albicans SC5314 biofilms, resulting in eradication of C. albicans biofilm cells* 
 
Compound(s) [rRsAFP2] (µg/mL) BEC-2 CAS (µM) ± SEM Fold change FICI (<) Significance level 
CAS alone 0 0.29 ± 0.01 NA NA  
CAS + rRsAFP2 10 0.10 ± 0.02 2.8 0.36  
 
5 0.12 ± 0.03 2.5 0.41  
 
2.5 0.19 ± 0.05 1.6 0.64 NS 
 
1.25 0.21 ± 0.04 1.4 0.71 NS 
 0.625 0.25 ± 0.02 1.2 0.86 NS 
0.3125 0.27 ± 0.02 1.1 0.92 NS 
 
*BEC-2 values were determined by CTB assay; n = 3 independent experiments; BEC-2, minimal concentration that eradicates biofilms by 50%; NA, not applicable; CAS: 
caspofungin. Synergistic compound combinations are presented in bold. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyze significant 
differences between the compound alone and the combination of compound and rRsAFP2; no significant differences were found (NS).  
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Synergistic effects between rRsAFP2 and caspofungin are observed in both biofilm inhibition and 
biofilm eradication assays (Table 1 and 2): a range of 2.5 µg/mL to 10 µg/mL rRsAFP2 reduces the 
BIC-2 of caspofungin by 2.4- to 5.7-fold, whereas 5 µg/mL and 10 µg/mL rRsAFP2 reduce the BEC-2 
of caspofungin by 2.5- and 2.8-fold, respectively. In addition, 5 µg/mL and 10 µg/mL rRsAFP2 act 
synergistically with amphotericin B with regard to inhibiting C. albicans biofilm formation, thereby 
reducing the amphotericin B BIC-2 by 2.3- and 2.2-fold, respectively (Table 1). As eradication of C. 
albicans biofilms by amphotericin B was not observed in MMH medium up to 50 µM amphotericin B, 
we did not perform additional checkerboard assays with rRsAFP2 and amphotericin B to analyze the 
biofilm eradication potential of the combinatorial approach. Note that when C. albicans biofilms are 
grown in RPMI-1640 medium, biofilm eradication by amphotericin B is observed at concentrations 
less than 5 µM.  
To assess whether the synergistic effects observed between rRsAFP2 and caspofungin or 
amphotericin B against C. albicans biofilms are biofilm-specific, a similar checkerboard assay was 
carried out on planktonic C. albicans cells (Table 3). Although no synergistic effects are observed 
between rRsAFP2 and caspofungin or amphotericin B against a planktonic C. albicans culture, we 
found that 0.3125 µg/mL, 0.625 µg/mL and 1.25 µg/mL rRsAFP2 reduce the caspofungin MIC-2 
significantly. No significant differences are observed between the MIC-2 of amphotericin B alone and 
that in combination with rRsAFP2.  As FICI values do not indicate synergy between rRsAFP2 and 
caspofungin or amphotericin B, we conclude that synergy between rRsAFP2 and caspofungin seems 
biofilm-specific. 
  
 
 
Table 3 Synergistic activity of rRsAFP2 with caspofungin against C. albicans SC5314 planktonic cultures* 
 
 
*MIC-2 values were determined by measuring the OD at 490 nm; n = 3 independent experiments; MIC-2, minimal inhibitory concentration that inhibits planktonic growth by 
50%; NA, not applicable; CAS: caspofungin; AmB: amphotericin B. Unpaired Student t-tests were performed in case FICI did not indicate synergy to analyze significant 
differences between the compound alone and the combination of compound and rRsAFP2; the significance level is presented (* represents P<0.05; NS, no significant 
difference). 
Compound(s) [rRsAFP2] (µg/mL) MIC-2 CAS or AmB  (µM) ± SEM Fold change FICI Significance level 
CAS alone 0 0.05 ± 0.01 NA NA  
CAS + rRsAFP2 2.5 0.04 ± 0.00 1.5 0.67 NS 
 
1.25 0.03 ± 0.00 1.6 0.62 * 
 
0.625 0.03 ± 0.00 1.6 0.64 * 
 
0.3125 0.04 ± 0.00 1.5 0.66 * 
 
0.15625 0.04 ± 0.01 1.5 0.67 NS 
 
0.078125 0.04 ± 0.01 1.4 0.71 NS 
AmB alone 0 0.61 ± 0.14 NA NA  
AmB + rRsAFP2 2.5 0.46 ± 0.11 1.3 0.76 NS 
 1.25 0.56 ± 0.10 1.1 0.92 NS 
 0.625 0.58 ± 0.12 1.0 0.96 NS 
 0.3125 0.64 ± 0.13 0.9 1.06 NS 
 0.15625 0.62 ± 0.23 1.0 1.02 NS 
 0.078125 0.60 ± 0.14 1.0 0.99 NS 
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4.3.4. Characterization of rRsAFP2 by NMR 
The solution structure of rRsAFP2 was determined by NMR analysis and compared with that of 
RsAFP1 [16]. The proton NMR spectrum of rRsAFP2 (Figure 4A) shows good dispersion in the amide 
region, indicative of a highly structured peptide, and two-dimensional spectra enabled full proton 
assignment (S1 Table). The TOCSY and NOESY spectra of rRsAFP2 are presented in Figure 4B and 
4C, respectively. 
 
Figure 4 Characterization of rRsAFP2 by NMR analysis at 600MHz, 10% D2O/90% H2O, pH 4.0, 298K. (A) 
Proton NMR spectrum of rRsAFP2; (B) Fingerprint region of the TOCSY spectrum of rRsAFP2; (C) Fingerprint 
region of the NOESY spectrum of rRsAFP2, showing sequential connectivity pattern. 
 
Secondary chemical shift analysis was used to confirm that there was a high degree of similarity in 
the elements of secondary structure of rRsAFP2 as compared to those of RsAFP1 [16]  (Figure 5A). 
The three-dimensional structure of rRsAFP2 was calculated from 655 distance restraints, 17 
hydrogen bond pairs, and 90 dihedral angle restraints. The disulfide connectivities (I-VIII, II-V, III-VI, 
IV-VII) were also included as restraints in the structure calculations. Two of the peptide’s three proline 
residues (Pro7 and Pro50) are confirmed to be in the trans conformation, based on diagnostic Hαi-1-
Hδi NOE crosspeaks. Pro41 is in a cis confirmation based on Hαi-1-Hαi crosspeaks. The final family of 
structures has good structural and energy statistics, as shown in S2 Table. 
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Figure 5 Comparison of RsAFP1 and rRsAFP2 secondary shift analysis and NMR structures. (A) 
Secondary shift analysis of rRsAFP2, pH 4.0 at 298K, as compared to that of RsAFP1 [16]. The amino acid 
sequence of RsAFP2 is displayed, with the substituted residues of RsAFP1 shown in brackets. White bars 
represent RsAFP1; grey bars represent RsAFP2; (B) NMR structures of rRsAFP2. A family of 20 lowest energy 
structures superimposed over all backbone heavy atoms. The N- and C-termini are labelled N-ter and C-ter 
respectively, and the disulfide bonds are shown in yellow; (C) Comparison of rRsAFP2 (dark blue) and RsAFP1 
(grey) structures is shown in ribbon format. The loops connecting the secondary structural elements are labelled, 
as are the residues corresponding to changes between the two peptides. 
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The structures overlay well over the entire molecule, with a RMSD for the backbone atoms of 1.16 ± 
0.40 Å (Figure 5B). Analysis of the structures with PROMOTIF [49] identified a 16.5 Å length of α-helix 
between Asn18 and Leu28 and a triple-stranded anti-parallel β-sheet comprising residues Leu3-Arg6, 
His33-Cys36, and Cys45-Pro50. These structural elements are connected by three loop regions. 
Loop 2, which connects the α-helix to strand 2, is better defined than either loop 1 (linking strand 1 to 
the α-helix) or loop 3 (linking strand 2 to strand 3). Loop 3 contains a type VIa1 β-turn but is also the 
region of greatest mobility. Figure 5C reveals that the backbone structures of the RsAFP1 and 
rRsAFP2 overlay well with an RMSD of 1.69 Å across the entire molecule and 1.17 Å across the 
structured elements. 
4.4. Discussion 
We generated recombinant (r) RsAFP2, a plant defensin from the seeds of radish [15], in Pichia 
pastoris with a yield of at least 100 mg of rRsAFP2 per liter of culture supernatant. The antifungal 
activity of rRsAFP2 is similar to that of native RsAFP2 with regard to antifungal potency and GlcCer 
dependency. As RsAFP2 was shown to impair the yeast-to-hypha transition in C. albicans [19], which 
is considered important for progression to mature biofilms [21], we analyzed the potential antibiofilm 
activity of rRsAFP2 against C. albicans biofilms. In these experiments, we used minimal medium 
supplemented with HEPES (MMH), as we found that rRsAFP2 did not show antifungal and antibiofilm 
activity in RPMI-1640. The latter is a reference medium, frequently used to assess the antibiofilm 
activity of compounds, as it mimics the in vivo environment. However, RsAFP2 was previously shown 
to be effective against a murine model of candidiasis [50], suggesting that media other than RPMI-
1640 can be relevant for the assessment of antifungal and/or antibiofilm activity of peptides. In this 
respect, it has already been reported that the type of medium can influence the potency of 
antimicrobial peptides and that their in vivo potency can transcend their in vitro activity. For instance, 
the proline-rich antimicrobial peptide A3-APO was found to have a modest activity against Escherichia 
coli and Acinetobacter baumannii in vitro in Mueller-Hinton broth, whereas in mouse models of 
systemic and wound infections it showed superior efficacy compared to conventional antibiotics [51, 
52]. Similarly, Malik and colleagues found that certain anuran peptides demonstrated weak in vitro 
inhibitory activity against Staphylococcus aureus in cation-adjusted Mueller-Hinton broth, but had 
potent antibacterial activity against S. aureus in a murine wound infection model [53]. This suggests 
that, as opposed to in vitro activity testing of small molecules, it can be better to use other, ‘non-
conventional’, media for in vitro activity testing of peptides.  
We found that rRsAFP2 can prevent C. albicans biofilm formation with a BIC-2 value of 1.65 ± 0.40 
mg/mL, whereas eradication of biofilms by this peptide was not observed up to 2 mg/ml. SEM images 
of C. albicans biofilms showed that biofilms grown in the presence of 1.65 mg/mL rRsAFP2 consist of 
cells adhered to the surface without the formation of a hyphal network, and as such, no true biofilm is 
formed. In contrast, cells in untreated biofilms are able to form a dense hyphal network. These 
observations can be explained by the fact that RsAFP2 was previously shown to block the yeast-to-
hyphae transition in C. albicans [19]. Checkerboard analyses indicated that a synergy exists between 
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rRsAFP2, and caspofungin or amphotericin B, to prevent C. albicans biofilm formation. Moreover, 
rRsAFP2 acts synergistically with caspofungin in the eradication of C. albicans biofilms as well. This 
synergy is apparent at low rRsAFP2 concentrations, i.e. 2.5 µg/mL to 10 µg/mL. Synergy between 
rRsAFP2 and caspofungin or amphotericin B was not observed against planktonic C. albicans cells, 
pointing to a biofilm-specific synergy. Interestingly, rRsAFP2 alone cannot eradicate C. albicans 
biofilms up to a concentration of 2 mg/mL, whereas a combinatorial approach of a 200-fold lower 
rRsAFP2 concentration with caspofungin results in efficient eradication of C. albicans biofilms. Similar 
observations are made for C. albicans biofilm prevention, as synergistic activity with amphotericin B 
and caspofungin is evident at 2.5 µg/mL to 10 µg/mL rRsAFP2, whereas the rRsAFP2 BIC-2 is at 
least 150-fold higher (i.e. 1.65 ± 0.40 mg/mL). We recently reported on the antibiofilm activity of 
another plant defensin, HsAFP1, which can inhibit C. albicans biofilm formation, but cannot eradicate 
C. albicans biofilms [30]. In that study, rHsAFP1 was shown to act synergistically with caspofungin in 
the prevention and eradication of C. albicans biofilms [30]. In line, the plant-derived decapeptide 
OSIP108 was shown to act synergistically with caspofungin and amphotericin B in vitro and in vivo in 
a Caenorhabditis elegans – C. albicans biofilm infection model, while OSIP108 alone cannot 
eradicate C. albicans biofilms [34]. Similarly, AS10, a derivative of the mouse cathelicidin-related 
antimicrobial peptide, was found to act synergistically with caspofungin and amphotericin B in 
eradication of C. albicans biofilms, whereas the latter is not observed when AS10 is applied alone 
[54]. Hence, diverse antimicrobial peptides seem to act synergistically with caspofungin or 
amphotericin B in prevention and/or eradication of C. albicans biofilms, suggesting that these peptides 
induce a weakening of the biofilm cells and/or biofilm matrix, resulting in facilitated targeting and 
killing of the biofilm cells by caspofungin and amphotericin B. All these data suggest that antimicrobial 
peptides, such as plant defensins, are interesting peptides as novel antibiofilm agents, in particular for 
their use in a multidrug approach to combat C. albicans biofilm-related infections. Interestingly, plant 
defensins are in general nontoxic towards mammalian cells,  and certainly not at the concentrations 
used in this study. Specifically regarding RsAFP2, we previously demonstrated that it can be used to 
successfully treat candidiasis in mice after intravenous injection without any detrimental effect on the 
animal [50]. 
Since RsAFP2 was found to be 2- to 30-fold more potent than RsAFP1 against several fungi, and 
their amino acid sequences only differ by two amino acids [15], we were interested in elucidating the 
solution structure of rRsAFP2 and comparing it to that of RsAFP1 reported by Fant and colleagues 
[16]. As such, we focused on the structural difference(s) that might result in the observed differential 
antifungal potency. NMR analysis revealed that rRsAFP2 has a comparable structure to that of 
RsAFP1, consisting of an α-helix and three β-strands held together in a typical cysteine-stabilized αβ 
motif. There are no discernible differences in the structured elements, nor in loop 2 or loop 3 (Figure 
5C). The backbone of loop 1 adopts a slightly different configuration, but this variance may be due to 
the flexibility of this long loop region. Interestingly, loop 3 is highly similar between these two defensin 
peptides. Apart from the N-terminus (pyroglutamate in RsAFP1 and glutamine in rRsAFP2), which 
has been shown to have no effect on activity [55], the primary structures differ at only two positions. 
Specifically, a glutamine in rRsAFP2 replaces glutamate 5 in RsAFP1 and an arginine replaces 
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asparagine 27. In both defensins, these residues are found on the helix and strand 1 and their 
substitution induces no structural differences. Moreover, the side chains of these residues extend with 
similar spatial orientation (Figure 5C). It has been proposed that the interactions between radish 
defensins and their fungal target sites are based in part on electrostatic interactions [16, 56]. Indeed, 
these changes at position 5 and 27 result in a higher net positive charge of rRsAFP2 relative to 
RsAFP1 and this change is more likely to be responsible for differences in biological activities than 
structural alterations. At this stage, we cannot exclude the possibility that the differences in activity 
reflect residue-specific interactions involving the two substituted positions. For example, it has been 
established that some defensins, such as RsAFP2, specifically interact with sphingolipids [4, 5] or 
phospholipids [6] and the amino acid differences might modulate such an interactions. 
In conclusion, we have shown here that P. pastoris is an ideal host for the production of highly 
structured peptides like plant defensins, resulting in their correct folding and highly specific activity. In 
addition, we showed that RsAFP2 is an interesting peptide for the development of novel antibiofilm 
agents, as it prevented C. albicans biofilm formation and acted synergistically with caspofungin and 
amphotericin B in prevention of C. albicans biofilms. In addition, synergistic interactions were also 
observed between rRsAFP2 and caspofungin in the eradication of C. albicans biofilms. These findings 
point to a novel approach that makes use of plant defensins alone or in combination with conventional 
antimycotics to combat fungal biofilms. 
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4.6. Supplemental information 
S1 Table 1H assignments for rRsAFP2 in 10% D2O /90% H2O, pH 4.0 at 298K. 
 Chemical shifts 
 Residue NH H H others 
Gln1  4.40 2.08, 2.08 CH2 2.58, 2.40; NH2 7.33, 6.80 
Lys2 8.38 4.31 1.87, 1.78 CH2 1.46, 1.46; CH2 1.72, 1.71; CH2 3.02, 3.01; NH3+ 7.55 
Leu3 8.40 5.12 1.84, 1.35 CH 1.69; CH3 0.74, 0.68 
Cys4 9.76 5.09 2.98, 2.98 
 
Gln5 8.71 4.66 1.62, 1.62 CH2NH2 7.30, 6.76 
Arg6 9.12 4.83 1.91, 1.74 CH2 1.69, 1.57; CH2 3.04, 2.91; NH 7.02
Pro7  4.49 2.31, 1.92 CH2 2.15, 1.92; CH2 3.85, 3.64 
Ser8 8.62 4.73 4.11, 3.71 
 
Gly9 10.64 4.41, 3.91 
 
Thr10 8.19 4.51 4.16 CH3 1.14 
Trp11 8.14 4.12 3.25, 3.11 CH 7.10; NH 8.58; CH 7.36; CH 7.24; CH 7.82; CH 6.80 
Ser12 7.39 4.64 3.56, 3.56 
 
Gly13 8.41 4.18, 3.88 
 
Val14 8.56 4.05 2.14 CH3 1.09, 0.98 
Cys15 8.24 4.93 2.91, 1.86 
 
Gly16 8.63 4.40, 3.70 
 
Asn17 7.33 4.87 3.03, 2.81 NH2 7.89, 7.11 
Asn18 9.00 4.25 3.14, 2.72 NH2 7.62, 7.04 
Asn19 8.45 4.39 2.91, 2.82 NH2 7.75, 7.11 
Ala20 8.00 4.32 1.77 
 
Cys21 7.27 4.17 2.20, 2.09 
 
Lys22 8.37 3.20 1.92, 1.92 CH2 1.30, 1.22; CH2 1.73, 1.73; CH2 3.04, 3.04; NH3+ - 
Asn23 8.31 4.40 2.89, 2.80 NH2 7.59, 6.88 
Gln24 8.20 4.12 2.39, 2.39 CH2NH2 7.81, 6.58 
Cys25 8.74 4.22 2.88, 2.53 
 
Ile26 8.18 3.83 1.72 CH2CH3CH3 
Arg27 8.68 4.13 1.99, 1.91 CH2 1.81, 1.65; CH2 3.25, 3.19; NH 7.30 
Leu28 8.57 4.71 2.20, 1.67 CH 1.77; CH3 0.99, 0.93 
Glu29 7.03 4.82 2.76, 2.65 CH2 2.38, 2.28 
Lys30 7.48 4.23 2.25, 2.15 CH2 1.43, 1.43; CH2 1.74, 1.73; CH2 3.06, 3.06; NH3+ 7.55 
Ala31 7.92 3.98 0.81 
 
Arg32 8.24 4.47 1.81, 1.62 CH2 1.81, 1.65; CH2 1.76, 1.70; NH 7.45 
His33 7.68 4.61 3.11, 2.42 CH 5.92; CH 7.76 
Gly34 6.31 5.30, 3.85 
 
Ser35 9.05 4.13 3.73, 3.73 
 
Cys36 8.55 5.48 2.85, 2.75 
 
Asn37 9.11 4.96 2.75, 2.75 NH2 -, - 
Tyr38 8.77 4.25 3.02, 2.57 CH 6.60; CH 6.69 
Val39 7.71 3.89 1.88 CH3 0.87, 0.87 
Phe40 8.44 3.96 3.02, 2.89 CH 7.30; CH 7.42 
Pro41  3.87 1.98, 1.02 CH2 1.71, 1.50; CH2 3.36, 3.28
Ala42 8.29 4.75 1.33 
His43 8.66 4.94 3.31, 3.16 CH 7.33; CH 8.27
Lys44 8.79 4.66 1.88, 1.54 CH2 1.51, 1.41; CH2 1.67, 1.67; CH2 2.95, 2.95; NH3+ 7.65 
Cys45 9.19 4.72 2.20, 1.59 
Ile46 8.73 4.21 2.09 CH2CH3CH3 
Cys47 8.58 5.38 3.01, 2.75 
Tyr48 7.99 5.30 2.68, 2.49 CH 6.75; CH 6.71
Phe49 9.21 4.94 3.29, 2.69 CH 7.22; CH 7.42
Pro50 - 4.87 2.38, 2.11 CH2 2.38, 1.95; CH2 4.11, 3.80
Cys51 8.35 4.55 3.38, 3.20 
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S2 Table Statistical analysis of 20 lowest energy structures of rRsAFP2  
NMR distance & dihedral constraints 
 
Distance restraints, total NOE 655 
intra-residue 185 
inter-residue  
sequential (|i-j|) 220 
medium-range (|i-j|≤4) 72 
long-range (|i-j|≥5) 178 
Hydrogen bondsa 34 
Dihedral angle restraints, total 90 
 42 
 29 
χ 19 
  
Structure statisticsb 
 
Deviations from idealized geometry 
bond lengths (Å) 0.011 ± 0.000 
bond angles (deg) 1.14 ± 0.03 
impropers (deg) 1.42 ± 0.08 
NOE (Å) 0.011 ± 0.001 
cDih (Å) 0.104 ± 0.089 
Mean energies (kcal/mol)  
Overall -1779 ± 34 
bonds 22.5 ± 1.4 
angles 67.4 ± 4.1 
improper 28.6 ± 3.0 
Van Der Waals -245.8 ± 8.0 
NOE 0.09 ± 0.02 
cDih 0.21 ± 0.28 
electrostatic -1880 ± 35 
Violations   
NOE violations exceeding 0.3Å 0 
Dihedral violations exceeding 2.0o 0 
Average pairwise rmsd (Å)  
backbone atoms  1.16 ± 0.40 
heavy atoms  1.85 ± 0.52 
  
Stereochemical Qualityc 
 
Ramachandran favoured, % 90.0 ± 3.7 
Ramachandran outliers, % 1.4 ± 2.3 
Unfavourable sidechain rotamers, % 0.3 ± 0.8 
Clashscore, all atomsd 13.5 ± 3.1 
MolProbity score 2.19 ± 0.10 
Percentile 65 ± 6 
 
a two restraints were used per hydrogen bond 
b statistics are given as mean  standard deviation 
c according to MolProbity (http://molprobity.biochem.duke.edu) 
d defined as the number of steric overlaps > 0.4 Å per thousand atoms 
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Abstract 
Scorpion potassium toxins and plant defensins both belong to the structural superfamily of CSαβ 
peptides, and hence, share a common structural fold. This observation hinted us to analyse the 
potential potassium channel inhibitory activity of plant defensins. In silico analysis of 18 plant 
defensin sequences with those of the representative scorpion potassium toxins α-KTx6.1 and α-
KTx23.1 revealed, based on the presence of a partial toxin sequence signature, potential potassium 
channel inhibitory activity for the Arabidopsis thaliana defensin AtPDF2.3. Hence, we heterologously 
produced AtPDF2.3 and analysed its activity against a panel of sodium and potassium channels in 
vitro. We showed that recombinant AtPDF2.3 (rAtPDF2.3) interacts with Kv1.2 and Kv1.6 channels by 
physically blocking the Kv channels, akin to the interaction between scorpion toxins and Kv channels. 
Comparable to many other plant defensins, rAtPDF2.3 inhibits the growth of the yeast 
Saccharomyces cerevisiae and several plant pathogenic fungi. We found that pathways regulating 
potassium transport and/or homeostasis confer tolerance of yeast to rAtPDF2.3. Finally, we found 
that the antifungal activity of rAtPDF2.3 is depending on the presence of the sphingolipid mannosyl-
diinositolphosphorylceramide in the fungal membrane, as is the case for the Dahlia merckii defensin 
DmAMP1. As DmAMP1 did not affect Kv channels, sphingolipid-dependent antifungal activity and Kv 
blocking activity seem not linked. 
 
Keywords: Arabidopsis thaliana, AtPDF2.3, plant defensin, fungi, sphingolipid, antifungal activity, 
potassium channel, potassium transport, scorpion toxin 
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5.1. Introduction 
Voltage-gated potassium channels (Kv) are a diverse family of membrane-spanning proteins that 
selectively transfer potassium ions across the cell membrane in both excitable and non-excitable 
cells. These proteins play important roles in cellular signaling processes, such as regulating heart 
rate and insulin secretion [1] and are involved in diverse physiological processes, including 
repolarization of action potential, cellular proliferation and migration and regulating cell volume [2]. Kv 
channels are considered to be ideal pharmacological targets for the development of new therapeutic 
drugs to treat cancer, autoimmune diseases and cardiovascular, neurological and metabolic 
disorders. For instance, Kv1.3 constitutes a promising target for treatment of autoimmune diseases, 
such as multiple sclerosis, as this channel is overexpressed in activated effector memory T cells [2-
4].  
Scorpion toxins, among others, are well reported to interact with Kv channels. In 1999, Tytgat and 
colleagues suggested a general nomenclature for scorpion toxins active on Kv channels (αKTxs), 
based on the similarity between the primary structures of those toxins [5]. Nowadays, more than 200 
different scorpion toxins specific for potassium channels are divided in over 30 subfamilies, based on 
amino acid sequence motifs and on the location of cysteine residues that are crucial for 3D-structure 
[5-7]. Recently, it was shown that a toxin signature sequence can be assigned to α-KTxs. This 
signature sequence comprises eight structurally and functionally important residues conserved 
across the family, in which six cysteines are involved in three disulfide bridges and two amino acids 
(Lys and Asn) in a four-residue long motif around the fourth cysteine (Lys-Cys4-Xaa-Asn) (Xaa, any 
amino acid) are key functional residues of α-KTxs [8]. Mutations at these two sites (Lys27 and 
Asn30) had the largest destabilizing effects on binding of agitoxin2 (AgTx2), an α-KTx isolated from 
the venom of the scorpion Leiurus quinquestriatus hebraeus, to the Shaker potassium channel in 
Drosophila [9, 10]. This is consistent with a toxin-channel complex model derived from solid-state 
nuclear magnetic resonance (NMR) studies in which the side chains of Asn30 on the toxin kaliotoxin 
and Asp64 on the pore helix of one chain of KcsA-Kv1.3 (structurally equivalent to Asp431 of 
Drosophila melanogaster Shaker potassium channel or Asp361 of rat Kv1.1) are predicted to form 
hydrogen bonds, whereas side chains of Lys27 directly enter into the pore region to contact the 
backbone carbonyls of Tyr78 on the channel filter (structurally equivalent to Tyr445 of D. 
melanogaster Shaker K+ channel or Tyr375 of rat Kv1.1) [11]. The functional importance of these two 
residues was also identified in a recent crystal structure of a Kv channel in complex with an α-KTx 
(charybdotoxin) though in this complex the location of the Asn slightly differs from the NMR-based 
complex model [8, 11, 12]. 
Plant defensins are small, basic, cysteine-rich peptides with biological activity against a wide  range 
of microorganisms [13-16]. These peptides have been studied extensively the past decades and their 
antifungal activity has been well documented. Plant defensins were shown to specifically interact with 
fungal membrane compounds, such as phospholipids [17, 18] and sphingolipids [19, 20]. Fungal 
sphingolipids are classified into two groups, being phosphosphingolipids and glycosphingolipids 
(GSL). The latter, on its turn, are subdivided into glycoinositolphosphorylceramides (GIPC) and 
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glucosylceramides (GlcCer) [21-24]. The Dahlia merckii defensin DmAMP1 was shown to interact 
with GIPC, and more specifically mannosyldiinositolphosphorylceramides M(IP)2C) [25-27], whereas 
GlcCer were shown to be important in the antifungal activity of RsAFP2 [28], MsDef1 [29] and Psd1 
[30, 31]. Upon membrane interaction, few plant defensins were found to subsequently enter the cell 
to interact with intracellular proteins [32-34], whereas others remain localized at the cell surface [35]. 
In addition, it was demonstrated that these peptides can induce apoptosis [36, 37] and/or oxidative 
stress [25, 33, 37-39], leading to fungal cell death. Plant defensins share a common structural fold 
with scorpion potassium toxins. They all belong to the structural superfamily of CSαβ peptides. 
Members of this family exhibit relatively diverse biochemical and biological functions. However, in 
most cases, these peptides share a common function in innate immunity of animals, plants, and 
microorganisms [19, 40, 41]. The extensive distribution of this common motif throughout diverse 
organisms highlights that this relatively stable and versatile scaffold has the potential to tolerate 
insertions, deletions and substitutions within the structure [42]. It is the noteworthy CSαβ 
resemblance suggesting some similarity to scorpion toxins that block potassium channels which 
hinted us to investigate the possible interaction between plant defensins and Kv channels. 
In the present study, we analysed the potential of several plant defensins to interact with potassium 
channels in silico, based on the presence of the highly conserved potassium toxin signature 
sequence. Based on this analysis, the Arabidopsis thaliana defensin AtPDF2.3 was chosen to verify 
our hypothesis with regard to potassium channel inhibitory activity on one hand, and antifungal 
activity on the other.  
5.2. Materials and methods 
5.2.1. In silico analysis 
Plant defensins and scorpion toxins were aligned matching their cysteine residues, using the 
COBALT alignment tool [43]. The sequence of all peptides analysed in this study are presented in 
Fig.1, including their corresponding accession numbers and references. 
5.2.2. Strains and reagents 
Pichia pastoris strain X33 was used for heterologous production of AtPDF2.3. Botrytis cinerea 
(B05.10 and R16, kindly provided by Rudi Aerts, KHK Geel, Belgium) ), Verticillium dahliae 
(MUCL19210), Fusarium culmorum (K0311; MUCL30162), Fusarium oxysporum (isolate 5176, kindly 
provided by Donald Gardiner, CSIRO, Australia) and Fusarium graminearum (PH-1; MUCL30161) 
WT and ∆gcs [29] strain were used to evaluate the antifungal activity of the recombinant peptide in a 
fungal growth inhibitory assay [44]. Candida albicans (SC5314) and Saccharomyces cerevisiae WT 
(BY4741 and BY4743), ∆ipt1 [26], ∆ipt1/∆skn1 [27] and other yeast knockout strains tested in this 
study (listed in Table 3; purchased from Euroscarf; http://www.euroscarf.de) were used in a yeast 
growth inhibitory assay. 
All culture media were purchased from LabM (UK), unless stated otherwise. For heterologous 
production, P. pastoris was cultured in YPD (1% yeast extract, 2% peptone and 2% glucose), BMGY 
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(buffered complex glycerol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 1% glycerol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin) or BMMY 
(buffered complex methanol medium; 1% yeast extract, 2% peptone, 1.34% yeast nitrogen base w/o 
amino acids (Becton Dickinson, UK), 0.5% methanol, 100 mM K3PO4 pH 6, 4 x 10-5% biotin). Plant 
pathogenic fungi used in the fungal growth inhibitory assay were grown in half strength PDB (1.2% 
potato dextrose broth). C. albicans and S. cerevisiae WT and knockout strains were grown in minimal 
medium (MM; 0.77 g/L complete amino acid supplement mixture (Bio 101 Systems), 6.7 g/L yeast 
nitrogen base w/o amino acids (Becton Dickinson, UK), 20 g/L glucose). 
DmAMP1 was purified from the seeds of Dahlia merckii, as previously described by Osborn and 
colleagues [44]. 
5.2.3. Production and purification of recombinant (r) rAtPDF2.3  
Recombinant AtPDF2.3 was produced using the pPICZαA transfer vector and the P. pastoris 
expression system as previously described for recombinant HsAFP1 [45], with a minor modification: 
during the induction phase, 2% methanol (v/v%) was added to the culture to maintain induction of 
gene expression. After induction, the supernatant was collected as previously described [45] and 
concentrated via automated tangential flow filtration (Spectrum Laboratories, CA, USA). rAtPDF2.3 
was purified by cation exchange chromatography, using 75 mL SP sepharose High Performance 
resin (GE Healthcare, UK) and 20 mM sodium phosphate buffers at pH 6.8. The flow rate was 
maintained at 5 mL/min. Elution of the peptides was carried out by a washing step with 50% (v/v%) 
elution buffer (20 mM sodium phosphate, 1 M sodium chloride, pH 6.8) for 10 column volumes (CV), 
followed by a linear gradient to 100% (v/v%) elution buffer in 15 CV, resulting in a peak at 
approximately 75% (v/v%) elution buffer. The eluted fraction was further purified by reversed phase 
chromatography employing a Gemini C18 250x10 column (Phenomenex, CA, USA) and acetonitrile 
(ACN) for elution of the bound peptides. The flow rate was maintained at 4.6 mL/min. Elution of the 
peptides was carried out by a washing step at 0% (v/v%) ACN for 1.2 CV, followed by a linear 
gradient to 45% (v/v%) ACN in 5.9 CV. Elution of rAtPDF2.3 occurred at 28%. The eluted fraction 
was vacuum dried by centrifugal evaporation (SpeedVac Savant, Thermo Fisher Scientific, MA, 
USA), re-dissolved in MilliQ water and subjected to a microbicinchoninic acid assay (Pierce, Thermo 
Scientific, USA) according to the manufacturer’s instructions, to determine the protein concentration. 
Bovine serum albumin served as a reference protein. At least 70 mg/L of culture of purified 
rAtPDF2.3 was obtained, which was verified by LC-MS. 
5.2.4. Expression of voltage-gated potassium channels  
For the expression of the voltage-gated potassium channels (rKv1.1, rKv1.2, hKv1.3, rKv1.4, rKv1.5, 
rKv1.6, Shaker IR, hKv3.1, rKv4.3, and hERG) in Xenopus laevis oocytes, the linearized plasmids 
were transcribed using the T7 or SP6 mMESSAGE-mMACHINE transcription kit (Ambion). The 
harvesting of stage V–VI oocytes from an anaesthetized female X. laevis frog was previously 
described [46]. Oocytes were injected with 50 nL of cRNA at a concentration of 1 ng/nL using a 
micro-injector (Drummond Scientific, USA). The oocytes were incubated in a solution containing (in 
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mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4), supplemented with 50 mg/L 
gentamycin sulfate. 
5.2.5. Electrophysiological recordings  
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 °C) using a 
Geneclamp 500 amplifier (Molecular Devices, USA) controlled by a pClamp data acquisition system 
(Axon Instruments, USA). Whole cell currents from oocytes were recorded 1–4 days after injection. 
Bath solution composition was ND96 (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 
(pH 7.4) or HK (in mM): NaCl, 2; KCl, 96; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4). Voltage and 
current electrodes were filled with 3 M KCl. Resistances of both electrodes were kept between 0.7 
and 1.5 MΩ. The elicited currents were filtered at 0.5 kHz and sampled at 2 kHz (for potassium 
currents) or filtered at 2kHz and sampled at 20 kHz (for sodium currents) using a four-pole low-pass 
Bessel filter. Leak subtraction was performed using a -P/4 protocol. Kv1.1–Kv1.6 and Shaker currents 
were evoked by 250 ms depolarizations to 0 mV followed by a 250 ms pulse to −50 mV, from a 
holding potential of −90 mV. Current traces of hERG channels were elicited by applying a +40 mV 
prepulse for 2 s followed by a step to −120 mV for 2 s. Kv2.1 and Kv4.2 currents were elicited by 
500 ms pulses to +20 mV from a holding potential of −90 mV. Sodium current traces were, from a 
holding potential of −90 mV, evoked by 100 ms depolarizations to Vmax (the voltage corresponding to 
maximal sodium current in control conditions). In order to investigate the current–voltage relationship, 
current traces were evoked by 10 mV depolarization steps from a holding potential of −90 mV. To 
assess the concentration dependency of the toxin induced inhibitory effects, a concentration–
response curve was constructed, in which the percentage of current inhibition was plotted as a 
function of toxin concentration. Data were fitted with the Hill equation: y = 100/[1 + (IC50/[toxin])h], 
were y is the amplitude of the toxin-induced effect, IC50 is the toxin concentration at half-maximal 
efficacy, [toxin] is the toxin concentration, and h is the Hill coefficient. Comparison of two sample 
means was made using a paired Student's t test (P < 0.05). All data represent at least three 
independent experiments (n ≥ 3) and are presented as mean ± standard error. 
5.2.6. Antifungal activity assays 
The antifungal activity of rAtPDF2.3 against a range of plant pathogenic fungi was analysed following 
the protocol previously described by Osborn and colleagues [44]. Briefly, a two-fold dilution series of 
the peptide in sterile water was prepared in 96-well plates, after which 10 µL of peptide was mixed 
with 90 µL of half strength PDB containing 104 spores/mL of the fungus. The IC50 value, which is the 
concentration required for 50% growth inhibition as compared to control treatment, was determined 
by microscopy after 48 hours of incubation. The antifungal activity of rAtPDF2.3 against S. cerevisiae 
and S. cerevisiae knockout strains was analysed according to the standard CLSI protocol M27-A3 
[47] with minor modifications: an inoculum of approximately 106 cells/mL was suspended in MM and 
added to a two-fold dilution series of the peptides in water. The IC50 value was determined by 
spectrophotometry (OD490nm) after 24 hours of incubation. Sigmoidal curves were generated with 
GraphPad Prism (GraphPad Software, Inc., CA, USA), using nonlinear regression. IC50 values were 
derived from the whole dose-response curves. All data represent at least three independent 
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experiments (n ≥ 3); IC50 values are presented as mean ± standard error. Unpaired Student’s t-tests 
were performed to analyse statistically significant differences between the rAtPDF2.3 IC50 values of 
the wild types and those of the knockout strains. 
5.3. Results 
5.3.1. In silico analysis points to potential ion channel activity of the Arabidopsis thaliana plant 
defensin AtPDF2.3 
To investigate whether the hyper-conserved toxin signature could be identified in plant defensins, 18 
plant defensins were aligned with representatives of the two α-KTx subfamilies that show the highest 
homology with these defensins, namely α-KTx6.1 [48] and α-KTx23.1 [49], using the COBALT 
alignment tool [43] (Figure 1). The selection of plant defensins comprised defensins from Arabidopsis 
thaliana (AtPDF1.1-1.4 and AtPDF2.1-2.6 [50, 51]), Pisum sativum (Psd1 [52]), Raphanus sativus 
(RsAFP1 and RsAFP2 [53]), Dahlia merckii (DmAMP1 [44]), Heuchera sanguinea (HsAFP1 [44]), 
Nicotiana alata (NaD1 [54]), Medicago sativa (MsDef1 [55]) and Medicago truncatula (MtDef4 [56]), 
representing a selection of diverse plant defensins with regard to mode of action and target 
specificity (for more details, we refer to the Discussion section).  
The α-KTx6.1, also known as Pi1, is a 35-residue toxin cross-linked by four disulfide bridges that has 
been isolated from the venom of the chactidae scorpion Pandinus imperator. Pi1 inhibits Kv1 
subtypes with lower nM (Shaker B) and even pM (Kv1.2, Kv1.3) affinities [57, 58]. The α-KTx23 
subfamily is represented by Vm24, a novel 36-residue Kv1.3-specific peptide isolated from the venom 
of the scorpion Vaejovis mexicanus smithi. Vm24 inhibits Kv1.3 channels of human lymphocytes with 
pM affinity [59]. Both α-KTx6.1 and α-KTx23.1 possess the toxin signature with the Lys27 and Asn30 
present.  
As shown in Figure 1, the hyper-conserved and functionally crucial Lys27 is only present in 
AtPDF2.3, but not in the other plant defensins analysed in this study. In addition, Psd1 is the only 
defensin that contains the Asn30 residue. For this study, we chose to focus on AtPDF2.3 and 
investigated its potential interaction with potassium and sodium channels and antifungal activity. To 
this end, AtPDF2.3 was produced in Pichia pastoris and recombinant (r) AtPDF2.3 was purified using 
cation exchange and reversed phase chromatography. At least 70 mg/L of culture of purified 
rAtPDF2.3 was obtained, which was verified by LC-MS.  
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Figure 1 In silico analysis of plant defensins used in this study. (A) Sequence alignment between 
representative scorpion toxins and plant defensins. Sequences were aligned, matching the conserved cysteine 
residues in plant defensin sequences, using the COBALT alignment tool [43]; (-) denotes gaps in the alignment. 
UniProtKB accession numbers and references are presented. Conserved cysteine residues in plant defensin 
sequences are highlighted in grey; Lys27 and Asn30 present in the toxin signature are highlighted in blue and 
red, respectively. (B) Phylogenetic tree of sequences presented in (A), calculated by COBALT using the Fast 
Minimum Evolution method and Grishin distance [43].  
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5.3.2. rAtPDF2.3 blocks Kv1.2 and Kv1.6 channels 
rAtPDF2.3 was subjected to a screening on a wide range of ion channels. The peptide’s activity was 
investigated on 14 cloned voltage-gated potassium channels (Kv1.1–Kv1.6, Kv2.1, Kv4.2, Shaker IR, 
and hERG) and four cloned voltage-gated sodium channels (Nav1.2, Nav1.4, Nav1.5, and the insect 
channel DmNav1) (Figure 2). rAtPDF2.3 does not show activity on Nav channels at a 5 µM 
concentration (n ≥ 4) (data not shown), however, 3 µM rAtPDF2.3 can block Kv1.2 and Kv1.6 
channels. The same concentration of rAtPDF2.3 has no effect upon other Kv channel isoforms from 
the Shaker (Kv1.1, Kv1.3, Kv1.4-Kv1.5 and Shaker IR), Shab (Kv2.1), Shal (Kv4.2), and hERG (Kv11.1) 
subfamilies. These data suggest that rAtPDF2.3 acts as a toxin active on Kv channels, and more 
specifically, Kv1.2 and Kv1.6 channels. 
 
 
Figure 2 Activity of rAtPDF2.3 on ion channels expressed in X. laevis oocytes. Traces shown are 
representative of at least three independent experiments (n ≥ 3). The dotted line indicates the zero current level. 
The asterisk (*) distinguishes the steady-state current after application of 3 µM defensin. 
Concentration response curves were constructed to determine the values at which half of the Kv1.2 
and Kv1.6 channels were blocked by rAtPDF2.3. The IC50 values yield 1.3 ± 0.2 µM for Kv1.2 and  
978 ± 113 nM for Kv1.6 (Figure 3D). Kv1.2 channels were used to further investigate the 
characteristics of inhibition by rAtPDF2.3. The inhibition of Kv1.2 channels induced by the defensin is 
not voltage-dependent as in a range of test potentials from -30 to +30 mV, no difference in the 
degree of block is observed (Figure 3C). To investigate whether the observed current inhibition is 
Chapter 5  
  105
attributed to obstruction of the pore rather than to altered channel gating upon defensin binding, the 
IV curves in ND96 and HK solutions were constructed and steady-state Boltzmann activation curves 
determined (Figure 3A and 3B). Application of 2 µM of rAtPDF2.3 causes 59 ± 3% and 66 ± 4% 
inhibition of the potassium current in ND96 (data not shown) and HK solutions, respectively (n ≥ 5) 
(Figure 3D). In ND96, the IV curves in control and in the presence of 2 µM defensin are 
characterized by V1/2 values of 18 ± 1 and 18 ± 2 mV (n ≥ 4), respectively (Figure 3A). It can be 
concluded that no significant shift in the midpoint of activation occurred (P < 0.05) and that 
rAtPDF2.3 current inhibition is attributed to obstruction of the pore, rather than to altered channel 
gating. rAtPDF2.3 does not significantly influence the reversal potential EK, as can be seen from the 
IV relationship in HK solution (P < 0.05; n ≥ 4), showing that ion selectivity is not changed (Figure 
3B). EK values yield -4 ± 1 mV in control and -2 ± 1 mV after application of defensin (Figure 3B). 
Altogether, these experiments imply that current inhibition upon rAtPDF2.3 binding does not result 
from changes in the voltage dependence of channel gating. The inhibition of Kv1.2 channels occurs 
rapidly and its binding was reversible because the current recovered quickly and completely upon 
washout (data not shown). 
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Figure 3 rAtPDF2.3 induced modulation of Kv1.2 channel gating. (A), (B) current-voltage relationship in 
ND96 and HK, respectively. Closed symbols represent control condition, open symbols after application of 2 µM 
rAtPDF2.3; (C) The percentage of inhibition at a broad range of potentials is shown. No voltage dependence of 
inhibition was observed; (D): concentration-response curve on Kv1.2 and Kv1.6 channels obtained by plotting 
the percentage of blocked current as a function of increasing toxin concentrations. 
5.3.3.  rAtPDF2.3 has a broad antifungal activity spectrum  
As plant defensins are reported to exert antifungal activity against a broad range of fungi and yeasts 
(reviewed in [13, 14]), we further analysed the ability of rAtPDF2.3 to inhibit the growth of several 
plant pathogenic fungi as well as Saccharomyces cerevisiae (Table 1). rAtPDF2.3 shows growth 
inhibitory activity against all plant pathogenic fungi tested in this study, with IC50 values ranging from 
3.9 µM to 31.3 µM. The IC50 value of rAtPDF2.3 against the yeast S. cerevisiae is found to be 8.1 ± 
0.9 µM.  
Table 1 Growth inhibitory assay with rAtPDF2.3 against yeast and plant pathogenic fungi*  
Microorganism IC50 (µM) 
  Botrytis cinerea B05.10 31.3 ± 0.0 
Botrytis cinerea R16 31.3 ± 0.0 
Fusarium oxysporum 23.4 ± 4.9 
Fusarium culmorum 5.2 ± 1.2 
Verticillium dahliae 23.4 ± 4.9 
Fusarium graminearum PH-1 
Saccharomyces cerevisiae BY4741 
3.9 ± 0.0 
8.1 ± 0.9 
*Fungi and yeast were treated with a concentration range of rAtPDF2.3 for 48 or 24 hours, respectively, after 
which the IC50 values were determined microscopically for fungi and spectrophotometrically for yeast. IC50, the 
concentration required for 50% growth inhibition as compared to control treatment after either 24 hours for 
yeast, or after 48 hours for fungi. Data of at least three independent experiments are shown (n ≥ 3). 
5.3.4. rAtPDF2.3 antifungal action is dependent on M(IP)2C 
As several plant defensins are reported to interact with fungal GlcCer [28, 29, 31] or M(IP)2C [25-27], 
and AtPDF1.1 and AtPDF1.3, other plant defensins from A. thaliana, were already shown to interact 
with fungal GlcCer [51], we investigated whether also rAtPDF2.3 interacts with GlcCer or M(IP)2C. To 
this end, several fungal strains with deletions in the corresponding sphingolipid biosynthesis genes 
were analysed for their sensitivity towards rAtPDF2.3. GlcCer are synthesized by glucosylceramide 
synthase, encoded by the GCS gene [23, 24]. Fungal deletion mutants in GCS were previously found 
to be resistant to the GlcCer-interacting plant defensins RsAFP2, MsDef1 and Psd1 [28-31]. Hence, 
potential involvement of GlcCer in rAtPDF2.3 antifungal action was analysed by challenging F. 
graminearum WT and the ∆gcs strain with this peptide (Table 2). Deletion of the GCS gene causes a 
moderate increase in sensitivity towards rAtPDF2.3 treatment, resulting in an IC50 value of 1.3 ± 0.3 
µM as compared to 3.9 ± 0.0 µM for the WT. 
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Table 2 Growth inhibitory assay with rAtPDF2.3 against S. cerevisiae and F. graminearum*  
Microorganism IC50 (µM) Significance level 
Saccharomyces cerevisiae BY4741 WT 8.1 ± 0.9 NA 
Saccharomyces cerevisiae BY4741 ∆ipt1 183.0 ± 1.3 ** 
Saccharomyces cerevisiae BY4741 ∆skn1 186.0 ± 1.8 ** 
Saccharomyces cerevisiae BY4741 ∆ipt1∆skn1 
Fusarium graminearum PH-1 WT 
173.0 ± 1.8 
3.9 ± 0.0 
** 
NA 
Fusarium graminearum PH-1  ∆gcs 1.3 ± 0.3 * 
 
  
*Yeast and fungi were treated with a concentration range of rAtPDF2.3 for 24 or 48 hours, respectively, after 
which the IC50 values were determined spectrophotometrically for yeast and microscopically for fungi. IC50, the 
concentration required for 50% growth inhibition as compared to control treatment after either 24 hours for 
yeast, or after 48 hours for fungi. Mean ± SEM of at least three independent experiments (n ≥ 3) is shown. 
Unpaired Student’s t-test were performed to analyse significant differences between the effect of rAtPDF2.3 on 
wild type (WT) yeast or fungus and knockout mutants; the significance level is presented (* and ** represent 
P<0.01 and P<0.001 respectively; NS, no significant difference). 
M(IP)2C sphingolipids are synthesized by sequential addition of inositolphosphate and mannose to 
phytoceramides, resulting in inositolphosphorylceramide (IPC), mannosyl-IPC (MIPC) and ultimately 
mannosyldi-IPC (M(IP)2C). In this final step, MIPC is converted to M(IP)2C by inositolphosphate 
transferase, encoded by the IPT1 gene [21, 22, 60]. Deletion of the IPT1 gene in yeast results in a 
lack of M(IP)2C and consequently, in increased amounts of the precursor MIPC in the cell membrane 
[60]. In addition, a ∆skn1 yeast strain was shown to be devoid of M(IP)2C, indicating an as yet 
unidentified role for Skn1p in M(IP)2C biosynthesis [27]. DmAMP1 was shown to interact with 
M(IP)2C in yeast and consequently, yeast deletion mutants ∆skn1, ∆ipt1 and ∆skn1∆ipt1 were found 
to be at least 6-fold more resistant to DmAMP1 as compared to WT yeast [25-27]. As shown in Table 
2, deletion of IPT1, SKN1 or both IPT1 and SKN1 in yeast results in a significant increase in 
resistance towards rAtPDF2.3 treatment, as the IC50s of rAtPDF2.3 for the single and double 
deletion mutants in IPT1 and/or SKN1 are at least 20-fold increased as compared to its IC50 for WT 
yeast. Altogether, these results point to the involvement of M(IP)2C, and not GlcCer, in rAtPDF2.3 
antifungal action, similar to results observed for DmAMP1.  
Since DmAMP1 and rAtPDF2.3 are both suggested to interact with M(IP)2C [26, 27, 61], and 
rAtPDF2.3 was shown to block voltage-gated Kv1.2 and Kv1.6 channels, we investigated the effect of 
DmAMP1 on a similar panel of potassium channels. The sequence alignment of DmAMP1 with 
AtPDF2.3 and the representative scorpion toxins α-KTx6.1 and α-KTx23.1 (Figure 1) shows that 
DmAMP1 does not possess the key functional residues of α-KTxs, i.e. Lys-Cys4-Xaa-Asn (Xaa, any 
amino acid) [8], which suggests that DmAMP1 is probably not able to interact with potassium 
channels.  
Indeed, DmAMP1 does not show activity on Kv channels up to 10 µM (n ≥ 4) (data not shown), which 
is 10-fold higher than the IC50 value of rAtPDF2.3 on Kv1.2 and Kv1.6 channels. These data suggest 
that sphingolipid-dependent antifungal activity and Kv blocking activity are not linked. In addition, 
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these observations support previous reports suggesting that the toxin signature sequence is 
important in activity on Kv channels [8].  
5.3.5. Potassium transport is involved in rAtPDF2.3 antifungal action against yeast  
Our above data indicate that rAtPDF2.3 blocks Kv1.2 and Kv1.6 voltage-gated potassium channels, 
expressed in X. laevis  oocytes. In yeast, potassium transport is mainly regulated by the Trk1p-Trk2p 
potassium transporter system [62]. In an attempt to translate the results from the electrophysiological 
recordings to yeast’s susceptibility to rAtPDF2.3, we analysed the rAtPDF2.3-sensitivity of ∆trk1 and 
∆trk2 yeast strains, in addition to other knockout strains for genes that play a role in potassium 
homeostasis (listed in Table 3) and compared the corresponding IC50 values to that of the WT.  
Table 3 Growth inhibitory assay with rAtPDF2.3 against S. cerevisiae wild type (WT) and knockout 
mutants*  
Microorganism IC50 (µM) Significance level 
Saccharomyces cerevisiae BY4741 WT 8.1 ± 0.9 NA 
Saccharomyces cerevisiae BY4743 WT 3.4 ± 0.1 NA 
Saccharomyces cerevisiae BY4741 ∆trk1 1.5 ± 0.0 *** 
Saccharomyces cerevisiae BY4741 ∆trk2 7.0 ± 0.6 NS 
Saccharomyces cerevisiae BY4741 ∆hal5 4.0 ± 0.4 ** 
Saccharomyces cerevisiae BY4741 ∆prm6 7.6 ± 0.2 NS 
Saccharomyces cerevisiae BY4741 ∆arl1 5.7 ± 0.2 * 
Saccharomyces cerevisiae BY4741 ∆qdr2 2.9 ± 0.2 ** 
Saccharomyces cerevisiae BY4741 ∆sat4 5.1 ± 0.1 * 
Saccharomyces cerevisiae BY4741 ∆vhc1 8.0 ± 0.2 NS 
Saccharomyces cerevisiae BY4741 ∆ppz2 8.6 ± 0.5 NS 
Saccharomyces cerevisiae BY4741 ∆tok1 7.7 ± 0.5 NS 
Saccharomyces cerevisiae BY4741 ∆nha1 9.1 ± 0.7 NS 
Saccharomyces cerevisiae BY4741 ∆ppz1 10.1 ± 0.5 NS 
Saccharomyces cerevisiae BY4741 ∆kch1 8.86 ± 0.33 NS 
Saccharomyces cerevisiae BY4741 ∆kkq8 7.06 ± 0.15 NS 
Saccharomyces cerevisiae BY4743 ∆frq1 3.12 ± 0.09 NS 
*WT and knockout yeast strains were treated with a concentration range of rAtPDF2.3 for 24 hours, after which 
the IC50 values were determined spectrophotometrically; IC50, the concentration required for 50% growth 
inhibition as compared to control treatment. Mean ± SEM is shown of at least three independent experiments (n 
≥ 3). Unpaired Student’s t-test were performed to analyse significant differences between the effect of 
rAtPDF2.3 on WT yeast and knockout mutants; the significance level is presented (*, ** and *** represent 
P<0.05, P<0.01 and P<0.001 respectively; NS, no significant difference). NA, not applicable; ND, not 
determined. 
We found that TRK1 plays an important role in mediating tolerance towards rAtPDF2.3 in yeast, as a 
significantly lower IC50 value for rAtPDF2.3 was found for the ∆trk1 strain as compared to the WT, 
i.e. 1.5 ± 0.0 µM and 8.1 ± 0.9 µM, respectively. Similarly, deletion of HAL5, ARL1, QDR2 and SAT4 
results in increased sensitivity towards rAtPDF2.3 treatment as compared to the WT. None of the 
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knockout strains was found more resistant to rAtPDF2.3 than WT yeast, suggesting that the tested 
potassium transporters are involved in generating tolerance towards rAtPDF2.3 treatment, rather 
than constituting its target.  
5.4. Discussion 
We showed that recombinant (r)AtPDF2.3, a plant defensin from Arabidopsis thaliana, is an inhibitor 
of voltage-gated potassium channels, capable of interacting with several different subtypes of the Kv1 
subfamily. Since no significant change in the kinetics of gating was observed after defensin 
application, it can be assumed that rAtPDF2.3 exerts its Kv channel inhibiting activity by physically 
blocking the channels, a phenomenon described previously for many Kv channel toxins isolated from 
scorpions, snakes, cone snails and sea anemones among others. To date, few plant defensins were 
shown to interact with ion channels: the defensin-like peptide ZmES1-4 from maize was reported to 
interact with the intrinsic rectifying potassium channel KZM1, resulting in KZM1 channel opening and 
potassium influx, leading to pollen tube burst in maize [63]. In addition, the alfalfa defensin MsDef1 
was shown to block the mammalian L-type Cav1.2 channel in a manner similar to the antifungal toxin 
KP4 from Ustilago maydis [55]. In contrast, MtDef2 and RsAFP2, defensins from barrel clover and 
radish seeds, respectively, failed to block Cav1.2. It was hypothesized that MsDef1 binds to the 
extracellular side of the Cav1.2 pore region, much like the blockage of potassium channels by 
charybdotoxin or the blockage of sodium channels by tetrodoxin [55]. In line, rAtPDF2.3 is suggested 
to physically block Kv channels in a similar manner as scorpion potassium toxins. Also the pea 
defensin Psd1 was suggested to function as a potassium channel inhibitor, based on its electrostatic 
surface potential that was similar to the known potassium channel inhibitors Agitoxin 2, αKTx7.2 and 
OSK1 toxin [64]. 
Recently, a specific toxin signature sequence was assigned to scorpion toxins active on potassium 
channels, in which the Lys at position 27 (Lys27) and the Asn at position 30 (Asn30) were found 
important for channel inhibitory activity [8]. AtPDF2.3, and by extinction other plant defensins, share 
a common structural fold with scorpion potassium toxins, i.e. the CSαβ motif, however, not all plant 
defensins possess the toxin signature sequence. The panel of plant defensins that was subjected to 
in silico analysis in this study, is diverse with regard to mechanisms of antifungal action. For instance, 
different membrane targets have been identified for different defensins: RsAFP2, MsDef1 and Psd1 
are characterized by GlcCer-depending activity [28-31] and DmAMP1 interacts with M(IP)2C [25-27], 
whereas the membrane target of HsAFP1 is not yet identified. Moreover, some defensins were 
shown to induce morphogenic growth defects, such as HsAFP1, RsAFP2 and MsDef1 [44, 65], 
whereas others, like MtDef4, did not [65]. Similarly, only few defensins, including RsAFP2, HsAFP1 
and NaD1 [33, 37, 38, 66], were found to induce oxidative stress. Finally, the (sub)cellular 
localisation differs among these defensins, pointing to different (sub)cellular targets for different 
defensins. In this respect, Psd1 was shown to interact with nuclear cyclin F, whereas MtDef4 was 
reported to bind cytosolic phophatidic acid [32, 34]. Hence, although a variety of plant defensins with 
a similar structural fold was subjected to in silico analysis for potential potassium channel inhibitory 
activity, only few defensins are suggested to interact with potassium channels, based on the 
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presence of the toxin signature sequence. Whereas the Asn30 is only present in Psd1, and hence, 
absent in all other plant defensins analysed in this study, including DmAMP1, (Figure 1), the hyper-
conserved and functionally crucial Lys27 is present in AtPDF2.3 (on position 33). The lack of Kv 
channel inhibition of DmAMP1 could be explained as such. The sequence alignment also provides 
some information on the lower potency of rAtPDF2.3 compared to α-KTx. rAtPDF2.3 displays a Gly 
instead of an Asn at the corresponding position 30 (position 36 in the AtPDF2.3 sequence). It thus 
can be assumed that rAtPDF2.3 forms a less stable interaction with the Kv channel due to the lack of 
stabilizing hydrogen bonds otherwise formed between Asn30 of the toxin and Asp residues within the 
channel filter. In future structure-function studies it would be interesting to investigate mutant 
AtPDF2.3 peptides for their potential to block potassium channels and compare the activity of these 
mutants to that of native AtPDF2.3. These mutants would include [G36N]AtPDF2.3, 
[K33A][G36N]AtPDF2.3 and [K33A]AtPDF2.3 (the residue numbers are based on the AtPDF2.3 
reference sequence). Testing them would gain insight into the role of the toxin signature in the 
AtPDF2.3 sequence. More specifically, loss of the ability of the [K33A]AtPDF2.3 to block potassium 
channels would reveal the importance of the Lys residue for potassium channel inhibitory action. 
Moreover, an increased potassium channel inhibitory activity of [G36N]AtPDF2.3 as compared to 
AtPDF2.3 would highlight the significance of possessing a complete toxin signature for this activity. In 
line, analysis of the potassium channel inhibitory activity of [K33A][G36N]AtPDF2.3 would indicate 
the role of the Asn residue in blocking potassium channels. Such results would reinforce previous 
findings for scorpion toxins [8] and broaden the knowledge on the mechanism of action of potassium 
channels inhibitors. In addition, the AtPDF2.3 mutants should be analysed for their antifungal activity 
towards yeast strains with deletion in genes involved in potassium transport and/or homeostasis, 
listed in Table 3. As such, our hypothesis on the link between potassium channel inhibitory activity 
and antifungal activity involving potassium transport and/or homeostasis in yeast will be either 
reinforced or rejected.  
As plant defensins possess antifungal activity against a broad range of fungi [13, 14], we further 
characterized the antifungal activity spectrum of rAtPDF2.3 and found that rAtPDF2.3 inhibits the 
growth of various plant pathogenic fungi, including Fusarium and Botrytis species with IC50 values 
ranging from 3.9 µM to 31.3 µM. However, these concentrations are 2- to 30-fold higher than those 
reported for several other plant defensins, including DmAMP1, HsAFP1, RsAFP2, MsDef1 and 
MtDef4, depending on the test fungus [44, 55, 65]. Similar observations were made for the 
rAtPDF2.3 growth inhibitory activity against the yeast S. cerevisiae: the IC50 for rAtPDF2.3 was 8.1 ± 
0.9 µM, whereas that for DmAMP1 was 2.5 ± 0.2 µM (data not shown). These observations led us to 
conclude that rAtPDF2.3 seems less potent than other plant defensins against yeast and a variety of 
fungi. Next, we investigated the potential role of M(IP)2C and GlcCer in rAtPDF2.3 antifungal activity, 
as some plant defensins were shown to specifically interact with these sphingolipids and this 
interaction was found essential in plant defensin-mediated antifungal activity [25, 27-31, 61]. 
rAtPDF2.3 is suggested to interact with M(IP)2C, as is DmAMP1 [26, 27, 61], since an at least 20-fold 
increased rAtPDF2.3-resistance was found for yeast mutants with deletions in IPT1 and SKN1, both 
involved in the M(IP)2C synthesis. As both rAtPDF2.3 and DmAMP1 are suggested to interact with 
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M(IP)2C, but only rAtPDF2.3 was found to block Kv channels, sphingolipid-dependent antifungal 
activity and Kv blocking activity seem not linked. 
In order to confirm the involvement of potassium channels in rAtPDF2.3 antifungal activity, we 
investigated the effect of rAtPDF2.3 against yeast strains with deletions in genes involved in 
potassium transport and homeostasis. Note that orthologues of the oocyte Kv channels studied here 
have not been identified in yeast. Hence, in this study, we focused on all yeast proteins known to be 
involved in potassium transport and homeostasis in general. Potassium homeostasis is important in 
yeast, as high intracellular levels are required for many physiological processes, such as protein 
synthesis, enzyme activation and regulation of intracellular pH [62, 67, 68]. We found several 
potassium transport- and homeostasis-related genes to be involved in mediating tolerance towards 
rAtPDF2.3 treatment, of which TRK1 was the most notable. Hence, potassium channel inhibitory 
activity of rAtPDF2.3 seems to be linked to the involvement of potassium transport in yeast for its 
antifungal activity. Trk1p is a component of the Trk1p-Trk2p potassium transport system in yeast, 
which plays a major role in potassium uptake [69-71], and was previously shown to respond to 
tunicamycin treatment in C. albicans. Indeed, activation of the high affinity Ca2+ influx system by 
tunicamycin was found to be dependent on Trk1p and Trk2p [72]. In line, Trk1p was found to be 
essential for Histatin 5 toxicity in C. albicans, as a strain with a 5-fold reduction of Trk1p function was 
quite insensitive to Histatin 5, and this result was not due to a reduced cellular uptake of the peptide 
[73]. Similarly, Trk1p was shown to be required for fungicidal activity by lactoferrin 11, bactenecin 16 
and virion-associated protein VPR 12 against C. albicans, pointing to Trk1p as a functional effector of 
these compounds [74]. In contrast, Trk1p was not required for killing of C. albicans by the human 
defensins HNP-1, hBD-2 and hBD-3 [74]. The latter is in line with our observation that Trk1p is not 
involved in rAtPDF2.3 antifungal activity as a functional effector, but is rather part of a tolerance 
mechanism towards rAtPDF2.3 treatment in S. cerevisiae. Since HAL5, SAT4 and ARL1 are 
modulators of the Trk1p-Trk2p transport system, it is not surprising that the corresponding knockout 
strains were found hypersensitive towards rAtPDF2.3 treatment as well.  More specifically, Hal5p 
activates the Trk1p-Trk2p transport system [75] and hence, deletion of HAL5 results in impairment of 
Trk1p-Trk2p function. Similarly, Sat4p functions as a regulator of the Trk1p-Trk2p transport system 
and is partially redundant with Hal5p [75]. ARL1 encodes for a soluble GTPase that was shown to 
regulate potassium influx via regulation of SAT4 and HAL5 [76]. Deletion of ARL1 might result in 
deregulation of Hal5p and Sat4p, which on its turn would lead to impairment of Trk1p-Trk2p function. 
Finally, we found that also QDR2 is involved in mediating tolerance towards rAtPDF2.3 treatment. 
Qdr2p functions as a plasma membrane transporter of many mono- and divalent cations [77], and 
actively transports a variety of drugs out of the cell, such as quinidine and barban [78]. In view of the 
latter, it was shown that QDR2, in addition to QDR3, confers resistance to cisplatin and bleomycin in 
yeast [79]. In addition, QDR2 was found to affect tolerance to oxidative stress, as strains 
overexpressing and lacking QDR2 exhibited phenotypes when reactive oxygen species-producing 
agents, such as hydrogen peroxide and menadione, were added to the growth medium. As several 
plant defensins are reported to induce reactive oxygen species in yeasts [33, 37-39], and we found 
that QDR2 is involved in tolerance towards rAtPDF2.3 treatment, it might well be that rAtPDF2.3 
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antifungal action involves the induction of oxidative stress. Whether this is the case, needs to be 
further investigated.  
In conclusion, we have shown that the A. thaliana defensin rAtPDF2.3 interacts with Kv1.2 and Kv1.6 
channels in a similar manner as was observed for scorpion toxins, i.e. by physically blocking the Kv 
channels. We have confirmed the involvement of potassium transport and/or homeostasis in 
rAtPDF2.3 antifungal action in yeast, more specifically by showing that several genes involved in 
regulating these processes confer tolerance towards rAtPDF2.3. This is to our knowledge the first 
evidence for a possible link between plant defensin channel inhibitory activity and antifungal activity 
involving potassium transport and/or homeostasis. In addition, we demonstrated that the antifungal 
activity of rAtPDF2.3 is depending on the presence of the sphingolipid M(IP)2C in the fungal 
membrane. Interestingly, we have previously shown that the antifungal activity of other  defensins 
from A. thaliana, namely AtPDF1.1 and AtPDF1.3, largely depended on the presence of the 
sphingolipid GlcCer [51]. As such this is, to our knowledge, the first example of the presence of 
different plant defensins in the same plant species, i.e. A. thaliana, targeting different types of fungal 
sphingolipids. Additional research is needed to further elucidate the mechanism of antifungal action 
of rAtPDF2.3. 
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Abstract 
Single cell analysis (SCA) has gained increased popularity for elucidating cellular heterogeneity at 
genomic, proteomic and cellular levels. Flow cytometry is considered as one of the most widely used 
techniques to characterize single cell responses, however, its inability to analyse cells with spatio-
temporal resolution poses a major drawback. Here, we introduce a digital microfluidic (DMF) platform 
as a useful tool for conducting studies on isolated yeast cells in a high-throughput fashion. The 
reported system exhibits (i) a microwell array for trapping single non-adherent cells by shuttling a 
cell-containing droplet over the array, and allows (ii) implementation of high-throughput cytotoxicity 
assays with enhanced spatio-temporal resolution. The system was tested for five different 
concentrations of the antifungal drug Amphotericin B, and the cell responses were monitored over 
time by time lapse fluorescence microscopy. The DMF platform was validated by bulk experiments, 
thereby mimicking the DMF experimental design. A correlation analysis revealed that results 
obtained on the DMF platform are not significantly different from those obtained in bulk, and hence, 
the DMF platform can be used as a tool to perform SCA on non-adherent cells, with spatio-temporal 
resolution. In addition, no external forces, other than the physical forces generated by moving the 
droplet, were used to capture single cells, thereby avoiding cell damage. As such, the information on 
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cellular behaviour during treatment could be obtained for every single cell over time making this 
platform noteworthy in the field of SCA. 
6.1. Introduction 
In a cell population, differential responses towards external perturbations are ubiquitous, which 
indicates cellular heterogeneity at genomic and functional levels1. To elucidate information 
concerning cellular heterogeneity within a specific population, analysis of single cells within this 
population needs to be performed. Depending on the growth cultures, cells can be categorised into 
adherent or non-adherent cells. Spatio-temporal studies performed on adherent cells are less tedious 
and complex to perform, as compared to non-adherent cells due to the free floating nature of the 
latter. Conventional approaches for conducting cell-based studies on non-adherent cells are usually 
performed in bulk format, in which flow cytometry is often used to analyse the responses of single 
cells based on their fluorescent properties. However, the obtained data are spatially and temporally 
unresolved and do not allow for analysis of single cells in time and space2. In addition, the number of 
available systems for precise manipulation and retention of non-adherent cells on a defined location 
is limited3. The development of platforms that support single cell analysis of non-adherent cells with 
spatio-temporal resolution is therefore crucial.  
Over the last two decades, channel-based microfluidics has come up with powerful strategies for 
confining4 and manipulating5 single cells within physical or chemical boundaries, while maintaining an 
in vivo-like environment. Several demonstrations have been reported in which hydrodynamic forces 
are implemented as a strategy for isolating cells in a microfluidic flow channel, such as integrated 
wall traps6-8 and obstructions9-119-11. Alternatively, incorporation of electrical12, optical13, magnetic14 or 
suction forces15 have been demonstrated for isolating single cells, such as in dielectrophoresis 
(DEP)16-18 and when using optical tweezers19, 20. Lately, the concept of microfabricated well arrays 
has also been exploited widely in research for trapping single cells in micron-sized cavities by 
gravitational force and implementing cell-based studies21-23. However, the current state-of-the-art 
employed for seeding single cells in channel-based microfluidics has certain drawbacks, such as the 
demand for high sample and reagent consumption. Moreover, the channel constrained microfluidics 
is more likely to clog when a cell-rich sample is introduced24. Lastly, with respect to the cell-capturing 
system, a thorough investigation and device optimization is required to avoid undesired effects such 
as cell stress. 
Digital microfluidics (DMF) has emerged as a channel-free microfluidic technology, in which small 
droplets of liquid are handled on planar surfaces. It offers several advantages over channel-based 
microfluidics for applications where a higher degree of flexibility is required25. In addition to the 
reduced reagent and sample consumption, droplets can be individually and precisely addressed 
through a software interface, leading to a minimal dead volume and low energy consumption. DMF 
technology has been demonstrated for conducting cell-based assays on adherent and non-adherent 
cells26-29. For instance, water permeability measurements were conducted on isolated Arabidopsis 
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thaliana protoplasts (approx. 10-25 µm) at single cell level by implementing an on-chip magnetic 
immobilization strategy27. In another report, an optoelectronic tweezers-integrated digital microfluidic 
device was used for manipulating a group of adherent HeLa cells26.  In addition, Rival and colleagues 
developed an EWOD-based microfluidic chip for mRNA extraction and subsequent transcriptome 
analysis via qRT-PCR of single human HaCaT adherent cells 28.  Recently, a hybrid droplet-to-digital 
microfluidic system was reported, in which droplets containing single yeast cells were dispensed and 
monitored for growth and their ability to produce ethanol 29. Although the number of available 
microfluidic systems for single cell analysis is gradually increasing,  the application of DMF 
technology for conducting single cell studies on non-adherent cells remains rather unexplored. 
In this paper, we develop a straightforward approach for real-time monitoring of single yeast cell 
responses during antifungal treatment in a high-throughput manner, using an electrowetting-on-
dielectric (EWOD) based DMF platform (Figure 1A). A recently developed strategy30 for seeding and 
sealing single superparamagnetic beads in femtoliter wells was extended and adjusted for trapping 
and subsequently analysing single yeast cells (Saccharomyces cerevisiae) in the microwell array. 
The effect of the antifungal membrane-permeabilizing agent Amphotericin B on membrane integrity 
of trapped yeast cells was investigated, using the fluorescent reporter dye propidium iodide and time 
lapse fluorescence microscopy. This DMF platform with microwell arrays is demonstrated as a 
promising tool for implementing various biological applications concerning single non-adherent cells 
in a high-throughput manner.  
6.2. Materials and methods 
6.2.1. Strains and chemical reagents 
Saccharomyces cerevisiae strain BY4741 was used in all experiments. Propidium iodide (PI; 540/608 
nm) was supplied by Sigma Aldrich (Saint Louis, MO, USA). Amphotericin B was purchased from 
Sigma Aldrich (Saint Louis, MO, USA). Fluoroinert FC-40 was purchased from 3M (St. Paul, MN, 
USA). Chemicals for photolithography, including S1818 and 351-developer, were supplied by Rohm 
and Haas (Marlborough, MN, USA). AZ1505 photoresist was purchased from Microchemicals GmbH 
(Ulm, Germany). Parylene-C dimer and Silane A174 were purchased from Plasma Parylene Coating 
Services (Rosenheim, Germany). Teflon-AF® was obtained from Dupont (Wilmington, DE, USA). 
6.2.2. Design and fabrication of digital microfluidic plates 
To obtain a high-throughput assay, the grounding and actuation plates of the DMF platform were 
designed to accommodate and optically visualise two arrays, consisting of 22,000 microwells each 
(Figure 1A). As such, two experiments could be conducted in parallel. Fabrication of DMF chips was 
performed in the ESAT-MICAS cleanroom facility of the KU Leuven, as described by Witters and 
colleagues30, with some minor modifications as briefly described below.   
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6.2.2.1. Actuation plate 
Cleaned glass wafers (1.1 mm thickness) were sputter coated with chromium (100 nm) and 
patterned using standard photolithographic processes. The plates were cleaned in acetone 
and IPA twice, and the surface was plasma activated (O2-plasma, 150 mtorr, 100 W). To 
promote adhesion, the plates were primed with silane A174 and then coated with a layer of 
Parylene-C (3 µm) using chemical vapour deposition. A thin layer of Teflon-AF® (approx. 200 
nm thickness using 3 % w/w in Fluorinert FC-40) was subsequently spin-coated (1200 rpm) 
on top of the Parylene-C layer, baked for 5 min at 110°C and 5 min at 200°C. Crenelated 
actuation electrodes of 2.8 mm × 2.8 mm were selectively actuated to manipulate individual 
droplets of 2.7 µL. A slight modification was made in the layout of electrodes from the one 
reported in our previous works, where the number of crossing paths between rows and 
columns was increased from one to two. This modification was required to improve the 
flexibility during droplet manipulations (Figure 1A). 
6.2.2.2. Grounding plate 
The grounding plate of the DMF device was fabricated as previously described30. Briefly, cleaned 
glass wafers (1.00 mm thickness) were coated with an aluminium layer (40 nm) using thermal 
evaporation, leaving two 2.5 × 2.5 mm visualization windows. The surface was then coated with the 
fluoroalkylsilane Dynasylan® F 8263, followed by spin-coating Teflon-AF® (approx. 3 µm). 
Fluoroalkylsilane improved the adhesion between Teflon-AF® and aluminium. In order to pattern the 
microwells in the Teflon-AF® surface, a hard contact masking procedure was developed by 
depositing Parylene-C (1 µm) and aluminium (60-80 nm) layers. A thin layer of AZ1505 photoresist 
was then spin-coated on the aluminium layer. Using standard photolithography processes, the 
aluminium was patterned and etched. Finally, for transferring the pattern from aluminum to Teflon-
AF®, the stack was subjected to an O2 plasma (150 mtorr, 100 W) for 10 min. At last, the aluminum-
Parylene-C mask was peeled off using a pair of forceps, revealing the two microwell arrays (1.9 mm 
× 1.9 mm) on a single grounding plate, consisting of 22,000 microwells each. The patterned 
microwells measured approximately 5.5 µm wide and 3 µm deep, and were arranged in a hexagonal 
pattern with a pitch distance of 14 µm. 
6.2.3. DMF platform operation 
A double-sided tape of 160 µm thickness was applied on the actuation plate as a spacer and for 
adhering the grounding plate to the actuation plate. The assembled plates were installed in the 
custom-made DMF microfluidic chip holder. The actuation sequence of electrodes was controlled 
with a customized Labview program (National Instruments Corp., Austin, TX, USA) and an in-house 
developed Matlab based program (MathWorks Inc., Natick, MA, USA). Droplets were driven by an 
AC-voltage of 120–130 Vrms, an activation time of 1000 ms and a relaxation time of 40 ms. The AC-
actuation voltage was realized by the oscillating waveforms, produced by the function generator 
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operating at 1 kHz (GFG-8216A-ISO-TECH, England) and further amplified by an amplifier (FLC 
Electronics A600, Origin Sweden). 
6.2.4. Cell culture 
Saccharomyces cerevisiae strain BY4741 was used in all experiments. Reagents were supplied by 
Lab M Ltd. (Lancashire, England), unless stated otherwise. Media used were YEPD (1 % Yeast 
Extract; 2 % Peptone; 2 % Dextrose) or 1/5 YEPD (YEPD diluted in distilled water). A yeast overnight 
culture grown at 200 rpm and 30°C, was diluted to an optical density (OD) measured at λ=600 nm of 
0.15 in a flask containing 50 mL YEPD and further cultured at 200 rpm and 30°C for 5 hours to obtain 
exponentially grown cells. Cells were then pelleted by centrifugation at 4000 rpm for 3 min, washed 
and re-suspended in 1/5 YEPD to OD 3. 
6.2.5. Single cell seeding in the microwell array and cytotoxicity assay 
Cell death can occur either via apoptotic or non-apoptotic mechanisms, depending on the influence 
of the stimuli on the cell health31. One of the hallmarks of apoptosis, in contrast to non-apoptotic 
mechanisms, is the presence of an intact cell membrane32. Propidium iodide (PI) is a fluorescent dye 
that can enter cells with a compromised plasma membrane (i.e. non-apoptotic cells). In this study, we 
investigated the effect of the antifungal drug amphotericin B (AmB) on these subpopulations by PI 
staining. 
One hour prior to cell seeding in the microwell array, the yeast culture was pre-treated with AmB, at 
final concentrations of 10 µM, 25 µM, 50 µM, 100 µM or 200 µM, in a dimethyl sulfoxide (DMSO) 
background of 1 % (v/v), or with 1 % DMSO alone (control treatment), while placed on a rotator mixer 
(14 rpm) (Figure 1A, i). The off-chip pre-treatment of cells with AmB was performed for pre-loading 
the cells with the drug. As membrane permeabilization events were only observed after 60 min of 
treatment, pre-treatment in bulk for 60 min was possible. After pre-treatment, cell seeding was 
performed in two steps. First, two 2.7 µL droplets, one containing pre-treated cells and the other 
containing the corresponding AmB concentration and 2 µg/mL propidium iodide (PI) in 1/5 YEPD 
(AmB/PI), were placed on two separate electrodes of the actuation plate. Upon assembling the 
microwell array in the grounding plate, the array would align with the cell droplet (Figure 1A) and 
sandwich it between the plates. In a next step, 80 µL of silicon oil was added in between the two 
plates using a pipette to prevent sticking and evaporation of the cell droplet (Figure 1B). The 
assembled plates were placed in the DMF chip holder, and the holder was flipped upside down and 
incubated for another 10 min at room temperature to allow the sedimentation of the cells. This step 
was followed by automated shuttling of the cell droplet over the microwell array using a software 
assisted EWOD actuation, referred to as seeding cycles (Figure 1A, ii). 
After seeding, the cell droplet was actuated away from the microwell array, after which the AmB/PI 
droplet was transported to the microwell array. The cell responses induced by AmB were monitored 
for the following 300 min (360 min, including the pre-treatment step) in 15 min intervals, using an 
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inverted fluorescence microscope (IX-71, Olympus, Tokyo, Japan) equipped with a CCD-camera 
(Figure 1A, iii). Using a 20x lens magnification (IX-71, Olympus, Tokyo, Japan), the complete array 
was scanned in 9 overlapping frames in approximately 15 seconds, in which a single frame covered 
approximately 4100 wells. After 360 min, the total number of trapped cells was determined by 
exposing the array to an intense beam of UV radiation for 20 min, thereby abruptly killing and 
permeabilizing all the cells, rendering them PI-positive (Figure 1A, iv). 
6.2.6. Assessing reproduction ability of trapped yeast cells 
In order to evaluate the reproduction ability of trapped cells after cell seeding, budding events were 
monitored for each trapped yeast cell. In a first step, yeast cells were seeded employing the protocol 
described earlier with a minor modification: the two 2.7 µL droplets that were placed on the 
electrodes consisted of a droplet containing untreated yeast cells and a droplet of 1/5 YEPD. After 
cell seeding, the cell droplet was actuated away from the microwell array and the 1/5 YEPD droplet 
was transported to the microwell array. The DMF chip was disassembled in order to use bright-field 
microscopy to monitor cell budding events, as no visualization window was present in the actuation 
plate and hence, budding events could not be monitored using an assembled chip. As such, solely 
the grounding plate was used for the remainder of the experiment and budding events were 
monitored during 180 min with 10 min intervals using bright-field microscopy (Zeiss Imager Z1 
microscope (Carl Zeiss, Germany); AxioCam MRm camera (Carl Zeiss, Germany)). Every 60 min, 
1/5 YEPD medium was added to the microwell array to compensate for evaporation of the droplet 
covering the array, as reproduction ability assays were carried out in an air environment and not in 
oil.  
6.2.7. Cytotoxicity assay in bulk 
Exponentially grown yeast cells (OD 3 in 1/5 YEPD) were supplemented with PI to a final 
concentration of 2 µg/mL. Cells were treated with either a dose of AmB (final concentration of 10 µM, 
25 µM, 50 µM, 100 µM or 200 µM in a 1 % DMSO background) or with 1 % DMSO (v/v) as a control 
treatment. The suspension containing cells, PI and AmB in 1/5 YEPD was then transferred to 
Eppendorf tubes, covered with a layer of silicon oil, placed on a horizontal rotator mixer (5 rpm) and 
incubated in the dark at room temperature for 6 h. At the start (t0) and the end (t6) of the treatment, a 
plating assay and fluorescence microscopy (540/608 nm) was performed (Figure 1C). In the plating 
assay, a 10-fold dilution series of the cell suspensions was prepared in phosphate buffered saline 
(PBS) to obtain appropriate cell concentrations (i.e. 300 to 3000 cells/mL). Subsequently, appropriate 
cell suspensions were spread on YEPD agar plates, after which the plates were allowed to dry for 10 
min and grown for 48 h at 30°C to visualize the number of Colony Forming Units (CFUs). The CFUs 
were counted manually (i.e. growth+) and plates containing 30 to 300 CFUs were used for further 
calculations. Fluorescence microscopy (Zeiss Imager. Z1, Carl Zeiss AG, Oberkochen, Germany) 
provided the number of cells with compromised cell membranes, i.e. non-apoptotic cells (PI+/growth-
)32, whereas the plating assay accounted for the number of living cells (PI-/growth+) after treatment. 
Subtracting these fractions from 100% yielded the percentage of apoptotic cells (PI-/growth-) after 
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treatment, which is relevant as low doses of AmB induce apoptosis in yeast33. Data were normalized 
to the control treatment. 
6.2.8. Statistical analysis 
All data were normalized to the control treatment within the same setup. In all statistics, a normal 
distribution of the data was assumed. A paired two-tailed student t-test was performed to evaluate 
differences between results obtained in bulk and DMF experiments after 360 min using the same 
concentration of AmB. A survival analysis was performed on the DMF data by the log-rank test for 
trend. Asymmetrical 95% confidence intervals are plotted, as they present the true uncertainty on the 
number of PI-negative cells, and are therefore more valid than symmetrical 95% confidence intervals, 
which present the uncertainty based on a fitted model. The statistical log-rank test, followed by 
Bonferroni correction to allow multiple comparisons, was used to evaluate differences between 
curves34, 35, and P < 0.005 was considered as statistically significant for these calculations. In all 
other cases, P < 0.05 was considered as statistically significant. Statistics were performed with 
GraphPad Prism (GraphPad Software, Inc., CA, USA).  
6.3. Results and discussion 
6.3.1. Single cell seeding 
6.3.1.1. Microwell size optimization 
In order to trap single cells in the microwells, we first analysed the cell size distribution in a 
population of cells using flow cytometry (BD Biosciences, San Jose, CA, USA). Although the cell 
sizes were dispersed between 3.5-8 µm, the size of majority of cells was between 4.5-5.5 µm and we 
selected this as our target size interval. In this way, either one or no cell is trapped in each microwell. 
To obtain reproducible feature sizes during the microwell array fabrication, photolithography 
parameters were optimized. The effect of the exposure dosage and the development time on the 
pattern developed on the photoresist was studied. Non-optimal exposure and development times 
lead to inadequate or over-etching of the photoresist, resulting in too small or too big wells. 
Consequently during cell seeding, either no cell, single cells or multiple cells were trapped in one 
well. In our experiments, we used an exposure dosage of 6 mJ/cm2 and a development time of 45 
seconds, resulting in wells sized 5.3 ± 0.1 µm (10000 measurements over 4 arrays; data not shown). 
 
6.3.1.2. Cell trapping  
After assembling the DMF plates in the holder, the chip was flipped upside down to allow cell 
sedimentation on the microwell array. At this step, cells either entered the microwells due to gravity 
or sedimented in between the microwell spaces. During cell seeding, the receding droplet meniscus 
generated an effective drag force in combination with surface tension, that manipulated the cells to 
enter and stay inside the microwells36. In addition, the hydrophilic-in-hydrophobic features, fabricated 
in the Teflon layer of the grounding plate, promoted cell trapping and favoured the retention of cells in 
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the microwell structures. No external forces, other than surface tension and physical forces 
generated by droplet movement, were used to trap single cells, thereby avoiding cell damage. The 
selective wetting properties of the array, combined with the surface tension generated by the 
receding droplet meniscus were accountable for removing single cells that settled in between the 
microwells.  The presence of an oil environment offered further advantages. It avoided the 
evaporation of the femtoliter droplets generated in the microwells, which in the absence of oil 
evaporate in less than a second, leading to an osmotic lysis of seeded cells37. Moreover, YEPD is a 
viscous medium and droplet manipulation of YEPD on a Teflon surface in an air environment is 
challenging. However, on the DMF platform, manipulation of 1/5 YEPD was performed effectively in 
an oil environment and the Teflon surface fouling was found to be greatly reduced. The use of 1/5 
YEPD did not affect the behaviour of the cells, since cell division in 1/5 YEPD occurred at 112 ± 5 
min (Figure S1B), which is in line with literature38, 39. 
6.3.2. Reproduction ability of trapped yeast cells 
Exposure of cells to certain physical or mechanical stresses may influence their tolerance towards 
antifungal agents, which might be an obstacle. To assess the stresses that the cells might have 
acquired by performing seeding cycles on the DMF platform, the ability of the seeded cells to 
reproduce was analysed. In these experiments, the division time of the seeded yeast cells was 
considered as a measure of cell sensitivity towards external stimuli. In each experiment, at least 30 
cells were monitored. The results are shown in supplemental information (Figure S1). Although only 
single yeast cells are trapped during seeding, the cells can reproduce while trapped inside a 
microwell when growth medium is provided. Reproduction of S. cerevisiae is marked by budding 
events (i.e. doubling), in which the mother and daughter cell are attached to each other during 
growth. As such, one cell is trapped inside the microwell whereas the other cell is situated outside 
the well on top of the trapped cell, as shown in Figure S1A. Assessment of the reproduction ability of 
trapped yeast cells was not performed in an oil environment, which is the case for all other 
experiments. To avoid that evaporation of the droplet covering the microwell array would affect the 
viability of the trapped cells, we carefully added 1/5 YEPD medium to the array every 60 min without 
affecting the location of the trapped cells. Since all cells showed reproduction ability within 180 min, 
all cells were defined as viable and therefore, cell viability was not affected in these experiments The 
doubling time of yeast is approximately 120 min33,34, and when seeded cells were incubated with 1/5 
YEPD, cell division occurred at 112 ± 5 min (Figure S1B). Hence it can be stated that the seeded 
cells respond in a normal way when incubated in growth medium, and therefore the DMF setup could 
be used to analyse cellular responses towards other external stimuli, such as antifungal drugs. 
6.3.3. On-chip cytotoxicity assay of single yeast cells using DMF  
Cytotoxicity assays were performed with different dosages of AmB and non-apoptotic cell death 
events were monitored using PI and fluorescence microscopy. To improve the throughput of the 
system, the complete array was imaged in a scanning mode.  AmB is a widely used antifungal drug 
that primarily kills yeast cells either via ergosterol binding or via channel-mediated membrane 
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permeabilization40. AmB can induce cell death either via necrosis, a type of non-apoptosis in which 
cells die with a compromised cell membrane, or via apoptosis or programmed cell death33. In this 
study, we analysed the fraction of these two subpopulations in a yeast culture treated with different 
AmB concentrations over time using the DMF platform. In each experiment, the cellular responses of 
500 to 3000  cells were monitored over a period of 360 min at single cell resolution, generating a 
seeding efficiency of 5.75 ± 3.14%. Although the seeding efficiency is rather low and is subject to 
improvement in a follow-up study, the number of cells that were monitored is sufficient for biology-
related studies, as 5- to 30-fold more cells were studied on-chip as compared to bulk experiments. 
One of the hallmarks of apoptosis, in contrast to necrosis, is the presence of an intact cell 
membrane32. PI is a fluorescent dye that enters cells with a compromised plasma membrane, and is 
therefore used as a marker for non-apoptotic cell death. After cell entry, PI irreversibly binds to the 
nucleus41. Incubation of untreated yeast cells with PI for 6 h did not affect cell viability (data not 
shown) and thus did not affect the results obtained in this study. 
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Figure 1 Flowchart of the DMF and bulk setup used for conducting cytotoxicity assays on single S. 
cerevisiae cells. (A) The DMF platform consists of actuating and grounding plates. The latter contains two 
microwell arrays consisting of 22000 microwells each for trapping single cells. After the (i) pre-treatment step 
with Amb or DMSO and PI, the cell droplet and the AmB droplet were added to the actuation electrodes. Then, 
the DMF platform was assembled, after which the cells were further incubated on the microwell array for 10 min, 
and (ii) cell seeding was performed. (iii) Seeded cells were subjected to treatment and the responses of single 
cells were monitored using time lapse fluorescence microscopy. (iv) Finally, to obtain the total number of seeded 
cells, the microwell array was illuminated with an intense UV beam for 20 min, resulting in 100% PI-positive 
cells. (B) Schematic overview of cell seeding on the DMF setup: cells sedimented either in between or inside the 
microwells; cells inside femtoliter droplets were retained inside the microwells due to the combination of drag 
force and surface tension. (c) The protocol that was used for conducting cytotoxicity assays in bulk, as the 
reference technology. 
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Figure 2A shows that AmB induced non-apoptotic cell death in a dose-dependent manner. In Figure 
2B a survival analysis on the DMF dataset is given, which was performed to evaluate whether 
treatment of cells with different AmB dosages affects non-apoptotic cell death events in a significant 
manner. A higher dose of AmB (200 µM) induced membrane permeabilization more rapidly than 
lower AmB dosages, as illustrated by a decreased median survival: 50% non-apoptotic cell death 
was reached at 210 min when cells were treated with 200 µM AmB, whereas a median survival of 
270 min was observed for treatment with 50 µM and 100 µM AmB. Fifty percent non-apoptotic cell 
death was not reached with AmB dosages lower than 50 µM within the time frame of the 
experiments. Significant differences between curves were analysed employing the log-rank test, 
followed by Bonferroni correction to allow multiple comparisons. The number of comparisons was 10 
and therefore, a threshold of P < 0.005 was considered statistically significant. Although no 
significant differences were found between treatment with 50 µM, 100 µM or 200 µM AmB (P<0.005; 
50 µM vs. 100 µM: P=0.8384; 50 µM vs. 200 µM: P=0.0233; 100 µM vs. 200 µM: P=0.0108), a 
significant trend was observed between AmB dose and median survival (P<0.0001), analysed by a 
log-rank test for trend. This indicates that treatment of cells with different AmB dosages affects non-
apoptotic cell death significantly. 
 
Figure 2 Analysis of non-apoptotic cell death during AmB treatment on the DMF platform. Yeast cells 
were treated with different dosages of AmB displayed by coloured lines, i.e. 10 µM (blue), 525 µM (orange), 50 
µM (black), 100 µM (green) and 200 µM (red), and monitored for membrane permeabilization events (i.e. PI-
positive cells, indicative of non-apoptotic cell death) for 6 hours in 15 min intervals using time lapse fluorescence 
microscopy. (A) Representation of the cumulative amount of PI-positive cells over time. Means and standard 
errors of the means (sems) (n = 4 independent biological repetitions) are presented. To avoid overcrowding of 
the figure, only the above fractions of the sems are plotted. (B) Survival analysis of DMF results to determine 
whether treatment of cells with different dosages of AmB affects non-apoptotic cell death events in a significant 
manner. Dotted lines represent asymmetrical 95% confidence intervals. 
6.3.4. DMF versus bulk experiments 
To validate the DMF platform for use in SCA, similar experiments were performed in bulk following 
the protocol presented in Figure 1C, thereby mimicking the protocol performed with the DMF setup. 
Yeast cells were subjected to treatment with different dosages of AmB and non-apoptotic cell death 
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events were monitored using PI and fluorescence microscopy at the start (0 min) and the end (after 
360 min) of treatment. In each experiment, at least 100 cells were analysed. In addition, cells were 
plated at these time points to analyse the number of dead cells.  The fraction of apoptotic cells was 
then calculated by subtracting the number of PI-positive cells, assessed by fluorescence microscopy, 
and the number of living cells, i.e. the number of CFUs in the plating assay, from 100 %. 
As shown in Figure 3, a dose-dependent increase of the subpopulation of non-apoptotic cells is 
obtained upon treatment with increasing doses of AmB. Moreover, 100% cell death is reached for all 
dosages of AmB after 360 min of treatment, as verified by CFU counting. These findings are in line 
with previous results that indicated that AmB induces 100% cell death in a yeast culture at a 
concentration of less than 5 µM, assessed by a plating assay (data not shown). In addition, these 
results demonstrate that AmB indeed induces cell death via non-apoptotic and apoptotic 
mechanisms, which is in line with literature33. Using low concentrations (i.e. less than 5 µM) of 
AmB, cell death is primarily caused by apoptosis and hence, cells are characterized as PI-
negative. 
 
Figure 3 Analysis of non-apoptotic and apoptotic fractions of cell populations upon treatment with AmB 
for 360 min in bulk. Yeast cells were treated with different dosages of AmB and at 0 min and 360 min, cells 
were analysed for membrane permeabilization events using PI and fluorescence microscopy and were plated to 
account for the apoptotic fraction. Means and sems (n = 3 independent biological repetitions) are presented. 
Dark grey bars represent the non-apoptotic fractions (PI+/growth-), and light grey bars represent the apoptotic 
fractions (PI-/growth-). 
The results obtained in bulk were subsequently compared to those obtained on the DMF platform. To 
this end, the results generated by fluorescence microscopy after 360 min of AmB treatment were 
compared between both setups. The results of the plating assays were not used for comparison, as 
we only performed these assays in bulk. Plating assays on the DMF platform are not possible as we 
currently have no technique to individually remove seeded cells from the wells. In Figure 4A, a 
correlation analysis is shown between bulk and DMF data. A significant correlation (P = 0.0015) was 
found between the two setups, with a Pearson correlation coefficient of 0.97. It was also observed 
that the bulk experimental design is more susceptible to variations between repetitions than the DMF 
setup. A higher variation in the bulk results can be caused by for example more and extensive 
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manual handling, which is not the case when using the DMF platform. This is also reflected in the 
higher SEMs for bulk results when compared to DMF results in Figure 4B. 
 
Figure 4 Comparison of results obtained in bulk and on the DMF platform. (A) Correlation analysis 
between bulk and DMF results at 360 min. Means and sems are plotted (bulk: n = 3; DMF: n = 4). The Pearson 
correlation coefficient was found to be 0.97. The bisector is a guide to the eye and does not represent a linear fit 
of the data. (B) Representation of bulk (dark grey bars) and DMF (light grey bars) results at 360 min. Means and 
sems (n = 3 and n = 4) are plotted. No significant differences were found between bulk and DMF (P < 0.05). In 
all cases, n represents the number of independent biological repetitions. 
In the lower AmB concentration range, the DMF platform appears to indicate a lower number of PI-
positive cells as compared to the bulk analysis, however, the fraction of PI-positive cells in bulk does 
not significantly differ from the fraction of PI-positive cells on the DMF platform for any AmB dose 
tested and analysed after 360 min (Figure 4B). This indicates that the DMF platform can potentially 
replace bulk analysis, thereby adding the advantage of conducting experiments with spatial and 
temporal resolution and with a much higher throughput as compared to bulk experiments. As such 
this DMF platform offers an invaluable tool for more biologically oriented follow-up experiments. 
Regarding the antifungal effect of AmB, an extension of the presented comparative study in bulk and 
on the DMF setup (performed at an AmB incubation time of 360 min) over time can be included, that 
allows unravelling the kinetics of the AmB-induced membrane permeabilization.  
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6.4. Conclusion 
In this article we have described DMF technology as a novel and automated tool for conducting 
single cell analysis (SCA) on non-adherent cells. Whereas conventional techniques that are often 
used for conducting SCA, lack either spatio- or temporal resolution, we presented a straightforward 
approach using the DMF platform to isolate single non-adherent cells and to monitor their dynamic 
responses at a defined position over time, in a well-controlled micro-environment. The spatio-
temporal study in our work consisted of two parts: the generation of microwells ensured that trapped 
cells were located at a defined position during the experiments, i.e. spatial resolution, whereas 
temporal resolution was achieved by monitoring single cell responses in intermediate time intervals. 
To avoid osmotic lysis of cells, the DMF platform offered a unique possibility to seal the femtoliter 
droplets with oil. No external forces, other than surface tension and the physical forces generated by 
moving the droplet, were utilized to seed single cells inside the microwells, thereby avoiding cell 
damage. In the DMF experiments, we targeted yeast cells sized 4.5-5.5 µm, since the majority of 
cells within a yeast cell population are within that range. As such, either one or no cell is trapped in 
each microwell. In the bulk assays, no subpopulation of cells was targeted. As no significant 
differences were found between bulk and DMF results, we can conclude that targeting the specified 
subpopulation of yeast cells did not affect our results. As such, the DMF technology holds great 
potential as a platform for assessing, for example, killing kinetics of antifungal agents at single cell 
resolution.  
As a proof of concept, the effect of different AmB dosages on membrane permeabilization events in 
yeast cells was investigated over time. We observed a dose-dependent response in the number of 
membrane permeabilization events. In addition, higher dosages of AmB (200 µM) caused membrane 
permeabilization more rapidly than low AmB dosages (< 50 µM), indicating that monitoring cells over 
time is valuable for screening purposes towards identification of fast-killing agents. The DMF platform 
was validated by bulk experiments mimicking the DMF experimental design. A significant correlation 
was found between the bulk and DMF platform, indicating that the DMF platform can be used for 
SCA without causing additional stress to the cells, as similar results were obtained in both setups. 
Moreover, the DMF platform can potentially replace bulk analysis, thereby conducting experiments 
with spatial and temporal resolution and with a much higher throughput as compared to bulk 
experiments. In addition, cellular heterogeneity can be studied thoroughly using the DMF platform, as 
we observed differential responses within a specific cell population. For instance, we observed that at 
a certain AmB dose and at a certain time point, some cells displayed membrane permeabilization, 
whereas others did not and this ratio fluctuated over time. 
Although we only present data obtained on membrane permeabilization of yeast cells during 
treatment, this platform can be further extended for analysis of the behaviour of cells in a multiplexed 
manner with regard to other features that play a role in cellular mechanisms, such as the production 
of reactive oxygen species and caspase activation. As such, different markers can be monitored 
simultaneously in individual cells at single cell resolution. In addition, incorporation of multiple 
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microwell arrays for trapping of single cells can further improve the throughput and efficiency of the 
DMF platform. This would extend the possibility of challenging each set of cells with different drug 
concentrations, as well as for analysing each array for different markers simultaneously. In 
conclusion, the DMF platform is an attractive tool for researchers interested in cellular processes and 
unravelling the mode of action of antifungal agents. 
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6.6. Supplemental information  
 
Figure S1 Analysis of the reproduction ability of trapped yeast cells. Yeast cells were monitored for 
budding events during 180 min with 10 min intervals using bright-field microscopy. (A) Images of budding yeast 
cells taken at 180 min of incubation in 1/5 YEPD at 40X magnification. Black arrows indicate mother cells 
trapped inside the microwells; red arrows indicate daughter cells on top of the trapped mother cells; (B) 
Representation of the number of budding cells, monitored during 180 min. Means and sems are plotted (n = 4 
independent biological repetitions, at least 30 cells were monitored). 
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Abstract 
Amphotericin B (AmB) was previously shown to induce oxidative and nitrosative stress, characterized 
by production of reactive oxygen and nitrogen species, respectively, in pathogenic fungi. However, 
no reports exist on how these toxic species contribute to AmB-induced fungal cell death. In this 
study, we investigated the role of superoxide and nitric oxide radicals in AmB-induced membrane 
permeabilization and loss of reproduction capacity in Saccharomyces cerevisiae using flow cytometry 
and plating assays. The nitric oxide synthases inhibitor L-NAME was used to block production of 
nitric oxide radicals and hence modulate the levels of superoxide and nitric oxide radicals. In 
addition, we analysed the kinetics of superoxide radical production and membrane permeabilization 
at single cell level, using a digital microfluidic platform that enabled monitoring individual cells with 
spatiotemporal resolution. We found that L-NAME increases and accelerates AmB-induced 
production of superoxide radicals, membrane permeabilization and loss of reproduction capacity in S. 
cerevisiae. In addition, we demonstrated that superoxide radicals are important in AmB fungicidal 
action, whereas nitric oxide radicals play a beneficial role and mediate tolerance towards AmB. As 
such, we gained novel insight in the mechanism of action of AmB. Furthermore, we found that also 
the human pathogen Candida albicans is more susceptible to AmB in the presence of L-NAME, 
indicating a potential clinical relevance of AmB treatment in combination with L-NAME. 
 
Keywords: amphotericin B, yeast, superoxide radicals, nitric oxide radicals, L-NAME 
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7.1. Introduction 
Pathogenic fungi, including Candida albicans, encounter diverse environmental stresses when 
colonizing human tissues. During the infection process, they are exposed to potent reactive oxygen 
and nitrogen species (ROS and RNS, respectively), including nitric oxide radical (NO●), peroxynitrite 
(ONOO‾), superoxide anion radical (O2‾●) and hydroxyl radical (●OH), generated by the respiratory 
burst of phagocytic cells (1-3). ROS and RNS cause damage to DNA, proteins and lipids, and are 
toxic to most fungi (4, 5). In contrast to most non-pathogenic fungi, Candida species and other fungal 
pathogens have developed responses to neutralize these toxic radicals and repair the molecular 
damage they might have caused (6). In this respect, various proteins that protect the fungus from 
oxidative and nitrosative stress have been identified, and include signalling proteins, transcription 
factors and a variety of other enzymes such as catalases, superoxide dismutases, peroxidases and 
nitric oxide dioxygenase (1, 7). Hence, antifungals (or combinations thereof) inducing an excess ROS 
and/or RNS in a pathogenic fungus that cannot be neutralized by their endogenous protection 
mechanisms are of great interest (8).     
Many antifungal agents are reported to induce oxidative (excess ROS) stress in pathogenic fungi. 
These agents include small molecules, such as miconazole (9, 10), fluconazole (11, 12), 
amphotericin B (AmB) (12-16) and caspofungin (17), but also antimicrobial peptides, such as 
protonectin (18), baicalin (19) and a variety of plant defensins (20-23). To date, the induction of 
nitrosative (excess RNS) stress in fungal species has only been demonstrated in the case of AmB in 
the pathogenic fungus Cryptococcus gattii (24) and for the tobacco defensin NaD1 in C. albicans 
(23). AmB belongs to the polyene class of antifungals and induces fungal cell death through 
apoptotic and non-apoptotic pathways (25-27). Recent findings indicated that AmB exerts its 
antifungal action by extracting ergosterol from the plasma membrane, referred to as the sponge 
model (28). Interestingly, in mammalian cells, AmB was shown to affect cell proliferation and to 
induce cell cycle arrest and autophagy (29, 30). However, no such findings are reported for its 
antifungal mechanism of action. Apparently, AmB can induce both excess ROS and RNS in 
pathogenic fungi. How the production of these different types of radicals contributes to AmB’s 
fungicidal action is hitherto not exactly known. Moreover, increased insight in these AmB-induced 
events may lead to more efficient AmB-based therapies, as exemplified in the current study.   
In this study, we further investigated the potential of AmB to induce ROS and RNS and looked at the 
interplay between these toxic radicals and their production kinetics, linking these events to AmB’s 
killing capacity. To investigate the kinetics of the AmB-induced ROS and RNS, we used a digital 
microfluidic platform (DMF) in which single cells are captured and monitored over time using time 
lapse fluorescence microscopy. This DMF platform has been previously optimized for seeding of 
Saccharomyces cerevisiae cells and subsequently for assessing the rate by which AmB-induced 
membrane permeabilization events occur at the single cell level (31). Hence, in this study, we used 
S. cerevisiae as a model. The latter has been widely used to investigate the mechanisms of action of 
antifungal agents, including that of AmB (14, 32-36). In addition, we translated the most prominent 
findings to the fungal pathogen C. albicans. 
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7.2. Materials and methods 
7.2.1. Strains and chemical reagents 
Saccharomyces cerevisiae strain BY4741 and Candida albicans strains SC5314 were used in the 
cytotoxicity assays. All culture media were purchased from LabM Ltd. (Lancashire, England), unless 
stated otherwise. Media used were YPD (1% yeast extract; 2% peptone; 2% glucose), 1/5 YPD (YPD 
diluted in distilled water) and RPMI-1640 (Roswell Park Memorial Institute-1640 medium; pH 7) with 
L-glutamine and without sodium bicarbonate (purchased from Sigma Aldrich, St.-Louis, MO, USA), 
buffered with MOPS (Sigma Aldrich, St.-Louis, MO, USA).  
Amphotericin B (AmB), Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME), propidium iodide 
(PI) and dihydroethidium (DHE) were purchased from Sigma Aldrich (St. Louis, MO, USA). 4-Amino-
5-Methylamino-2’,7’-Difluorofluorescein Diacetate (DAF-FM DA) was supplied by Life Technologies 
(Carlsbad, CA, USA).  
Fluorinert FC-40 was purchased from 3M (St.-Paul, MN, USA) and chemicals for photolithopgraphy 
were supplied by Rohm and Haas (Marlborough, MN, USA). Fluoroalkylsilane Dynasylan® F 8263 
was supplied by Evonik (Essen, Germany). AZ1505 photoresist and Teflon-AF® were obtained from 
Microchemicals GmbH (Ulm, Germany) and Dupont (Wilmington, DE, USA), respectively. Parylene-C 
dimer and Silane A174 were purchased from Plasma Parylene Coating Services (Rosenheim, 
Germany). 
7.2.2. Cell culture 
S. cerevisiae or C. albicans, grown overnight in YPD at 30 °C and 250 rpm, were diluted to an optical 
density (OD) of 0.15 measured at λ = 600 nm in a flask containing 50 mL of fresh YPD and further 
cultured for 5 hours at 30 °C and 250 rpm or 37 °C and 200 rpm, respectively, to obtain exponentially 
growing cells. Cells were then pelleted by centrifugation (3 minutes, 4000 rpm), washed and re-
suspended in 1/5 YPD for S. cerevisiae or RPMI-1640 medium for C. albicans to an OD of 3 for 
further use in the experiments.  
7.2.3. Cytotoxicity assays in bulk 
Exponentially growing cells were supplemented with PI, DHE or DAF-FM DA to a final concentration 
of 3 µM, 17 µM and 5 µM, respectively, and subsequently treated either with DMSO or water 
(controls), a range of AmB dosages (dissolved in DMSO), 200 mM L-NAME (dissolved in water) or a 
combination of the above, with a final DMSO concentration of 1% (v/v%). After mixing, the cell 
suspensions were transferred to Eppendorf tubes, covered with a layer of silicon oil, placed on a 
horizontal shaker at 5 rpm and incubated in the dark at room temperature for 3 hours. A plating 
assay was carried out at the start of the treatment to account for the number of cells at this point. 
After 3 hours, cells were pelleted (3 minutes, 4000 rpm), washed and re-suspended in phosphate 
buffered saline (PBS), and subsequently plated or subjected to flow cytometry on a BD InfluxTM cell 
sorter. In the plating assay, a 10-fold dilution series of the cell suspensions was prepared in PBS and 
appropriate cell suspensions were spread in YPD agar plates, after which the plates were allowed to 
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dry for 10 minutes and incubated for 48 h at 30 °C to visualize the number of Colony Forming Units 
(CFUs). For flow cytometry, cells were monitored for fluorescence at 540/608 nm (FL3 610_20), 
485/>515 nm (FL1 580_30) or 495/515 nm (FL2 530_40) for detection of membrane permeabilization 
with PI, detection of superoxide radical production with DHE or detection of nitric oxide radical 
production with DAF-FM DA, respectively. 
7.2.4. Fabrication of digital microfluidic plates 
Digital microfluidic plates were fabricated as described previously (31). Briefly, cleaned glass wafers 
(1.1 mm) were sputter coated with chromium (100 nm) and patterned using standard 
photolithographic processes. After cleaning the plates with acetone and IPA twice, the surface was 
plasma activated (O2-plasma, 150 mtorr, 100 W) and the plates were primed with Silane A174 to 
promote adhesion of the Parylene-C layer (3 µm) that was subsequently coated using chemical 
vapour deposition. Next, a thin layer of Teflon-AF® (200 nm, using 3% w/w in Fluorinert FC-40) was 
spin-coated (1200 rpm) on top of the Parylene-C layer, and baked for 5 minutes at 110 °C and 5 
minutes at 200 °C. Crenelated actuation electrodes with dimensions of 2.8 mm × 2.8 mm were 
selectively actuated to manipulate individual droplets of 2.7 µL, using custumized software.  
For fabrication of the grounding plate of the DMF device, cleaned glass wafers (1 mm) were coated 
with an aluminium layer (40 nm) using thermal evaporation, leaving two 2.5 × 2.5 mm visualization 
windows. Fluoroalkylsilane Dynasylan® F 8263 was coated on the aluminium to improve adhesion of 
the subsequent spin-coated Teflon-AF® layer (3 µm). Microwells were patterned in the Teflon-AF® 
layer following a hard contact masking procedure, developed by depositing Parylene-C (1 µm) and 
aluminium (60-80 nm) layers. A thin layer of AZ1505 photoresist was spin-coated on the aluminium 
layer and the aluminium was patterned and etched using standard photolithography processes. The 
pattern was then transferred from the aluminum to the Teflon-AF® using O2 -plasma (150 mtorr, 100 
W) for 10 minutes. Finally, the aluminium-Parylene-C mask was peeled off using a pair of forceps, 
revealing two microwell arrays (1.9 mm × 1.9 mm) on a single grounding plate, consisting of 22 000 
microwells each, arranged in a hexagonal pattern with a pitch distance of 14 µm. The dimensions of 
the microwells were measured to be approximately 5.5 µm in width and 3 µm in depth. 
7.2.5. Cytotoxicity assays on DMF platform 
Exponentially growing cells were supplemented with PI or DHE to a final concentration of 3 µM and 
17 µM, respectively, and subsequently treated either with DMSO or water (controls), a range of AmB 
dosages (dissolved in DMSO), 200 mM L-NAME (dissolved in water), or a combination of the above, 
with a final DMSO concentration of 1% (v/v%). After 5 minutes, two droplets, one containing the 
mixed cell suspension and one containing the corresponding composition without cells, were placed 
on two separate electrodes of the actuation plate. The actuation and grounding plate were 
assembled, thereby aligning the microwell array with the cell droplet and sandwiching it between the 
plates. To prevent sticking and evaporation of the droplets, 80 µL of silicon oil was added between 
the plates by pipetting. The assembled plates were placed in the DMF chip holder and the device 
was flipped upside down and incubated for 10 minutes to allow sedimentation of the cells. This step 
was followed by automated shuttling of the cell droplet over the microwell array for 15 times, i.e. 15 
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seeding cycles, using software-assisted EWOD actuation. After seeding, the cell droplet was 
actuated away from the array and the droplet without cells was transferred to the array. The cell 
responses, i.e. membrane permeabilization detected by PI or superoxide radical production detected 
by DHE, were monitored for 3 hours in 15 minutes intervals using an inverted fluorescence 
microscope (IX-71, Olympus, Tokyo, Japan) equipped with a CCD camera. The whole array was 
scanned in 9 overlapping frames in approximately 15 seconds, in which a single frame covered 
approximately 4100 wells, using a 20x lens magnification. Both fluorescence and bright field images 
were collected. 
7.2.6. Calculation of fluorescence intensity per cell 
The DMF array was imaged for 3 hours in 15 minutes intervals (i.e. 12 time points) and images were 
processed in ImageJ (imagej.nih.gov/ij) for background correction using rolling ball algorithm with a 
radius of 50 pixels. Salt-and-pepper noise was removed using the despeckle option in ImageJ. Next, 
the images were loaded in MATLAB (www.mathworks.com) and a custom-made MATLAB code was 
executed. The single image captured  at 180 minutes was processed by MATLAB to identify the 
single fluorescent cells in contrast with the background. The MATLAB code detected the area of a 
single cell and a unique numerical digit was allotted to each cell. Within the detected area of a single 
cell, the maximum pixel value was registered together with its respective coordinate in a vector array. 
Next, the MATLAB code was executed on all the images captured between 15 minutes and 165 
minutes. The fluorescence intensity of each individual cell in different time frames was monitored by 
detecting the pixel values for the  registered coordinates. The final output was a tabular data with 
pixel intensity of single cells identified with unique numerical digits, as detected in 12 consecutive 
time points. 
7.2.7. Data analysis 
Flow cytometric data were normalized to the control data and DMF data were normalized to the first 
data point, i.e. 15 minutes. For plating assays, the number of Colony Forming Units (CFU) per mL is 
displayed in Log scale. Data were analysed with GraphPad Prism 6 SPPS (GraphPad Software, Inc., 
CA, USA). Pearson’s Product-Moment Correlation was performed to analyse the relation between 
the results obtained in the bulk and the DMF experiments. Survival analyses (Kaplan-Meier) using 
the Log-rank test were performed on DMF data to compare survival curves and analyse whether 
treatment significantly affects survival. Two-way ANOVA and subsequent Tukey or Dunnett’s multiple 
comparisons tests were performed to analyse differences between bulk results for treatment with 
AmB in the presence or absence of L-NAME for each AmB concentration, or to analyse differences 
in bulk results between the first data point and other data points within the same treatment, 
respectively. In all cases, P < 0.05 was considered statistically significant. Multiplicity adjusted P-
values for each comparison are presented, taking into account the total number of groups in the 
ANOVA and the data in all groups.   
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7.3. Results 
7.3.1. Amphotericin B induces nitric oxide and superoxide radical production in Saccharomyces 
cerevisiae 
First, we assessed whether AmB can induce production of superoxide and nitric oxide radicals in the 
model organism Saccharomyces cerevisiae. To this end, yeast cultures were treated with different 
concentrations of AmB for 3 hours, and subjected to flow cytometry to analyse the number of cells 
with increased superoxide and nitric oxide radical levels using the fluorescent dyes DHE and DAF-
FM DA, respectively. In addition, the number of cells with compromised plasma membranes was 
analysed, using the fluorescent dye PI. PI only enters cells with compromised plasma membranes, 
and hence, is a marker for non-apoptotic cell death (37). To quantify the fungicidal activity of AmB, 
the treated cultures were subjected to plating assays, thereby assessing the number of cells that are 
able to reproduce after AmB treatment.  
AmB affects the number of cells with increased production of superoxide and nitric oxide radicals, as 
well as the number of cells with permeabilized membranes in a dose-dependent manner (Figure 1). 
This dose-dependency is different for the tested responses: a maximum number of cells producing 
nitric oxide radicals in AmB-treated yeast cultures is found at 2.5 µM AmB (Figure 1B), whereas the 
highest number of cells with increased superoxide radical production and compromised membranes 
is observed at 10 µM AmB (Figure 1A and 1D, respectively). Hence, it seems that production of nitric 
oxide radicals can be induced at AmB doses that do not trigger the production of superoxide radicals 
or membrane permeabilization, e.g. at 2.5 µM AmB. In line, also the reproduction capacity of cells 
can be affected by AmB without evidence of membrane permeabilization and superoxide radical 
production at 2.5 µM AmB. 
7.3.2. Inhibition of nitric oxide radical production results in increased superoxide radical production 
and loss of reproduction capacity by amphotericin B 
As it was previously shown that superoxide radicals react with nitric oxide radicals, resulting in 
strongly oxidizing RNS causing damage to proteins and nucleic acids (38-40), we investigated 
whether the AmB-induced superoxide radical levels can be increased by blocking production of nitric 
oxide radicals. To this end, the nitric oxide blocker L-NAME was used. L-NAME inhibits nitric oxide 
synthases in mammalian cells and thus prevents the generation of nitric oxide radicals (41). Although 
in yeast only nitric oxide synthases-like enzymes are identified to date, L-NAME was shown to also 
reduce the levels of nitric oxide radicals in yeast (42-44). Reduction of the levels of nitric oxide 
radicals by L-NAME in S. cerevisiae was microscopically confirmed in this study (data not shown). 
Next, the effect of administering L-NAME together with different concentrations of AmB on the 
number of cells producing superoxide radicals and membrane permeabilization events was 
investigated using flow cytometry. In addition, the effect of the treatment on the number of cells that 
are able to reproduce was assessed by plating assays. 
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Figure 1 AmB induces production of superoxide and nitric oxide radicals and membrane 
permeabilization in S. cerevisiae. Yeast cultures were treated with different concentrations of AmB for 3 hours 
and subjected to flow cytometry or plating assays. (A) Levels of superoxide radical detected by dihydroethidium 
(DHE) fluorescence and flow cytometry; (B) Levels of nitric oxide radical detected by 4-Amino-5-Methylamino-
2’,7’-Difluorofluorescein Diacetate (DAF-FM DA) fluorescence and flow cytometry; (C) Membrane 
permeabilization events detected by propidium iodide (PI) fluorescence and flow cytometry; (D) Number of 
CFU/mL in Log-scale, assessed by plating assays and CFU counting. Means and standard errors of the means 
(SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. 
In the presence of L-NAME, the number of cells with AmB-induced production of superoxide radicals 
is significantly increased as compared to that after AmB treatment alone, this in case of 2.5 µM or 10 
µM AmB (Figure 2A; P = 0.05 and P < 0.0001, respectively). In addition, treatment of yeast cultures 
with 1.25 µM or 2.5 µM AmB supplemented with L-NAME results in significantly reduced number of 
cells that are able to reproduce, as compared to treatment with AmB alone (Figure 2C; P = 0.01 and 
P < 0.0001, respectively). In contrast, only 10 µM AmB with L-NAME increases the number of cells 
with compromised membranes in a significant manner (P = 0.02), as compared to that after 
treatment with AmB alone (Figure 2B), suggesting that the combination of low concentrations of AmB 
with 200 mM L-NAME does not affect membrane permeabilization by AmB. In addition, it seems that 
nitric oxide radical production plays a role in mediating tolerance towards AmB in yeast, as inhibition 
of nitric oxide radical production results in an increased number of cells that produce superoxide 
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radicals and are characterized by membrane permeabilization events and a reduced number of cells 
that are able to reproduce.  
 
Figure 2 AmB-induced superoxide radical production, membrane permeabilization and loss of 
reproduction capacity can be increased by blocking nitric oxide radical production using L-NAME. 
Exponential yeast cultures were treated with different concentrations of AmB in the presence or absence of 200 
mM L-NAME for 3 hours. (A) Levels of superoxide radical detected by dihydroethidium (DHE) fluorescence and 
flow cytometry; (B) Membrane permeabilization events detected by propidium iodide (PI) fluorescence and flow 
cytometry; (C) Number of CFU/mL in Log-scale, assessed by plating assays and CFU counting. Means and 
standard errors of the means (SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. 
Solid lines represent treatment with AmB alone; dashed lines represent treatment with AmB supplemented with 
200 mM L-NAME. Two-way ANOVA followed by Tukey multiple comparisons test was performed to analyse 
significant differences between the two treatments. * and **** represent P < 0.05 and P< 0.0001, respectively. 
Multiplicity adjusted P-values are presented in the text. 
7.3.3. Inhibition of nitric oxide radical production results in faster and increased superoxide radical 
production and faster membrane permeabilization by amphotericin B 
To gain more insight into the action of L-NAME on AmB-induced superoxide radical levels, time lapse 
experiments were performed on a DMF platform, described in our previous study (45). To this end, 
yeast cultures were treated with either 0 µM (control), 5 µM or 10 µM AmB in the presence or 
absence of 200 mM L-NAME, as these concentrations were shown to have the most profound effect 
on membrane permeabilization and production of superoxide radicals in the bulk experiments. During 
treatment, each cell was monitored over time for 3 hours in 15 minutes intervals for its DHE or PI 
fluorescence. 
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In a first instance, we validated the DMF platform using correlation analyses to test whether similar 
results were obtained on the DMF platform as for the bulk analyses by flow cytometry after 180 
minutes. The correlation analyses comprised only 3 data points for each experimental design, and 
hence, the significance levels have to be interpreted with care. For this reason, the conclusions are 
solely based on the Pearson coefficient (Pearson r). In all experiments, the Pearson r ranged from 
0.97 to 1.00, suggesting a good correlation between bulk and DMF results in all experiments (Figure 
3). 
 
Figure 3 Pearson Product-Moment Correlation analysis suggests a good linear correlation between 
results obtained in bulk and on the DMF platform.  Exponential yeast cells were treated with 0 µM, 5 µM or 
10 µM AmB in the absence (A and C) or presence (B and D) of 200 mM L-NAME for 3 hours either in bulk or on 
the DMF platform, after which the number of PI- or DHE-positive cells in both setups was determined and 
correlation analyses were performed. Means and standard errors of the means (SEMs) of at least 3 independent 
biological experiments are plotted (n ≥ 3). The bisector (dashed line) is a guide to the eye and does not 
represent a linear fit of the data. 
Next, detailed analyses were performed on the DMF results in order to investigate the kinetics by 
which AmB and AmB supplemented with 200 mM L-NAME induce superoxide radical production and 
membrane permeabilization in S. cerevisiae. We found an increased number of DHE- (Figure 4A) 
and PI- (Figure 4B) positive cells when yeast cultures are treated with AmB supplemented with 200 
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mM L-NAME as compared to treatment with AmB alone, starting from 30 minutes and 45 minutes 
respectively. This observation is in line with the bulk results after 3 hours of incubation that were 
obtained by flow cytometry (Figure 2). 
Figure 4 AmB co-incubation with L-NAME results in fast superoxide radical production and membrane 
permeabilization. S. cerevisiae cells were treated either with 0 µM (yellow), 5 µM (green) or 10 µM (blue) AmB 
in the presence (dashed lines) or absence (solid lines) of 200 mM L-NAME and monitored for their responses 
during 3 hours in 15 minutes intervals, i.e. production of superoxide radicals (A) and membrane permeabilization 
(B). Log-rank tests were performed to analyse significant differences between AmB treatment and treatment of 
AmB in combination with 200 mM L-NAME for each AmB dose. Data of at least 3 independent biological 
experiments is presented (n ≥ 3). * and **** represent P = 0.03 and P < 0.0001, respectively. 
Survival analyses were performed on the DMF results to test the hypothesis that different treatments 
(i.e. AmB in the presence or absence of L-NAME) affect survival in a significant different manner, in 
which survival is defined as the occurrence of a specific event (46). Here, we analysed whether the 
occurrence of superoxide radical production and membrane permeabilization upon treatment with 
AmB in the presence and absence of L-NAME is significantly different between the two treatments. 
The survival curves for treatment with 10 µM AmB in the presence or absence of 200 mM L-NAME 
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are significantly different in both DHE and PI experiments (P < 0.0001 and P = 0.0305, respectively) 
(Figure 4), indicating that L-NAME significantly affects the number of superoxide radical producing 
cells and the number of membrane permeabilization events induced by AmB over time. When cells 
are treated with 10 µM AmB in combination with 200 mM L-NAME, a median survival of 45 minutes 
is observed in the DHE experiments, i.e. 50% of the cells in the cultures is DHE-positive after 45 
minutes of treatment. In contrast, when AmB is applied alone, 50% DHE-positive cells in the treated 
yeast culture is not reached after 180 minutes (median survival > 180 minutes), implying that AmB-
induced superoxide radical production occurs faster in cells treated in the presence of L-NAME. In 
addition, a hazard ratio (Log-rank) of 4.21 is found when comparing the survival curve of cells treated 
with 10 µM AmB supplemented with 200 mM L-NAME to that of cells treated with 10 µM AmB, 
indicating that the slope of the former is 4.21 times steeper than that of the latter and hence, the rate 
of cells showing superoxide radical production (i.e. cells becoming DHE-positive) during treatment 
with AmB in the presence of L-NAME is 4.21 times the rate of cells showing superoxide radical 
production during treatment with AmB alone.  
Fifty percent PI-positive cells in a yeast culture treated with 10 µM AmB supplemented with 200 mM 
L-NAME is only reached after 3 hours of incubation, as indicated by a median survival of 180 
minutes. The median survival for cells treated with 10 µM AmB alone is more than 180 minutes, 
suggesting that also membrane permeabilization occurs faster when cells are subjected to AmB in 
the presence of L-NAME, as compared to treatment with AmB alone. This observation is supported 
by a hazard ratio (Log-rank) of 1.56 when survival curves of both treatments are compared, 
indicating that the rate of membrane permeabilization in cells treated with 10 µM AmB supplemented 
with 200 mM L-NAME is 1.56 times the rate of membrane permeabilization in cells treated with 10 
µM AmB alone. 
So far, we showed that the number of cells producing superoxide radicals is increased when cells are 
treated with AmB in the presence of L-NAME, as compared to cells treated with AmB alone, and that 
the rate by which superoxide radicals are produced is different between these two treatments. To 
investigate whether also the intracellular levels of superoxide radicals are increased when cells are 
subjected to AmB treatment in the presence of L-NAME, we analysed the fluorescence intensity of 
individual cells for each time point. Figure 5 shows the DHE fluorescence intensity of individual cells 
treated with 10 µM AmB (Figure 5A) or 10 µM AmB supplemented with 200 mM L-NAME (Figure 
5B), monitored over time in 15 minutes intervals. As such, the fluorescence intensity of each cell, 
represented by one dot, is re-analysed every 15 minutes.  
Figure 5 L-NAME increases and accelerates AmB-induced intracellular superoxide radical production. 
Exponential yeast cells were treated with 10 µM AmB in the absence (A; solid line in C) or presence (B; dashed 
line in C) of 200 mM L-NAME and single cells were monitored for their DHE-fluorescence during treatment for 3 
hours in 15 minutes intervals using fluorescence microscopy and the DMF platform. (A and B): The fluorescence 
intensity of each cell is presented as arbitrary units (AU) and each dot represents a single cell. Means and 95% 
confidence intervals of at least 3 independent biological experiments, with at least 780 cells each, are 
presented;  (C): Overlay of the means with 95% confidence intervals presented in A and B.  
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The DHE-fluorescence intensity of cells during AmB treatment gradually increases over time, and the 
highest fluorescence intensity is measured at 180 minutes, the end point of this study (Figure 5A). In 
contrast, analysing the DHE-fluorescence intensity of cells treated with 10 µM AmB supplemented 
with 200 mM L-NAME revealed two sub-populations, suggesting that superoxide radical production 
takes place in a biphasic manner: the first and highest superoxide radical production peak is 
observed at approximately 75 minutes, followed by a rather slow decrease and a second peak at 
approximately 150 minutes (Figure 5B). A clear difference in intracellular fluorescence intensity 
between the two treatments is presented by an overlay in Figure 5C. Hence, it seems that not only 
the number of cells producing superoxide radicals increases when subjected to AmB treatment in the 
presence of L-NAME, but also the intracellular levels of superoxide radicals are altered in a time-
dependent manner, as compared to treatment of cells with AmB alone. 
7.3.4. Inhibition of nitric oxide radical production results in faster arrest of reproduction capacity of 
Saccharomyces cerevisiae cells by amphotericin B 
The results above indicate that cells treated with 10 µM AmB supplemented with 200 mM L-NAME 
are more affected in (i) the number of superoxide radical-producing cells, (ii) the rate of superoxide 
radical production, (iii) intracellular superoxide radical levels, (iv) the number of cells with 
compromised membranes, and (v) the rate of membrane permeabilization, as compared to treatment 
of cells with AmB alone. This tempted us to further investigate whether the reproduction capacity of 
cells treated with AmB in the presence of L-NAME is affected in a time dependent manner as well, as 
compared to treatment of cells with AmB alone. To this end, plating of S. cerevisiae cultures 
subjected to both treatments was carried out every 15 minutes, and the number of cells that are 
unable to reproduce (and form CFU) was determined (Figure 6C). 
At all time points, we found the reproduction capacity of cells treated with 10 µM AmB and 200 mM 
L-NAME to be significantly reduced as compared to cells treated with 10 µM AmB alone (P < 0.0001) 
(Figure 6C). In addition, it seems that the reproduction capacity of cells subjected to AmB treatment 
in the presence of L-NAME is affected very fast, i.e. within 15 minutes (P < 0.0001), whereas the 
capacity of cells to reproduce during treatment with AmB alone is affected in a significant manner 
from 45 minutes onwards (P < 0.0001). This suggests that the fast decrease in reproduction capacity 
of cells within 15 minutes of incubation with AmB and L-NAME is independent of superoxide 
production nor membrane permeabilization. Similar observations were made in our survival analyses 
(Log-rank) for superoxide radical production and membrane permeabilization (Figure 4), and are 
supported by a second statistical analysis (Two-way ANOVA followed by Dunnett’s multiple 
comparisons test) shown in Figure 6A and 6B. More specifically, a significant difference in the 
number of cells producing superoxide radicals (Figure 6A) and showing membrane permeabilization 
(Figure 6B) is found at earlier time points (i.e. 45 minutes vs. 105 minutes for superoxide radical 
production, and 60 minutes vs. 105 minutes for membrane permeabilization) when cells are treated 
with AmB in the presence of L-NAME, as compared to cells treated with AmB alone.  
However, although approximately 99.5% of the treated population is not able to reproduce from 15 
minutes onwards when subjected to treatment with 10 µM AmB and 200 mM L-NAME, they are still 
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able to produce superoxide radicals at that point, resulting in a superoxide radical boost starting at 30 
minutes (Figure 6A). Hence, it seems that these cells are still metabolically active and might use 
increased intracellular superoxide radical levels to enter a programmed cell death pathway, as 
membrane permeabilization alone (i.e. the number of PI-positive cells) cannot account for the loss of 
reproduction capacity of cells subjected to AmB treatment in the presence of L-NAME (Figure 6B). In 
contrast, loss of reproduction capacity of cells treated with 10 µM AmB alone might be explained by 
the gradual increase in the number of membrane permeabilization events, as a similar trend in both 
curves is observed (Figure 6B). 
 
Figure 6 L-NAME decreases the reproduction capacity of cells during AmB treatment, which seems 
independent of superoxide radical production. Exponential yeast cells were treated with 10 µM AmB in the 
presence (dashed lines) or absence (solid lines) of 200 mM L-NAME for 3 hours. Cells were analysed for their 
DHE-and PI-fluorescence in the DMF setup (A and B) or subjected to bulk plating assays (C) every 15 minutes. 
Means and standard error of the means (SEMs) of at least 3 independent biological experiments (n ≥ 3) are 
presented. Two-way ANOVA followed by Tukey multiple comparisons test was performed to analyse significant 
differences between the two treatments (represented by vertical brackets or stand-alone asterisks); Two-way 
ANOVA followed by Dunnett’s multiple comparisons test was performed to analyse significant differences 
between the first data point (i.e. 0 minutes or 15 minutes) and other data points within the same treatment 
(represented by horizontal brackets; only the primary significant difference is presented to avoid overcrowding of 
the figure); *, ** and **** represent P < 0.05, P < 0.01 and P < 0.0001, respectively. A dotted line is shown at 15 
minutes to point out the clear differences between the responses at this time point. 
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7.3.5. Candida albicans is more susceptible to amphotericin B treatment in the presence of nitric 
oxide radical production inhibitors 
To validate the results obtained in yeast and in support of the clinical relevance of AmB treatment in 
the presence of L-NAME, we investigated the effects of this treatment on the human pathogen 
Candida albicans. In a first instance, we confirmed that AmB induces superoxide radical and nitric 
oxide radical production in C. albicans, in a similar dose-dependent way as is observed for S. 
cerevisiae (Figure 7A and 7B). These results indicate that the range of AmB concentrations used for 
S. cerevisiae, are applicable for C. albicans as well. 
 
 
Figure 7 AmB induces production of superoxide and nitric oxide radical in C. albicans and decreases 
the number of cells that are able to reproduce. Exponential C. albicans cultures were treated with different 
concentrations of AmB for 3 hours and subjected to flow cytometry or plating assays. (A) Levels of superoxide 
radical detected by dihydroethidium (DHE) fluorescence and flow cytometry; (B) Levels of nitric oxide radical 
detected by 4-Amino-5-Methylamino-2’,7’-Difluorofluorescein Diacetate (DAF-FM DA) fluorescence and flow 
cytometry; (C) Number of CFU/mL in Log-scale, assessed by plating assays and CFU counting. Means and 
standard errors of the means (SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. 
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Next, we assessed whether treatment with AmB in the presence of 200 mM L-NAME significantly 
affects the number of cells that are able to reproduce as compared to treatment with AmB alone. As 
shown in Figure 8, addition of 200 mM L-NAME to various AmB concentrations (2.5 µM to 10 µM 
AmB) significantly reduces the number of cells that are able to reproduce (P < 0.0001), indicating 
that the potentiating effect of L-NAME to AmB is also observed for the human pathogen C. albicans. 
Figure 8 L-NAME significantly decreases the number of AmB-treated cells that are able to reproduce in 
C. albicans. Exponential C. albicans cultures were treated with different dosages of AmB in the presence 
(dashed line) or absence (solid line) of 200 mM L-NAME for 3 hours and subjected to plating assays. Means and 
standard errors of the means (SEMs) of at least 3 independent biological experiments (n ≥ 3) are presented. 
Two-way ANOVA followed by Tukey multiple comparisons test was performed to analyse significant differences 
between the two treatments; **** represents P < 0.0001.  
7.4. Discussion 
The aim of this study was to investigate and understand how AmB-induced oxidative and nitrosative 
stresses (characterized by excess of superoxide radicals and nitric oxide radicals, respectively) are 
linked to fungal cell death by altering the levels of these toxic radicals. To this end, we used the nitric 
oxide synthases inhibitor L-NAME, resulting in the absence of nitric oxide radicals and nitrosative 
stress. We found that superoxide radical production, and not nitric oxide radical production, is 
important for AmB’s antifungal activity and therefore, we assessed the kinetics of superoxide radical 
production, membrane permeabilization and loss of reproduction capacity in an attempt to further 
elucidate the role of these events in AmB-induced fungal cell death.  
The kinetics of superoxide production and membrane permeabilization were investigated using a 
DMF platform in which individual S. cerevisiae cells are captured and monitored for their responses 
over time during treatment. As such, analyses were performed with spatiotemporal resolution and 
information on cellular heterogeneity with respect to dynamic cell responses could be elucidated. 
Such an analysis is not possible with flow cytometry, highlighting the strength of this DMF platform. 
The kinetics of the loss of reproduction capacity were assessed by plating assays. We showed that 
L-NAME increases and accelerates the effect of AmB on the production of superoxide radicals, 
membrane permeabilization and loss of reproduction capacity in S. cerevisiae. Moreover, treatment 
of the human pathogen C. albicans with AmB in the presence of L-NAME significantly increased loss 
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of reproduction capacity, as compared to treatment with AmB alone, suggesting that treatment of 
AmB in the presence of L-NAME might have a clinical relevance.  
L-NAME has been extensively studied in in vitro, ex vivo and in vivo systems (reviewed in (47)). It 
was shown to inhibit corneal angiogenesis under chemical of growth factor stimulation in rabbits (48) 
and improve leucocyte adherence and emigration to venular endothelium, characteristic of acute 
inflammation, in cat jejuni (49), In addition, L-NAME was found to modulate hemodynamics in dogs 
(50), ewes (51) and guinea pigs (52), and was shown to reverse sepsis-associated hypotension in 
various animal models (53). In humans, L-NAME was tested to treat hypotension, asthma and 
sepsis. In view of the latter, L-NAME increased the systemic vascular resistance and blood pressure 
in septic patients (54, 55). In treatment of asthma, no adverse effects were found in healthy 
volunteers and patients with asthma, and results on exhaled nitric oxide levels indicated that L-NAME 
might be used for treatment of asthma (56). Finally, L-NAME increased the mean arterial pressure 
and cerebral blood flow, treating hypotension in patients with tetraplegia. No adverse effects on 
healthy volunteers or patients were found (57-59). Hence, although L-NAME as such is not used in a 
clinical setting to date, it has been studied extensively during the past decades.  
AmB, on the other hand, is used in clinical settings to treat invasive fungal infections. However, its 
applicability is limited due to its nephrotoxicity and hence, it must be used with care (25). Recent 
findings indicated that AmB exerts its antifungal action by extracting ergosterol from the plasma 
membrane, referred to as the sponge model, resulting in loss of cell membrane integrity, interference 
with ergosterol-depending cellular processes and ultimately cell death (28). In addition, AmB 
treatment causes a significant loss of replication competency and numerous morphological and 
physiological disorders, including cytoplasm shrinking, abnormal nuclear and mitochondrial 
morphology and oxidative stress (60). Finally, Teixeira-Santos and colleagues showed that 
pathogenic and non-pathogenic yeast cells develop compensatory responses towards AmB 
treatment, related to membrane polarization, metabolic activity and ROS production, depending on 
the drug concentration and the duration of the treatment (14). Likewise, we found that treatment of 
yeast cells with clinically relevant AmB concentrations (i.e. 0.1 µM to 21.6 µM AmB (14, 61)) induces 
the production of superoxide radicals, in addition to nitric oxide radicals, in S. cerevisiae and C. 
albicans. Moreover, we revealed that superoxide radicals are important in AmB-induced fungal cell 
death, whereas nitric oxide radicals play a role in mediating tolerance towards this agent, indicating a 
beneficial role of nitric oxide radicals in yeast response towards AmB (Figure 9). 
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Figure 9 Schematic overview of the major findings on AmB mechanism of action in this study. 
Production of nitric oxide radicals is suggested to occur within 15 minutes of treatment, and acts as a tolerance 
mechanism (red lines) towards AmB-induced stress, independent of superoxide radical production and 
membrane permeabilization. AmB induces loss of reproduction capacity in yeast via two routes, presented in 
green and blue arrows, respectively. In a first route (green), loss of reproduction capacity appears within 15 
minutes of treatment, induced through a mechanism yet to be elucidated (X), and is completely elicited by 
beneficial action of nitric oxide radicals. In a second route (blue), loss of reproduction capacity and membrane 
permeabilization is associated with production of superoxide radicals after 30 to 45 minutes of AmB treatment, 
and is partially blocked by beneficial action of nitric oxide radicals. 
Nitric oxide radicals were previously shown to affect fungal cell death, both in beneficial and 
destructive manners. For instance, increased intracellular nitric oxide radical levels are suggested to 
play a cytoprotective role in yeast during stress from heat-shock and hydrostatic pressure (62). In 
contrast, PAF26-induced production of nitric oxide radicals was correlated to its antifungal activity 
and administering L-NAME partially restored yeast growth in the presence of PAF26, indicating that 
nitric oxide radicals play an important role in PAF26-induced cell death (42). In line, Almeida and 
colleagues showed that nitric oxide is a crucial mediator of H2O2-induced apoptosis in yeast, and that 
blockage of nitric oxide radical production by L-NAME decreased the intracellular levels of ROS, 
thereby increasing survival (44). Interestingly, in our study, L-NAME increases the production of 
superoxide radicals during AmB treatment, while decreasing the reproduction capacity of cells in 
presence of AmB, and thus decreasing survival. It seems that a nitric oxide radical-dependent 
tolerance system is switched on upon AmB treatment in yeast, perhaps similar to the system recently 
described by Nasuno and colleagues (63). In that study, a downstream pathway of nitric oxide 
radicals involved in high-temperature stress-tolerance in yeast was unravelled. They showed that 
nitric oxide radicals activate the transcription factor Mac1, that on its turn induces the CTR1 gene and 
results in increased cellular copper levels, which then results in activation of Sod1, a superoxide 
dismutase (63). Whether tolerance to AmB via nitric oxide production acts via a similar mechanism 
needs to be further investigated. 
Not only an increased level of superoxide radicals was found upon treatment of S. cerevisiae with 
AmB in the presence of L-NAME, as compared to treatment with AmB alone, but also an accelerated 
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effect on these levels was observed (Figure 4). Our DMF approach allowing a detailed kinetic study 
at single cell level showed that superoxide radicals are produced in a biphasic manner during AmB 
treatment in the presence of L-NAME, resulting in two superoxide radical production peaks at 75 
minutes and 150 minutes, respectively. This was not observed for cells treated with AmB in the 
absence of L-NAME, where a superoxide radical production peak seems to manifest at 180 minutes, 
the endpoint of this study (Figure 5). Interestingly, all cell responses, being superoxide radical 
production, membrane permeabilization and loss of reproduction capacity, presented themselves 
significantly faster, as compared to these responses during treatment with AmB alone. Therefore, it 
might well be that L-NAME solely accelerates AmB action and hence, similar outcomes might be 
expected for treatment with AmB alone over a longer period of time (i.e. > 180 minutes). Whether this 
is the case, needs to be further investigated. This hypothesis is supported by the fact that L-NAME 
acts fungistatic, however not fungicidal, on S. cerevisiae and C. albicans cells when administered 
alone (data not shown), and does not affect the level of superoxide radicals, membrane 
permeabilization and reproduction capacity of control cells (Figure 2), suggesting that the observed 
effect on cell responses is not caused by a similar and dual action of L-NAME and AmB, as is often 
the case for synergistic interactions. As for superoxide radical production, it would be interesting to 
investigate in which cell compartment these radicals are produced and whether the two superoxide 
radical production peaks, observed in this study, are associated with a different intracellular location 
of superoxide radical production. The main sources of these radicals are the mitochondria, in which 
superoxide radicals are generated from leakage of electrons from the mitochondrial respiratory chain 
as by-products of aerobic respiration. Upon production, superoxide radicals are either subsequently 
dismutated to H2O2 or metabolised to peroxynitrite by reaction with nitric oxide radicals in the 
mitochondria, or they are released to the cytosol and the mitochondrial intermembrane space, where 
they are further metabolised to other ROS or RNS (64, 65). However, also an NADPH-dependent 
manner of superoxide radical production has been reported in yeast. The yeast NADPH oxidase 1 
(Yno1p), located in the endoplasmic reticulum, has been shown to produce superoxide radicals, 
independent of mitochondrial respiration ad mitochondrial ROS production (66). As such, it would be 
interesting to investigate whether the superoxide radical production observed in this study is linked to 
the mitochondria and/or the endoplasmic reticulum. 
Secondly, and most notable, L-NAME seems to have a strong potentiating effect on AmB-induced 
loss of reproduction capacity in yeast: within 15 minutes, approximately 99.5% of the cells lost the 
capacity to reproduce on plate when cells were subjected to AmB treatment in the presence of L-
NAME. In contrast, treatment with AmB alone did not reach a similar level in reproduction capacity of 
cells within 180 minutes. This suggest that also here nitric oxide radicals play an important, 
beneficial, role in the response towards AmB, and hence, nitric oxide radical production is suggested 
to occur within 15 minutes of AmB treatment. Whether this is the case, needs to be further 
investigated. Interestingly, cells receiving treatment with AmB and L-NAME were able to produce 
superoxide radicals only after 15 to 30 minutes, suggesting that (i) these reproduction-negative cells 
are still metabolically active, and (ii) AmB – L-NAME treated cells might use increased levels of 
superoxide radicals, and thus oxidative stress, to enter a programmed cell death pathway. Oxidative 
stress can elicit a range of stress responses in yeast cells, resulting in either cell survival (by 
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upregulation of transcription factors, increased activity of antioxidants and proteasomal degradation 
of oxidized proteins) or programmed cell death (reviewed in (67)). A high degree of oxidative stress 
often results in apoptosis, necrosis or other programmed cell death pathways. In addition, yeast cells 
have the ability to activate autophagic pathways, thereby removing irreparably oxidized 
macromolecules or dysfunctional organelles, and elicit cell rescue. However, depending on the status 
of the cells, autophagy and cell death can act in a cooperative or competitive manner (68, 69). If and 
how autophagy and programmed cell death are involved in AmB-induced cell death, is yet to be 
investigated. 
Finally, cell responses other than the ones investigated in this study might play a role in the observed 
effects under treatment with AmB in the presence of L-NAME, especially in view of reproduction 
capacity of cells. As superoxide radical production and membrane permeabilization were not 
observed before 15 minutes of treatment, the rapid loss of reproduction capacity of cells cannot be 
explained by these events. Hence, it seems that mechanisms other than superoxide radical 
production and membrane permeabilization underlie the effect on the reproduction capacity of cells 
during the first 15 minutes of AmB treatment in the presence of L-NAME (i.e. event ‘X’ in Figure 9). A 
plausible explanation for loss of reproduction capacity, independent of oxidative stress and non-
apoptotic cell death, is cell cycle arrest. It was shown that yeast cell growth is maximal during the 
anaphase and G1, and more limited in S phase and mitosis (70). Moreover, AmB was previously 
shown to induce an increase in sub-G1 and a decrease in G2/M population in a myofibroblast cell 
line, in addition to induction of autophagy and apoptosis (29). In the human cancer cells RPMI7951 
and MG63, treatment with AmB alone did not induce cell cycle arrest, however, a combination of 
AmB with a Taiwanofungus camphoratus extract triggered cell cycle arrest in the G2/M phase in both 
cell lines. In addition, an AmB dose-dependency of cell cycle arrest was observed in MG63 cells (30). 
Whether cell cycle arrest is one of the factors influencing the reproduction capacity of cells treated 
with AmB in the presence of L-NAME, has to be further investigated. 
In conclusion, we showed that L-NAME can increase and accelerate AmB-induced superoxide 
radical production and loss of reproduction capacity in S. cerevisiae, the latter confirmed in the 
human pathogen C. albicans. Moreover, we found that the production of nitric oxide radicals seems 
to constitute a tolerance mechanism that is switched on upon AmB treatment. The effects of both 
AmB and L-NAME have been extensively studied in various in vitro and in vivo models, pointing 
towards a clinical potential of AmB treatment in the presence of L-NAME. However, further research 
on pharmacology and toxicology of the AmB – L-NAME combination needs to be performed in order 
to assess its potential clinical relevance.   
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8.1. General discussion and perspectives 
The incidence of invasive fungal infections (IFIs), caused by species of, for instance, Aspergillus, 
Fusarium, Cryptococcus and Candida, is increasing worldwide. Factors contributing to this 
observation are patient characteristics, patient medical status, increased use of antibiotics and 
increased drug resistance (1-6). IFIs caused by Candida spp. are the most common, and although C. 
albicans has been considered the most frequently isolated pathogen in IFIs for decades, a change in 
trend is observed in the past couple of years, highlighting an increased prevalence of non-albicans 
Candida spp. in candidemia (4,6-8). This shift in epidemiology of Candida spp. is attributed to the 
widespread use of azole-, and more specifically fluconazole-, based prophylaxis (9,10).  
Candida spp. are highly associated with medical device-related infections, e.g. catheters, 
orthopaedic implants and implantable electronic devices (such as cardiovascular pacemakers), on 
which biofilms are easily formed (11-14). Biofilms are self-organised microbial communities 
embedded in a polymeric matrix that grow on biotic or abiotic surfaces (15). Biofilm cells are different 
from cells in planktonic cultures with respect to cellular phenotype and physiology, which translates 
into their increased resistance to antimicrobial treatment (13,16-18). There are only a few antifungal 
agents that are effective against fungal biofilms, such as miconazole, caspofungin, anidulafungin and 
liposomal formulations of AmB (13,19,20). It is clear that there is a need for identification and 
characterization of novel antifungal agents or therapies with potent antibiofilm activity to combat IFI.  
Naturally occurring antimicrobial peptides (AMPs), including plant defensins, are of great interest as 
potential novel therapeutic agents, as their multiple modes of action reduce the ability of 
microorganisms to develop resistance, and they have a high cidal activity and a rapid kill across a 
range of microorganisms (21,22). In this PhD study, we focused on unravelling the mechanisms of 
antifungal action of a variety of plant defensins and small molecules, thereby using pathogenic and 
non-pathogenic yeasts as models. More specifically, we analysed the antifungal and antibiofilm 
activity of RsAFP1, RsAFP2 and HsAFP1 and their ability to act synergistically with caspofungin and 
AmB in C. albicans biofilms and planktonic cultures. In addition, we evaluated the potential of 
AtPDF2.3 to interact with specific ion channels, linked to its antifungal activity. Finally, we 
investigated the mechanism of antifungal action of the standard antifungal agent amphotericin B 
(AmB) using a DMF platform that allowed us to monitor single cells over time and thus analyse the 
kinetics of specific cell responses in a time-dependent manner. In the following section, we discuss 
the obtained results in a broader context and elaborate on the future perspectives. 
8.1.1. Therapeutic potential of plant defensins  
In this thesis, we demonstrated that plant defensins can have various biological activities (see 
Chapters 3, 4 and 5). In view of the latter, we showed that recombinant (r) HsAFP1 and RsAFP2, 
defensins from coral bells (23) and radish seeds (24) respectively, inhibit C. albicans biofilm 
formation and act synergistically with the conventional antimycotics caspofungin and AmB in the 
prevention and eradication of these biofilms. Furthermore, we found that the Arabidopsis thaliana 
defensin rAtPDF2.3 specifically blocks voltage-gated potassium channels and that pathways 
regulating potassium transport in yeast confer tolerance towards rAtPDF2.3 antifungal action. 
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Indeed, plant defensins possess biological activity towards a broad range of organisms. Although 
mainly their fungicidal action has been studied (reviewed in (25-27)), they are reported to have 
bactericidal (28-31) and insecticidal (32,33) activity, inhibit protein synthesis (34,35) and enzyme 
activity (36,37) and possess ion channel inhibitory function (Chapter 5 and (38-40)). 
Given that plant defensins specifically interact with the fungal membrane, and therefore, are 
suggested to be devoid of toxic activity towards mammalian cells, plant defensins show great 
promise as putative antimycotics. In this respect, RsAFP2 was shown to interact with specific fungal 
glucosylceramides (GlcCer), but not with human or soybean GlcCer. In addition, growth of fungal 
species devoid of GlcCer was not inhibited by RsAFP2, indicating a crucial role for fungal GlcCer in 
RsAFP2 antifungal activity (41). The presence of specific fungal membrane compounds was also 
found essential for other plant defensins to exert their antifungal activity (Chapter 5 and (42-46)). 
However, some defensins were shown to be toxic to human cells: NaD1, a tobacco defensin, 
induced cell lysis in monocytic lymphoma cells, epithelial cervical cancer cells and prostatic cancer 
cells (46), and a defensin from Capsicum chinense inhibited the viability of epithelial cervical cancer 
cells (47). In addition, sesquin, from Vigna sesquipedalis, inhibited the proliferation of human 
leukemia and breast cancer cell lines (48), and, in line, the Phaseolus limensis defensin limyin 
blocked proliferation of hepatoma and neuroblastoma cells (49). Hence, potential toxicity of plant 
defensins towards mammalian cells should always be investigated. 
8.1.1.1. In vivo potential of plant defensins 
To date, only the RsAFP2 plant defensin has been tested in vivo for its potential to treat fungal 
infections (50). In that study, RsAFP2 was found prophylactically effective against murine 
candidiasis, to at least the same extent as the standard drug fluconazole, as the fungal burden in the 
kidneys of infected mice was found considerably reduced when RsAFP2 was administered. In 
addition, RsAFP2 was found nontoxic to human brain microvascular endothelial cells and primary 
glioblastoma cells (50). Similarly, the insect defensin heliomicin variant EDT151 performed well in 
murine models infected with Candida and Aspergillus species, when compared to AmB and various 
azoles, with very low toxicity towards mammalian cells (51). It is clear that there is a need to test 
other (plant) defensins for their in vivo performance, in order to gain insight in the relevance of using 
(plant) defensins as novel therapeutic lead molecules to combat fungal infections.  
To evaluate the in vivo performance of an antifungal agent with C. albicans as a target organism, 
primarily murine models of candidiasis are used. A first murine model of candidiasis that can be used 
to test the in vivo performance of an antifungal, is a vaginal or oral candidiasis mouse model. Wang 
and colleagues established a mouse model of candidiasis with concurrent oral and vaginal mucosal 
infection, which was evaluated by in vivo pharmacodynamics of fluconazole (52). Also the antifungal 
agent VT-1161 was tested in a murine model of vaginal candidiasis to investigate its 
pharmacokinetics (53), and an oral candidiasis mouse model was used to assess miltefosine’s in 
vivo efficacy as topical treatment (54). Alternatively, a model of persistent murine gastrointestinal 
tract colonization by C. albicans, in which the antifungal drug is administered orally or 
subcutaneously, is used to study the in vivo efficacy of antifungals. For instance, several 
echinocandins (55) and azoles (56) were tested in such a model for their ability to eradicate C. 
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albicans from murine gut. Lastly, a murine model of invasive candidiasis can be used, in which the 
antifungal agent is administered intraperitoneally, orally or parenteral. Such a model has been used 
to analyse the in vivo efficacy of, for instance, caspofungin (57), fluconazole (57,58), AmB (59), 
liposomal thymoquinon (58), SM21 (60), and the plant defensin RsAFP2 (50). 
8.1.1.2. Lead optimization of plant defensins 
Peptide-based drug discovery has gained interest in the pharmaceutical sector to address 
therapeutic challenges. Peptides have several advantages over other drugs with respect to 
therapeutics. They can penetrate further into tissues due to their small size and are less 
immunogenic than antibodies (61). As compared to traditional small molecules, peptides have in 
general a greater efficacy, selectivity and specificity and are less accumulated in tissues due to their 
short half-life (61,62). In addition, they have a low risk of causing systemic toxicity, as degradation 
products are amino acids, and thus drug-drug interactions are minimized (63). Major drawbacks of 
peptides as drug candidates include (i) low stability and high susceptibility to proteases and 
peptidases in plasma and the digestive system (61,64), (ii) rapid removal from the circulation and 
thus a low in vivo plasma residence time (61), (iii) poor ability to cross physiological barriers due to 
their hydrophilic nature (65,66) and (iv) in comparison with small molecules, high synthetic and 
production costs (67). However, several of these limitations can be overcome through thorough lead 
peptide optimization (68).  
Generally, the size of the peptide determines the most suitable technology for production and hence, 
determines the manufacturing costs. As such, decreasing the size of the lead peptide and hence, 
searching for the minimum active sequence in truncated analogues, is appreciated. Detailed 
examples of testing such truncated analogues are presented further in this section. Next, alanine 
scanning and/or D-scanning can be performed to simplify and optimize the structure to eliminate 
potential (endo)peptidase cleavage sites and to determine important functional groups involved in the 
interaction with its target (68,69). In this respect, alanine scanning of the frog-skin temporin-1Ta 
assisted in optimizing the design of temporin-based lead structures (70) and suggested a sequence 
lead for the antibacterial α-helix of human lactoferrin (71). Furthermore, peptide cyclization is often 
performed to decrease the linear peptide’s conformational flexibility, reduce hydrogen bonding, 
enhance membrane permeability and increase its stability to proteolysis (62,68,72,73). Cyclic 
peptides have the advantages over linear peptides that they are more resistant to enzymatic 
degradation (74,75), as was shown for the cyclotide kalata B1 (76), and they can exhibit improved 
activity. In view of the latter, cyclization of the conotoxin gm9a increased its potency at high voltage-
activated calcium channels as compared to its acyclic counterpart (77). The in vivo plasma stability 
and residence time can be further increased by introducing for instance unnatural amino acids or β-
amino acids and by blocking N- or C-terminal ends, thereby increasing its resistance towards endo- 
and exopeptidases (68,69,78). 
For lead peptide optimization, structure-activity relationship (SAR) studies of newly synthesized 
peptide derivatives are performed in which the above alterations in peptide sequence and structure 
are investigated. In an earlier collaborative research, our laboratory performed such a SAR study for 
RsAFP2, in which linear 19-mer RsAFP2-derivatives were synthesized and analysed for their 
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antifungal activity (79). Derivatives spanning the β2-β3 loop of RsAFP2 were found almost as potent 
as the mature peptide with regard to antifungal activity against Fusarium culmorum, indicating that 
the sequence comprising the β2-β3 loop mimics the RsAFP2 active site. In addition, replacement of 
the cysteines by α-aminobutyric acid in these 19-mer derivatives improved the antifungal activity, and 
cyclization of these sequences maintained their antifungal activity (79).  
Also for HsAFP1, lead peptide optimization was initiated, as discussed in Chapter 3. To this end, 
linear 24-mer synthetic HsAFP1-derivatives were synthesized and analysed for their activity towards 
C. albicans planktonic and biofilms cells. We found that the γ-core and adjacent regions are 
important in HsAFP1 antibiofilm activity, as only the peptide with that sequence (i.e. HsLin06) 
inhibited C. albicans biofilm formation to the same extent as mature HsAFP1. Follow-up experiments 
in view of lead peptide optimization would include testing shorter N- or C-terminally truncated 
HsLin06-derived peptides for their potential to prevent and/or eradicate C. albicans biofilms and to 
act synergistically with conventional antimycotics, in order to further minimize the minimal active 
sequence. Moreover, alanine scanning can reveal crucial amino acids with respect to antifungal, 
antibiofilm and/or synergistic activity, which can then be substituted to improve the peptide’s activity, 
whereas D-scanning and introduction of, for instance, disulfide bonds can increase the peptide’s 
stability for potential use in vivo. Such lead peptide optimization is currently investigated in 
collaboration with Prof. Drijfhout from the Department of Immunohematology and Bloodtransfusion, 
Leiden Unversity Medical Center (LUMC) in the Netherlands.  
In Chapter 4 of this thesis, we showed antibiofilm activity of RsAFP2 against C. albicans and 
discussed its ability to act synergistically with caspofungin in prevention and eradication of C. 
albicans biofilms. As such, it would be interesting to also analyse the truncated analogues for their 
potential to prevent and/or eradicate C. albicans biofilms and to act synergistically with caspofungin 
in these events. Such a study could reveal surprising and interesting results, as we showed that in 
the case of HsAFP1-derivatives, antibiofilm and antifungal activity are not linked, and moreover, that 
synergistic interactions between the synthetic peptide and the antifungal agent (in this case 
caspofungin) can exist without evidence of peptide activity when applied alone (Chapter 3).  
8.1.1.3. Administration routes of peptides 
Once a lead peptide is found, the administration route should be considered. Oral administration is 
the preferred method, however, as mentioned earlier, oral administration of peptides is mainly 
hampered by their susceptibility to proteolysis. Oral bioavailability can be improved by for instance 
co-administration of the peptide with protease inhibitors, enteric coating or encapsulation of the 
peptide with pH-sensitive or mucoadhesive polymers, and incorporation of absorption enhancers. 
Alternatively, the use of oral delivery carriers, including nanoparticles, liposomes and nano-
aggregates using amphiphilic polymers, can be explored for advanced oral uptake of therapeutic 
peptides (64,80-82). For instance, in collaboration with Nobex®, Kipnes and colleagues designed 
and produced an oral insulin product, in which insulin is covalently linked to a single amphiphilic 
oligomer (83). This product was tested in phase III clinical trials, with successful outcome: single oral 
doses of the product were safe and well tolerated and treatment was as effective as subcutaneous 
regular insulin (83). Similarly, a liposomal approach for delivery of an oral tetanus vaccine was 
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designed and executed in collaboration with ImuXen®, and was tested in preclinical trials (84). In 
addition, oral delivery of peptides can be achieved by the use of hydrogels (85,86). In this respect, 
hydrogels loaded with growth hormone, salmon calcitonin and several model drugs showed 
promising applications in oral drug delivery (87-89). Hence, it seems that there are definitely 
possibilities in view of marketing plant defensins for treatment of fungal infections. 
8.1.1.4. Coating and release of antibiofilm peptides on/in medical substrates 
In view of preventing fungal biofilm formation, it might be interesting to explore the possibility of 
coating plant defensin-based lead peptides onto medical devices, such as catheters and implants. 
Such an approach was already reported for conventional antibiotics, In this respect, amikacin and 
vancomycin-loaded implant coatings were shown to inhibit biofilm formation and bacterial growth on 
catheters in mice. In  that study, purified phosphatidylcholine was mixed with 25% amikacin or a 
combination of 12.5% amikacin and 12.5% vancomycin, and coated by the use of a syringe onto 
stainless steel wires that were placed within catheters. Two catheters from the same experimental 
group (i.e. no coating, amikacin coating or amikacin/vancomycin coating) were implanted onto the 
dorsa of each mouse and the lumen of the catheters was inoculated with a mixture of S. aureus and 
P. aeruginosa. After 48 hours, catheters and wires were retrieved and analysed for the number of 
CFUs or subjected to scanning electron microscopy. Results showed a 2.5 and 0.8 log-fold reduction 
in S. aureus and P. aeruginosa biofilm formation, respectively, as compared to controls, indicating 
that phosphatidylcholine coatings are capable of local delivery of active antibiotics (90). In addition, 
also hydrogel-based coatings seem promising candidates in development of biofilm-resistant 
implants, as hydrogels loaded with several antibacterials were shown to reduce bacterial colonization 
and biofilm formation in vitro. Here, a Disposable Antibacterial Coating hydrogel (CE-marked) was 
used, composed of covalently linked hyaluronan and poly-D,L-lactide, which completely degrades in 
a hydrolytic manner in vivo. For assessing antibiofilm activity, sand-blasted titanium, cobalt-chrome 
or polyethylene disks were inoculated with S. aureus and S. epidermidis and a mature biofilm was 
formed. Then, the hydrogel mixed with vancomycin, gentamycin or N-acetylcysteine was spread onto 
the disk with mature biofilm using a syringe and each disk was incubated with fresh medium, after 
which biomass was measured via crystal violet staining. Results showed that hydrogels containing 
the above antibiotics reduced the amount of mature biofilm to a larger extent than that measured for 
any antibacterial alone, highlighting their clinical potential (91). In what type of coating plant 
defensins or their derivatives are the most successful, needs to be further investigated. 
An alternative approach could be the incorporation of plant defensin-based lead structures in porous 
substrates that allow for controlled release of the peptides. We recently demonstrated such an 
approach for toremifene (92). More specifically, macroporous titanium disks were supplied with a 
mesoporous silica oxide diffusion barrier, fitted in a polystyrene cup and placed in the wells of a 12-
well plate as a model for implants with internal reservoir. A toremifene solution was added to the 
wells and water was added inside the cups. As such, toremifene was allowed to diffuse in the cup 
through the titanium disk and compound release was assessed at specific time points for 10 days. 
Then, the release sample was removed, RPMI medium containing C. albicans was added inside the 
cup and biofilm formation was assessed after three days using CellTiter-Blue® staining. Results 
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indicated that controlled release of toremifene in mesoporous silica-containing macroporous titanium 
significantly inhibits C. albicans biofilm growth in vitro, thereby highlighting its potential as an anti-
infective implant substrate (92). Similarly, in another study it was shown that controlled and sustained 
release of the antimicrobial peptide HHC-36 in titanium nanotubes was highly effective against 
bacteria, whereas no cytotoxicity was observed towards MG-63 osteoblast-like cells and red blood 
cells (93). In this study, the nanotubes were coated with calcium phosphate and phospholipids to 
allow a steady release of HHC-36. To assess the antibacterial activity of these structures, HHC-36 
was pipetted onto the surface of the nanotubes, air-dried and these disks were then placed on agar 
plates inoculated with S. aureus or P. aeruginosa. Results showed that HHC-36 released from the 
implants was able to kill both bacteria and also scanning electron microscopy images showed very 
few bacteria on the implants, in strong contrast with control titanium disks (93). Whether controlled 
release of plant defensin-based lead peptides is an option, needs to be further investigated. 
8.1.2. DMF platform as a novel tool to obtain more insight in the mode of action of novel antifungal 
compounds 
Prior to marketing a novel therapeutic, its target and underlying mechanism of action need to be 
identified and understood (94). In the case of investigating antifungal agents, yeast mutant libraries 
and transcriptomic tools are often used to identify the compound’s target(s) and gain insight in their 
mechanism of action at the molecular level. These type of analyses are performed in bulk, and 
therefore represent a population response. In a cell population, however, cellular heterogeneity is 
observed at genomic and functional levels, which arises from stochastic expression of genes, 
proteins and metabolites (95). Hence, to investigate cellular processes more in-depth, thereby 
focussing for instance on signalling pathways, and elucidate information in respect of cellular 
heterogeneity, single cell analysis (SCA) is of great interest (96). 
In Chapter 6 of this thesis, we described the development of a novel SCA digital microfluidic platform 
for monitoring of single yeast cells with spatiotemporal resolution. Using this device, individual cells 
are seeded in microwells, resulting in an array of single cells at a well-defined location. As a proof of 
concept, we monitored the occurrence of membrane permeabilization in individual yeast cells during 
antifungal treatment with AmB for 6 hours and validated the setup by correlating DMF results to bulk 
results. In Chapter 7, we further demonstrated the use of the DMF device for elucidating mechanisms 
of action of antifungal compounds. We analysed the kinetics of membrane permeabilization and 
superoxide radical production in cells subjected to AmB treatment and found that inhibition of nitric 
oxide radical production by L-NAME increases and accelerates AmB fungicidal activity in yeast. In 
this respect, we were not only able to further unravel the mechanism of AmB action by demonstrating 
the importance of superoxide and nitric oxide radicals in AmB activity, but we also identified and 
characterized a synergistic interaction between AmB and L-NAME. This is especially interesting from 
a clinical perspective, given that cells were affected both in number and over time.  
8.1.2.1. Importance of spatiotemporal resolution in SCA 
In SCA, in addition to microscopy-based techniques, flow cytometry frequently combined with 
fluorescence-activated cell sorting (FACS), is considered as one of the most used techniques. 
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Microscopy-based techniques lack high-throughput, whereas with flow cytometry, up to 20 
parameters can be measured simultaneously for any given cell in a high-throughput fashion, thereby 
creating a vast amount of interesting data (97). Still, a major drawback of flow cytometry is the lack of 
spatiotemporal resolution. Using this technique, individual cells cannot be monitored over time and 
therefore, results only display a snapshot of the cell’s responses at a defined time. Several reports 
have already indicated that spatiotemporal studies are an asset in elucidating cellular responses 
towards various stimuli, as individual cells tend to respond differently to stimuli at different time 
points. In view of the latter, Jing and colleagues showed that osteocytes and osteoblasts have 
different calcium signalling properties in response towards mechanical stimuli (98). More specifically, 
osteocytes exhibited more calcium peaks than osteoblasts and these peaks were observed much 
faster in osteocytes than in osteoblasts (98). Moreover, it was reported that apoptosis induced by the 
viral oncoprotein Tax in HeLa cells occurs after cell cycle arrest with concomitant changes in cell 
morphology, which correlates closely with the expression kinetics of several genes involved in cell 
cycle regulation and apoptosis, as assessed by spatiotemporal gene expression profiling and time 
lapse microscopy (99). Also we found that cellular responses alter over time during treatment, and 
showed that studying the kinetics of cellular responses is a valuable tool to gain insight in 
mechanisms of action (Chapter 7), pointing to the importance of spatiotemporal studies. 
8.1.2.2. Techniques for spatiotemporal SCA 
Well-established techniques that allow for spatiotemporal analysis of individual cells mainly include 
microfluidic devices, coupled to time lapse microscopy. These devices require only small sample 
volumes, thereby saving expensive reagents, and are user friendly, as several, if not all, steps are 
easily automated (reviewed in (100)). Microfluidic devices have been used for real-time dynamic 
monitoring of the release of specific (bio)chemical molecules from single cells (reviewed in (101)), 
including nitric oxide (102-104), insulin (105,106) and calcium (107,108). In addition, microfluidic 
tools were established to analyse and simulate kinetic models of cellular reactions and metabolites. 
In view of the latter, the heterogeneity in the response of individual yeast cells in glycolytic 
oscillations was modelled (109). In addition, lactate levels (110) and the release of ROS and RNS 
(111-113) from single cells were monitored using chip-based technologies.  
8.1.2.3. Expanding the DMF platform repertoire  
We demonstrated that the DMF platform is an asset for in-depth studies of the kinetics of cellular 
responses towards specific stimuli, and as such is a valuable tool to gain insight in compounds’ 
mechanisms of action and synergistic interactions. In this respect, this DMF device can be used to 
identify fast-killing agents or drug combinations, which is interesting from a clinical perspective. 
Future interesting upgrades in our DMF platform can include generating the opportunity to perform 
single cell transcriptomics, proteomics and metabolomics on the seeded cells, this to unravel and 
understand the molecular basis of aberrant cell states and responses.  
In view of transcriptomics, single seeded cells have to be removed from the wells, lysed and 
subjected to PCR-based methods. Such removal can be done by the use of optical tweezers, 
whereas transcriptomics can be performed using single-cell quantitative real-time PCR on a 
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microfluidic platform (114,115) or by implementation of a single-cell digital gene expression assay 
(116) (reviewed in (117)). The most straightforward method to perform single cell proteomics and 
metabolomics, is the use of mass spectrometry, as it can detect all proteins, post-translational 
modifications and peptides in a single cell (118,119). In this respect, high-density functional micro-
arrays for mass spectrometry, described by Urban and colleagues, can be used (120). Similarly, 
Wang and colleagues successfully determined trace metals in human cells, using a chip-based array 
with a magnetic solid phase microextraction system coupled to mass spectrometry (121). Recently, a 
microfluidic device coupled to matrix-assisted laser desorption/ionization mass spectrometry (MALDI-
MS) was reported to study phospholipids of single cells (122). In that study, a microwell array-based 
chip was used in which cells were seeded, treated for lipid extraction and subjected to mass 
spectrometry imaging. That is the first report on the combination of microfluidics and MALDI-MS 
(122). The above examples highlight the potential of performing thorough mass spectrometry on 
single cells in the near future, and hence, indicate the possibility of implementing single cell 
proteomics and metabolomics on our DMF platform. Although implementation of such techniques on 
our setup is challenging, it is worthwhile to explore these options in the future, as it will gain more 
insight in cellular responses towards various stimuli and hence, increase our understanding in 
fundamental cellular processes.  
 
8.2. Conclusions 
In summary, this PhD manuscript describes plant defensins as potential novel antimycotics to 
combat fungal infections, either as antifungal or antibiofilm compounds. In addition, it demonstrates 
the development, validation and implementation of a novel microfluidic device for SCA of yeast cells, 
thereby elucidating the compounds’ mechanisms of action and characterizing potential synergistic 
interactions.  
Future perspectives include analysing and characterizing mechanisms of action of (plant) defensins 
using the DMF platform as a tool. As such, it would be interesting to unravel the kinetics by which 
plant defensins exert their antifungal activity. In line, it would be useful to develop a platform for 
seeding and monitoring of C. albicans cells to further exploit the clinical relevance of using this 
platform in antifungal drug screening and/or discovery. A similar approach can be developed for 
instance for antibacterial or even anticancer therapies, using bacteria and human cancer cell lines, 
respectively. Implementation of a microfluidic anticancer drug discovery platform, combined with 
single cell proteomics and metabolomics, definitely holds great promise for the future.   
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